

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

19 May 2022 (19.05.2022)



(10) International Publication Number

WO 2022/101469 A1

(51) International Patent Classification:

A61K 9/51 (2006.01) A61K 39/00 (2006.01)

A61K 9/19 (2006.01) A61P 31/14 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/081674

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

15 November 2021 (15.11.2021)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/114,478 16 November 2020 (16.11.2020) US

63/115,588 18 November 2020 (18.11.2020) US

(71) Applicant: BIONTECH SE [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: PANZNER, Steffen; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). REINSCH, Christian; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). THANKI, Kaushik; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). SOMANI, Sukrut; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). TCHESSALOV, Serguei A.; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). BHATNAGAR, Bakul Subodh; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). DARVARI, Ramin; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). LUTHRA, Sumit; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US).

(74) Agent: SCHNAPPAUF, Georg; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: COMPOSITIONS AND METHODS FOR STABILIZATION OF LIPID NANOPARTICLE MRNA VACCINES

(57) Abstract: The present disclosure provides technologies relating to stabilization of lipid nanoparticle mRNA compositions (e.g., vaccines).



WO 2022/101469 A1

COMPOSITIONS AND METHODS FOR STABILIZATION OF LIPID NANOPARTICLE MRNA VACCINES

Background

[1] Messenger RNA (mRNA) is proving to be an exciting therapeutic modality and has garnered significant recent attention, particularly in the vaccine space.

Summary

[2] The present disclosure provides technologies relating to formulation of RNA (*e.g.*, mRNA) therapeutics, and particular to lipid nanoparticle (LNP) formulations comprising RNA (*e.g.*, mRNA) payloads. Among other things, the present disclosure provides therapeutic RNA formulations (*i.e.*, LNP formulations) that are amenable (*e.g.*, stable) to storage and/or handling at temperatures above about -80°C, or even above about -70°C, about -60°C, about -50°C, about -40°C, about -30°C, or about -20°C. In some embodiments, provided formulations may be amenable to storage and/or handling at temperatures above freezing (*e.g.*, above about 0°C), at standard refrigeration temperature (*e.g.*, within a range of about 1°C to about 8°C, or about 2°C to about 8°C, or about 2°C to about 6°C, or about 2°C to about 4°C), and/or at room temperature (*e.g.*, within a range of about 15°C to about 25°C, or about 20°C to about 23°C).

[3] In some embodiments, the present disclosure provides formulations that are amendable to drying and/or that are dry (*e.g.*, that are lyophilized formulations).

[4] The present disclosure particularly provides certain formulations useful as (and/or in the preparation of) vaccines.

[5] In some embodiments, the present disclosure provides formulations (and specifically LNP formulations) of RNA encoding a viral antigen (*e.g.*, a SARS-CoV2 antigen such as an S-protein or epitope thereof). Specific exemplified formulations include an RNA construct that is a BNT162 construct (*e.g.*, as described in Walsh, E. *et al.* RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. *medRxiv* (2020)), *e.g.*, BNT162b2; and PCT Application Number No. PCT/EP2020/081981 filed November 12, 2020 and entitled

“Coronavirus Vaccine”, the contents of each of which are incorporated herein by reference for purposes described herein.)

[6] In one aspect, a formulation provided herein comprises: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; (b) sucrose at a concentration of about 10% w/v in the formulation; and (c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[7] In some embodiments, a formulation provided herein is a frozen formulation comprising: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; (b) sucrose at a concentration of about 10% w/v in the formulation; and (c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[8] In some embodiments, a formulation provided herein is a dry formulation comprising: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; (b) sucrose at a concentration of about 10% w/v in the formulation before drying; and (c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[9] Methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
 - ii) sucrose at a concentration of about 10% w/v in the formulation.

[10] In some embodiments, a method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
 - b) sucrose at a concentration of about 10% w/v;
 - c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- wherein the formulation is diluted into the dosage form prior to administration.

[11] In one aspect, provided herein is a formulation comprising: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: (i) a payload that is or comprises one or more mRNAs; (ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; (b) trehalose at a concentration of about 10% w/v in the formulation; and (c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[12] In some embodiments, a formulation provided herein is a frozen formulation comprising: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; (b) trehalose at a concentration of about 10% w/v in the formulation; and c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[13] In some embodiments, a formulation provided herein is a dry formulation comprising: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; (b) trehalose at a concentration of about 10% w/v in the formulation before drying; and (c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[14] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
 - ii) trehalose at a concentration of about 10% w/v in the formulation.

[15] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) trehalose at a concentration of about 10% w/v;
- c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[16] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[17] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[18] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation before drying; c) trehalose at a concentration of about 5% w/v in the formulation before drying; d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[19] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

(a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- ii) sucrose at a concentration of about 5% w/v in the formulation; and
- iii) trehalose at a concentration of about 5% w/v in the formulation.

[20] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
- v) cholesterol at a concentration of about 3.1 mg/ml;

- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[21] In one aspect, a formulation provided herein comprises: (a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

[22] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

[23] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation before drying; c) Tris buffer, wherein the Tris

buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[24] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) sucrose at a concentration of about 10% w/v in the formulation.

[25] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

- v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[26] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation; c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

[27] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation; c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

[28] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation before drying; c) Tris buffer, wherein the Tris

buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[29] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; and
 - ii) trehalose at a concentration of about 10% w/v in the formulation.

[30] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

- v) cholesterol at a concentration of about 3.1 mg/ml;
- b) trehalose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[31] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

[32] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

[33] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation before drying; c) trehalose at a concentration

of about 5% w/v in the formulation before drying; d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[34] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation;
- ii) sucrose at a concentration of about 5% w/v in the formulation; and
- iii) trehalose at a concentration of about 5% w/v in the formulation.

[35] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

v) cholesterol at a concentration of about 3.1 mg/ml;

b) sucrose at a concentration of about 5% w/v in the formulation;

c) trehalose at a concentration of about 5% w/v in the formulation;

d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[36] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[37] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[38] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-

ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation before drying; c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[39] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) sucrose at a concentration of about 10% w/v in the formulation.

[40] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

v) cholesterol at a concentration of about 3.1 mg/ml;

b) sucrose at a concentration of about 10% w/v in the formulation;

d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[41] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation; c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[42] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation; c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[43] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at

relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation before drying; c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[44] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) trehalose at a concentration of about 10% w/v in the formulation.

[45] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

v) cholesterol at a concentration of about 3.1 mg/ml;

b) trehalose at a concentration of about 10% w/v in the formulation;

d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[46] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[47] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[48] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-

ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation before drying; c) trehalose at a concentration of about 5% w/v in the formulation before drying; d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[49] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- ii) sucrose at a concentration of about 5% w/v in the formulation; and
- iii) trehalose at a concentration of about 5% w/v in the formulation.

[50] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
- v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[51] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[52] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[53] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or

comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation before drying; c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[54] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) sucrose at a concentration of about 10% w/v in the formulation.

[55] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;
- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
- v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 10% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[56] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation; c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[57] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation; c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[58] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-

6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) trehalose at a concentration of about 10% w/v in the formulation before drying; c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[59] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) trehalose at a concentration of about 10% w/v in the formulation.

[60] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

v) cholesterol at a concentration of about 3.1 mg/ml;

b) trehalose at a concentration of about 10% w/v in the formulation;

d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[61] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[62] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation; c) trehalose at a concentration of about 5% w/v in the formulation; d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

[63] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or

comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 5% w/v in the formulation before drying; c) trehalose at a concentration of about 5% w/v in the formulation before drying; d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

[64] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- ii) sucrose at a concentration of about 5% w/v in the formulation; and
- iii) trehalose at a concentration of about 5% w/v in the formulation.

[65] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) mRNA at a concentration of about 0.5 mg/ml;

- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
- v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; wherein the formulation is diluted into the dosage form prior to administration.

[66] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride.

[67] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride.

[68] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation before drying; c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride.

[69] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride; and
- ii) sucrose at a concentration of about 10% w/v in the formulation.

[70] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;

- ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
 - b) sucrose at a concentration of about 10% w/v;
 - c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride;
- wherein the formulation is diluted into the dosage form prior to administration.

[71] In one aspect, a formulation provided herein comprises: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation.

[72] In some embodiments, a formulation provided herein is a frozen formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation; c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation.

[73] In some embodiments, a formulation provided herein is a dry formulation comprising: a) a lipid nanoparticle (LNP), wherein the LNP comprises: i) a payload that is or

comprises one or more mRNAs; ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and b) sucrose at a concentration of about 10% w/v in the formulation before drying; c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation before drying.

[74] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation; and
 - ii) sucrose at a concentration of about 10% w/v in the formulation.

[75] In some embodiments, provided herein is a method comprising a step of administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
 - b) sucrose at a concentration of about 10% w/v in the formulation;
 - c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride;
- wherein the formulation is diluted into the dosage form prior to administration.

[76] In some embodiments, methods of providing such formulations described herein are also described herein. In some embodiments, provided herein is a method of preparing a formulation comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation; and
 - ii) sucrose at a concentration of about 10% w/v in the formulation wherein the first buffer system comprises sucrose at a concentration of about 10% w/v.

[77] In some embodiments, provided herein is a method of delivering a nucleic acid into a cell in a subject comprising a step of administering a formulation as described in any of the preceding claims.

[78] In some embodiments, provided herein is a method of inducing an immune response in a subject comprising a step of administering to the subject a formulation as described in any of the preceding claims.

Definitions

[79] In this application, unless otherwise clear from context, (i) the term “a” may be understood to mean “at least one”; (ii) the term “or” may be understood to mean “and/or”; (iii) the terms “comprising” and “including” may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; and (iv) the terms “about” and “approximately” may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (v) where ranges are provided, endpoints are included.

[80] **Administration:** As used herein, the term “administration” refers to the administration of a composition to a subject. Exemplary routes of administration may include bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal. In many embodiments, provided technologies relate to LNP compositions (*e.g.*, comprising a BNT162 construct) that are administered by intramuscular injection. In some embodiments, LNP compositions are administered in a first administration followed by one or more administrations (*e.g.*, one or more booster administrations). In some embodiments, a period of time, *e.g.*, about 24, 48, 72, 96 hours or more, including for about 1, 2, 3, 4, or more weeks, separates each administration of an LNP compositions, *e.g.*, between a first administration and a second administration. In some embodiments, a period of time separating administrations is about 3 weeks (*e.g.*, about 21 days).

[81] **Antibody agent:** As used herein, the term “antibody agent” refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses any polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient

to confer specific binding. Exemplary antibody agents include, but are not limited to monoclonal antibodies or polyclonal antibodies. In some embodiments, an antibody agent may include one or more constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody agent may include one or more sequence elements that are humanized, primatized, chimeric, etc., as is known in the art. In many embodiments, the term “antibody agent” is used to refer to one or more of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, in some embodiments, an antibody agent utilized in accordance with the present invention is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi-specific antibodies (*e.g.*, Zybodies®, etc); antibody fragments such as Fab fragments, Fab’ fragments, F(ab’)2 fragments, Fd’ fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (*e.g.*, shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (*e.g.*, Probodies®); Small Modular ImmunoPharmaceuticals (“SMIPsTM”); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies® minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®, and KALBITOR®s. In some embodiments, an antibody may lack a covalent modification (*e.g.*, attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (*e.g.*, attachment of a glycan, a payload [*e.g.*, a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [*e.g.*, poly-ethylene glycol, etc.]. In many embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (*e.g.*, at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.

[82] Antigen: The term “antigen”, as used herein, refers to an agent or moiety that elicits an immune response; and/or that is specifically bound by an antibody or to a T cell receptor (*e.g.*, when presented by an MHC molecule). In some embodiments, an antigen elicits a humoral response (*e.g.*, which may involve or include production of antigen-specific antibodies); in some embodiments, an antigen elicits a cellular response (*e.g.*, which may involve or include T-cells whose receptors specifically interact with the antigen). In some embodiments, an antigen binds to an antibody and may or may not induce a particular physiological response in an organism. In general, an antigen may be or include any chemical entity such as, for example, a small molecule, a nucleic acid, a polypeptide, a carbohydrate, a lipid, a polymer (in some embodiments other than a biologic polymer [*e.g.*, other than a nucleic acid or amino acid

polymer), etc. In some embodiments, an antigen is or comprises a polypeptide or epitope thereof. In some embodiments, an antigen is a recombinant antigen.

[83] Associated: Two events or entities are “associated” with one another, as that term is used herein, if the presence, level, degree, type and/or form of one is correlated with that of the other. For example, a particular entity (*e.g.*, polypeptide, genetic signature, metabolite, microbe, etc) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and/or form correlates with incidence of and/or susceptibility to the disease, disorder, or condition (*e.g.*, across a relevant population). In some embodiments, two or more entities are physically “associated” with one another if they interact, directly or indirectly, so that they are and/or remain in physical proximity with one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.

[84] Combination therapy: As used herein, the term “combination therapy”, or reference to agents being administered “in combination”, refers to those situations in which a subject is simultaneously exposed to two or more therapeutic regimens (*e.g.*, two or more therapeutic agents or modalities). In some embodiments, the two or more regimens may be administered simultaneously; in some embodiments, such regimens may be administered sequentially (*e.g.*, all “doses” of a first regimen are administered prior to administration of any doses of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, “administration” of combination therapy may involve administration of one or more agent(s) or modality(ies) to a subject receiving the other agent(s) or modality(ies) in the combination. For clarity, combination therapy does not require that individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents, or active moieties thereof, may be administered together in a combination composition, or even in a combination compound (*e.g.*, as part of a single chemical complex or covalent entity).

[85] Expression: As used herein, “expression” of a nucleic acid sequence refers to one or more of the following events: (1) templated synthesis of a complementary nucleic acid (*e.g.*, production of an RNA template from a DNA sequence, for example by transcription); (2) processing of an RNA transcript (*e.g.*, by splicing, editing, 5’ cap formation, and/or 3’ end formation), *e.g.*, to produce an mRNA; (3) translation of an RNA (*e.g.*, an mRNA) into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein. Those skilled in the art will appreciate that, in some circumstances, “expression” may comprise multiple steps of templated synthesis (*e.g.*, reverse transcription of an RNA to generate a DNA strand, followed by transcription of such DNA strand and/or optionally synthesis of complementary DNA strand, for example so as to generate a double-stranded DNA).

[86] Formulation: A “formulation” is a composition prepared and/or provided as described herein. In many embodiments, the term “formulation” is used to refer to LNP compositions - *i.e.*, which comprise an RNA (especially a therapeutic RNA such as an mRNA) and lipids as recited herein.

[87] Fragment: A “fragment” of a material or entity as described herein has a structure that includes a discrete portion of the whole, but lacks one or more moieties found in the whole. In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole. In some embodiments, a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (*e.g.*, residues) as found in the whole polymer (*e.g.*, in contiguous association). In some embodiments, a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (*e.g.*, residues) found in the whole polymer. The whole material or entity may in some embodiments be referred to as the “parent” of the fragment.

[88] Functional: As used herein, the term “functional” is used to refer to a form or fragment of an entity that exhibits a particular property and/or activity. In some embodiments, the property and/or activity of such “functional” fragment is comparable to a its whole.

[89] **Identity:** As used herein, the term “identity” refers to overall relatedness between polymeric molecules, *e.g.*, between nucleic acid molecules (*e.g.*, DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “substantially identical” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. As will be understood by those skilled in the art, a variety of algorithms are available that permit comparison of sequences in order to determine their degree of homology, including by permitting gaps of designated length in one sequence relative to another when considering which residues “correspond” to one another in different sequences. Calculation of the percent identity between two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-corresponding sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. Representative algorithms and computer programs useful in determining the percent identity between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

[90] **Nucleic Acid:** As used herein, the term “nucleic acid,” in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from

context, in some embodiments, “nucleic acid” refers to individual nucleic acid residues (*e.g.*, nucleotides and/or nucleosides); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a “nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is, comprises, or consists of one or more “peptide nucleic acids”, which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present disclosure. Alternatively or additionally, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleosides (*e.g.*, adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleoside analogs (*e.g.*, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a nucleic acid comprises one or more modified sugars (*e.g.*, 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or a polypeptide; in some embodiments, such nucleotide sequence may be codon optimized for expression in a particular host (*e.g.*, in a recipient subject). In some embodiments, a nucleic acid that includes a coding sequence also includes one or more introns. In some embodiments, a nucleic acid that includes a coding sequence does not include introns. In some embodiments, nucleic acids are prepared by one or more of: isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in some embodiments *in vivo*; in some embodiments *in vitro*),

reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long.

[91] Specific: The term “specific”, when used herein with reference to an agent having an activity, is understood by those skilled in the art to mean that the agent discriminates between potential target entities or states. For example, in some embodiments, an agent is said to bind “specifically” to its target if it binds preferentially with that target in the presence of one or more competing alternative targets. In many embodiments, specific interaction is dependent upon the presence of a particular structural feature of the target entity (*e.g.*, an epitope, a cleft, a binding site). It is to be understood that specificity need not be absolute. In some embodiments, specificity may be evaluated relative to that of the binding agent for one or more other potential target entities (*e.g.*, competitors). In some embodiments, specificity is evaluated relative to that of a reference specific binding agent. In some embodiments specificity is evaluated relative to that of a reference non-specific binding agent. In some embodiments, the agent or entity does not detectably bind to the competing alternative target under conditions of binding to its target entity. In some embodiments, binding agent binds with higher on-rate, lower off-rate, increased affinity, decreased dissociation, and/or increased stability to its target entity as compared with the competing alternative target(s).

[92] Stable: The term “stable,” when applied to compositions herein, means that the compositions maintain one or more aspects of their physical structure and/or activity over a period of time under a designated set of conditions. In some embodiments, the period of time is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, weeks or more, including for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more; in some embodiments, the designated set of conditions is or comprises a temperature above a low temperature threshold. In some embodiments, a low temperature threshold is above about -80°C, -70°C, -50°C, -30°C, -20°C, 0°C, 2°C, 4°C, 8°C, 15°, 20°C, 30°C, 40°C or higher. In some embodiments, a composition is considered to be stable based on maintenance of colloidal content comprising lipid nanoparticles (LNPs). In some embodiments, a composition is considered to be stable based on maintenance of one or more of

LNP characteristics (including, *e.g.*, but not limited to its Z-average and/or polydispersity index (PDI)). In some embodiments, a composition is considered to be stable based on maintenance of nucleic acid integrity, degree (*e.g.*, percent) of nucleic acid encapsulation, and/or nucleic acid expressibility (*e.g.*, level of expression of an encoded polypeptide, as may be expressed for example as percent of a relevant reference level). In some embodiments, compositions described herein are considered stable if lipid nanoparticles within such compositions exhibit less than about 20 nm change in Z-average (including, *e.g.*, less than 19 nm, 18 nm, 17 nm, 16 nm, 15 nm, 14 nm, 13 nm, 12 nm, 11 nm, or less change in Z-average) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, compositions described herein are considered stable if lipid nanoparticles within such compositions exhibit less than about 10 nm change in Z-average (including, *e.g.*, less than 9 nm, 8 nm, 7 nm, 6 nm, 5 nm, 4 nm, 3 nm, 2 nm, 1 nm, 0.5 nm, or less change in Z-average) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, compositions described herein are considered stable if at least 50% (including *e.g.*, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more) nucleic acid encapsulation is maintained in such compositions over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, compositions described herein are considered stable if at least 50% (including *e.g.*, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more) of expression level of an encoded polypeptide is maintained over a certain period of time under a designated set of conditions compared to a relevant reference level.

[93] Subject: As used herein, the term “subject,” or “patient,” refers to any organism to which a provided composition is or may be administered, *e.g.*, for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical subjects include animals (*e.g.*, mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a subject is a human. In some embodiments, a subject is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a subject displays one or more symptoms of a disorder or condition. In some embodiments, a patient has been diagnosed with one or more disorders or conditions. In some embodiments, a subject is at risk for viral infection, or diseases or disorders associated with viral infection.

[94] **Substantially:** As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[95] **Therapeutically effective amount:** As used herein, the term “therapeutically effective amount” means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition. Those of ordinary skill in the art will appreciate that the term “therapeutically effective amount” does not in fact require successful treatment be achieved in a particular individual. Rather, a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be “refractory” to a “therapeutically effective amount.” To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount as measured in one or more specific tissues (*e.g.*, a tissue affected by the disease, disorder or condition) or fluids (*e.g.*, blood, saliva, serum, sweat, tears, urine, etc.). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount may be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.

[96] **Variant:** As used herein, in the context of molecules, *e.g.*, nucleic acids, proteins, or small molecules, the term “variant” refers to a molecule that shows significant structural identity with a reference molecule but differs structurally from the reference molecule, *e.g.*, in the presence or absence or in the level of one or more chemical moieties as compared to

the reference entity. In some embodiments, a variant also differs functionally from its reference molecule. In general, whether a particular molecule is properly considered to be a “variant” of a reference molecule is based on its degree of structural identity with the reference molecule. As will be appreciated by those skilled in the art, any biological or chemical reference molecule has certain characteristic structural elements. In some embodiments, a variant is a distinct molecule that shares one or more such characteristic structural elements but differs in at least one aspect from the reference molecule.

[97] To give but a few examples, a polypeptide may have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular structural motif and/or biological function; a nucleic acid may have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to one another in linear or three-dimensional space. In some embodiments, a variant polypeptide or nucleic acid may differ from a reference polypeptide or nucleic acid as a result of one or more differences in amino acid or nucleotide sequence and/or one or more differences in chemical moieties (*e.g.*, carbohydrates, lipids, phosphate groups) that are covalently components of the polypeptide or nucleic acid (*e.g.*, that are attached to the polypeptide or nucleic acid backbone). In some embodiments, a variant polypeptide or nucleic acid shows an overall sequence identity with a reference polypeptide or nucleic acid that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%. In some embodiments, a variant polypeptide or nucleic acid does not share at least one characteristic sequence element with a reference polypeptide or nucleic acid. In some embodiments, a reference polypeptide or nucleic acid has one or more biological activities. In some embodiments, a variant polypeptide or nucleic acid shares one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid lacks one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid shows a reduced level of one or more biological activities as compared to the reference polypeptide or nucleic acid. In some embodiments, a polypeptide or nucleic acid of interest is considered to be a “variant” of a reference polypeptide or nucleic acid if it has an amino acid or nucleotide sequence that is identical to that of the reference but for a small number of sequence alterations at particular positions.

[98] In some embodiments, typically, fewer than about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, or about 2% of the residues in a variant are substituted, inserted, or deleted, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 substituted residues as compared to a reference. In some embodiments, a variant polypeptide or nucleic acid comprises a very small number (*e.g.*, fewer than about 5, about 4, about 3, about 2, or about 1) number of substituted, inserted, or deleted, functional residues (*i.e.*, residues that participate in a particular biological activity) relative to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises not more than about 5, about 4, about 3, about 2, or about 1 addition or deletion, and, in some embodiments, comprises no additions or deletions, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly fewer than about 5, about 4, about 3, or about 2 additions or deletions as compared to the reference. In some embodiments, a reference polypeptide or nucleic acid is one found in nature. In some embodiments, a reference polypeptide or nucleic acid is a human polypeptide or nucleic acid.

[99] In some embodiments, a "variant" of an amino acid sequence (peptide, protein or polypeptide) may be or comprise an amino acid insertion variant, an amino acid addition (*i.e.*, terminal addition) variant, an amino acid deletion variant and/or an amino acid substitution variant.

[100] In some embodiments, a "variant" may be or comprise a mutants, splice variants, post-translationally modified variants, conformations, isoforms, allelic variants, species variants, and species homologs, in particular those which are naturally occurring. In some embodiments, the term "variant" includes, in particular, fragments of an amino acid sequence.

[101] In some embodiments, an amino acid insertion variant differs from a relevant reference polypeptide by insertion of a single, or of two or more, amino acid(s)

[102] In some embodiments, an amino acid addition variant may comprise an amino- and/or carboxy-terminal fusion (*i.e.*, extension) of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids.

[103] In some embodiments, an amino acid deletion variant is characterized by removal of one or more amino acids from a sequence, such as by removal of 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. In some embodiments, a deletion may be of one or more N-terminal amino acids, one or more C-terminal amino acids, one or more internal amino acids, or a combination thereof.

[104] In some embodiments, an amino acid substitution variant is characterized by at least one residue in a sequence being removed and another residue being inserted in its place. In some embodiments, a substitution is of a residue that is not highly conserved among related polypeptides that, *e.g.*, share one or more common motifs (*e.g.*, characteristic sequence elements) and/or functions. In some embodiments, a substitution is a “conservative” substitution in that the original residue and its replacement share one or more structural or functional attributes or properties (*e.g.*, identity and/or type of charge, or absence thereof; hydrophobicity or hydrophilicity of side chain, three dimensional bulk of side chain, linear or branched character of side chain, presence and/or type of heteroatom in side chain, etc). For example, in some embodiments, a substitution is conservative if it involves swapping residues within a family such as: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine), aromatic amino (phenylalanine, tryptophan, tyrosine). In some embodiments, conservative amino acid substitutions within the following groups are considered to be conservative substitutions: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[105] In some embodiments, a variant may refer a composition (*e.g.*, a buffer) that is identical to that of a reference composition but for a small number of component alterations, *e.g.*, presence or absence of certain components, or differences in concentrations of certain components.

[106] **Wild type:** As used herein, the term “wild-type” or “WT” or “native” has its art-understood meaning that refers to an entity having a structure and/or activity as found in nature in a “normal” (as contrasted with mutant, diseased, altered, etc) state or context. Those of ordinary skill in the art will appreciate that wild-type genes and polypeptides often exist in

multiple different forms (*e.g.*, alleles). In many embodiments, as used herein, “wild-type” may refer to an amino acid sequence that is found in nature, including allelic variations. A wild type amino acid sequence, peptide or protein has an amino acid sequence that has not been intentionally modified.

Brief Description of the Drawing

[107] FIG. 1A-1F shows an exemplary workflow for production of certain formulations of the present disclosure. In an exemplary first buffer system, particle forming lipids suspended in an organic solvent (*e.g.*, ethanol), and nucleic acids (*e.g.*, mRNA) suspended in an aqueous buffer (*e.g.*, citrate buffer), are admixed for a period of time (A) until nucleic acid containing lipid particles (*e.g.*, LNPs) are formed (B). In some embodiments, such nucleic acid containing lipid particles can be concentrated and/or transferred to a second buffer system which comprises a protectant (*e.g.*, sucrose, trehalose, etc.) (C). In some embodiments, lipid particles may then be stored or diluted for use, or dried (*e.g.*, by lyophilization or other drying method) (D), or frozen (E), or frozen after drying (F). In some embodiments, after drying, and/or freezing, lipid particles may be stored and/or thawed and/or diluted for use.

[108] FIG. 2A-2B shows certain exemplary formulations of the present disclosure (A) and certain exemplary cycles designed for formulations of the present disclosure (B).

[109] FIG. 3A-3B show exemplary colloidal stability data at various time points and temperatures for exemplary sucrose and trehalose formulations.

[110] FIG. 4A-4B show exemplary % encapsulation data at various time points and temperatures for exemplary sucrose and trehalose formulations.

[111] FIG. 5 shows an exemplary graph of water content for exemplary sucrose and trehalose formulations.

[112] FIG. 6A-6C show exemplary %expression data at various time points and temperatures for exemplary sucrose and trehalose formulations.

[113] FIG 7A-7D show exemplary data characterizing exemplary formulations of the present disclosure.

[114] FIG 8A-8B show exemplary colloidal stability data at various time points and temperatures for exemplary sucrose and trehalose formulations.

Detailed Description of Certain Embodiments

[115] The present disclosure provides, among other things, technologies relating to nucleic acid/ lipid nanoparticle (LNP) compositions, and particularly RNA/LNP compositions, such as therapeutic RNA/LNP compositions.

[116] Those skilled in the art are aware that one challenge often encountered with nucleic acid/LNP formulations, and particularly with RNA/LNP formulations, is that they require low temperature storage in order to maintain stability over time. Various reports described requirements for temperatures as low as -90°C; others mention temperatures below -80°C, -70°C, or -60°C. Temperatures as high as -20°C can often be tolerated for only a short amount of time (*e.g.*, 1, 2, 3, 4 to several days). Temperatures above freezing (*e.g.*, above about 0°C) and/or achieved by refrigeration (*e.g.*, within a range of about 1°C to about 8°C, or about 2°C to about 8°C, or about 2°C to about 6°C, or about 2°C to about 4°C) can often be tolerated only for hours to 1-2 days. Room temperature storage, and particularly long term room temperature storage (*e.g.*, for at least 1-2 days, and desirably for a 1, 2, 3, 4, 5, 6, weeks or more, including for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more) remains a goal.

[117] In some embodiments, the present disclosure provides nucleic acid/LNP formulations, and particularly RNA/LNP formulations, including particular components (*e.g.*, protectant and/or buffer components), and/or that are prepared according to particular processes, that differ from those of a reference formulation and that modify (*e.g.*, improve) one or more properties relative to that reference formulation. For example, in some embodiments, provided formulations show improvement(s) relative to a reference formulation that comprises the same lipids and nucleic acid, but that differs in protectant and/or buffer, and/or in certain production or processing steps.

[118] In some embodiments, provided technologies achieve preparation of compositions that are dry formulations, or that are amenable to (*e.g.*, stable upon) drying.

[119] In some embodiments, provided compositions can be effectively dried using a lyophilization cycle that is shorter than that required to comparably dry a reference formulation, *e.g.*, an otherwise identical formulation produced using a buffer that includes NaCl, *e.g.*, at a concentration within a range of about 5 to 10 mg/ml (*e.g.*, at about 6 mg/ml).

[120] In some embodiments, provided technologies achieve preparation of compositions that are frozen formulations, or that are amenable to (*e.g.*, stable to) freezing.

[121] In some embodiments, provided technologies achieve preparation of compositions that are stable to storage for at least a specified period of time at temperatures above a low temperature threshold. In some embodiments, the specified period of time may be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, weeks or more, including for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more. In some embodiments, the low temperature threshold may be about -80°C, -70°C, -50°C, -30°C, -20°C, 0°C, 2°C, 4°C, 8°C, 15°, 20°C, 30°C, 40°C or higher.

[122] In some embodiments, provided technologies are useful to deliver a nucleic acid payload to a subject, *e.g.*, by administration of LNPs that comprise the payload encapsulated by lipids as described herein; in some embodiments, the lipids comprise a cationic lipid, a neutral lipid, a polymer conjugated lipid, and a steroid. In some embodiments, LNPs for use in accordance with the present disclosure are formed from ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159), distearoylphosphatidylcholine (DSPC), and cholesterol, and are combined in relative mass ratios within the range of about 8:1:1.5:3 to about 9:1:2:3.5, respectively.

[123] In some embodiments, a nucleic acid payload is or comprises RNA and/or DNA; in some embodiments, a nucleic acid payload may encode a polypeptide product (*e.g.*, a functional polypeptide, for example that may complement or replace an activity that is needed or desired in a subject, or an immunomodulatory polypeptide, for example that may induce or enhance a desired immune response or activity in a subject).

[124] In some embodiments, provided compositions comprise LNPs (*i.e.*, nucleic acid/LNPs), a protectant, and a buffer. In some embodiments, the buffer does not include sodium ions. In some embodiments the buffer does not include a salt. In some embodiments, the buffer is a HEPES buffer, a Tris buffer, or a His buffer as described herein. In some

embodiments, the buffer is a phosphate buffered saline variant that is made without NaCl. In some embodiments, the buffer is a PBS variant that has a reduced level of sodium ions relative to a reference PBS that comprises NaCl, KCl, Na₂HPO₄, and KH₂PO₄; in some embodiments, such reference PBS is a “standard” PBS that comprises (or consists of) 137 mM NaCl (*i.e.*, 8 g/L NaCl), 2.7 mM KCl (*i.e.*, 0.2 g/L KCl), 10 mM Na₂HPO₄ (*i.e.*, 1.44 g/L Na₂HPO₄), and 1.8 mM KH₂PO₄ (*i.e.*, 0.24 g/L KH₂PO₄). In some embodiments, a buffer utilized in accordance with the present disclosure is a PBS variant that has a lower level of sodium ions than found in such reference standard PBS.

[125] In some embodiments, a protectant utilized in accordance with the present disclosure comprises a disaccharide. In some embodiments, a protectant utilized in accordance with the present disclosure is or comprises sucrose and/or trehalose.

[126] In some embodiments, a protectant is or comprises mannitol. In some embodiments, a protectant is substantially free of mannitol.

[127] In some embodiment, the present disclosure provides technologies by which an LNP preparation (*i.e.*, a nucleic acid/LNP preparation, and particularly an RNA/LNP preparation) is generated and then stored, frozen, and/or dried. In some embodiments, a frozen composition is stored. In some embodiments, a dried composition is stored.

[128] In some embodiments, a dried composition is resuspended and then administered to a subject. In some embodiments, a frozen composition is thawed and then administered to a subject. In some embodiments, a composition may be subjected to one or more rounds of freezing and thawing, to one or more rounds of drying and resuspending, and/or to one or more rounds of freezing and thawing and also one or more rounds of drying and resuspending.

[129] In some embodiments, a composition is diluted prior to being administered.

Nucleic Acid Payloads

[130] The present disclosure provides, among other things, LNP compositions that comprise a nucleic acid payload (*i.e.*, nucleic acid-LNP compositions).

[131] In some embodiments, a nucleic acid payload may comprise or encode a functional nucleic acid such as, for example, an antisense oligonucleotide (*e.g.*, that may promote RNaseH degradation and/or exon skipping, etc), a ribozyme, a gRNA, a miRNA, and shRNA, an siRNA, etc.

[132] In some embodiments, a nucleic acid payload may encode one or more polypeptides (*e.g.*, as described further hereinbelow).

[133] In some embodiments, a nucleic acid payload utilized in accordance with the present disclosure is or comprises one or more natural nucleic acid residues, or entirely natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more non-natural nucleic acid residues (*i.e.*, one or more nucleic acid analogs), or is entirely non-natural nucleic acid residues.

[134] In some embodiments, a nucleic acid payload utilized in accordance with the present disclosure includes one or more internucleotide linkages that is not a phosphodiester bond. For example, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid includes some phosphodiester bonds and some non-phosphodiester bonds.

[135] In some embodiments, a nucleic acid is or comprises one or more natural nucleosides (*e.g.*, adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleoside analogs (*e.g.*, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof).

[136] In some embodiments, a nucleic acid comprises one or more modified sugars (*e.g.*, 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids.

[137] In some embodiments, a nucleic acid is or comprises one or more peptide nucleic acids.

[138] In some embodiments of the present disclosure, nucleic acids are modified with modifications described herein that impart one or more desirable characteristics, *e.g.*, enhanced stability, potency, etc.

RNA Payloads

[139] In some embodiments, a nucleic acid payload for use in accordance with the present disclosure is an RNA (*e.g.*, an mRNA). In some embodiments, an RNA is produced by templated synthesis. In some embodiments, an RNA is produced by enzymatic synthesis, *e.g.*, by *in vitro* transcription (*e.g.*, from a DNA template). In some embodiments, an RNA is produced by chemical synthesis.

[140] In some embodiments, an RNA is a “replicon RNA” or simply a “replicon,” in particular “self-replicating RNA” or “self-amplifying RNA.” In some embodiments, a replicon or self-replicating RNA is derived from or comprises elements derived from a ssRNA virus, in particular a positive-stranded ssRNA virus such as an alphavirus. Alphaviruses are typical representatives of positive-stranded RNA viruses. Alphaviruses replicate in the cytoplasm of infected cells (for review of the alphaviral life cycle see José *et al.*, Future Microbiol., 2009, vol. 4, pp. 837–856). The total genome length of many alphaviruses typically ranges between 11,000 and 12,000 nucleotides, and the genomic RNA typically has a 5'-cap, and a 3' poly(A) tail. The genome of alphaviruses encodes non-structural proteins (involved in transcription, modification and replication of viral RNA and in protein modification) and structural proteins (forming the virus particle). There are typically two open reading frames (ORFs) in the genome. The four non-structural proteins (nsP1–nsP4) are typically encoded together by a first ORF beginning near the 5' terminus of the genome, while alphavirus structural proteins are encoded together by a second ORF which is found downstream of the first ORF and extends near the 3' terminus of the genome. Typically, the first ORF is larger than the second ORF, the ratio being roughly 2:1. In cells infected by an alphavirus, only the nucleic acid sequence encoding non-structural proteins is translated from the genomic RNA, while the genetic information encoding structural proteins is translatable from a subgenomic transcript, which is an RNA molecule that resembles eukaryotic messenger RNA (mRNA; Gould *et al.*, 2010, Antiviral Res., vol. 87 pp. 111–124).

Following infection, *i.e.* at early stages of the viral life cycle, the (+) stranded genomic RNA directly acts like a messenger RNA for the translation of the open reading frame encoding the non-structural poly-protein (nsP1234). Alphavirus-derived vectors have been proposed for delivery of foreign genetic information into target cells or target organisms. In simple approaches, the open reading frame encoding alphaviral structural proteins is replaced by an open reading frame encoding a protein of interest. Alphavirus-based trans-replication systems rely on alphavirus nucleotide sequence elements on two separate nucleic acid molecules: one nucleic acid molecule encodes a viral replicase, and the other nucleic acid molecule is capable of being replicated by said replicase in trans (hence the designation trans-replication system). Trans-replication requires the presence of both these nucleic acid molecules in a given host cell. The nucleic acid molecule capable of being replicated by the replicase in trans must comprise certain alphaviral sequence elements to allow recognition and RNA synthesis by the alphaviral replicase.

[141] In some embodiments, an RNA for use in accordance with the present disclosure may include one or more modified nucleosides. In some embodiments, the present disclosure provides RNA comprising a modified nucleoside in place of at least one uridine. In some embodiments, modified nucleosides are in place of all uridines in an RNA. In some embodiments, modified nucleosides replacing at least one uridine include, but are not limited to, pseudouridine (ψ), N1-methyl-pseudouridine (m1 ψ), and 5-methyl-uridine (m5U), or combinations thereof. In some embodiments, a modified nucleoside replacing at least one, *e.g.*, all, uridine in an RNA may be any one or more of: 3-methyl-uridine (m³U), 5-methoxy-uridine (mo⁵U), 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s²U), 4-thio-uridine (s⁴U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho⁵U), 5-aminoallyl-uridine, 5-halo-uridine (*e.g.*, 5-iodo-uridine or 5-bromo-uridine), uridine 5-oxyacetic acid (cmo⁵U), uridine 5-oxyacetic acid methyl ester (mcmo⁵U), 5-carboxymethyl-uridine (cm⁵U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm⁵U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm⁵U), 5-methoxycarbonylmethyl-uridine (mcm⁵U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm⁵s²U), 5-aminomethyl-2-thio-uridine (nm⁵s²U), 5-methylaminomethyl-uridine (mnm⁵U), 1-ethyl-pseudouridine, 5-methylaminomethyl-2-thio-uridine (mnm⁵s²U), 5-methylaminomethyl-2-seleno-uridine (mnm⁵se²U), 5-carbamoylmethyl-uridine (ncm⁵U), 5-carboxymethylaminomethyl-uridine

(cmnm⁵U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm⁵s²U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (tm⁵U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (tm⁵s²U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-2-thio-uridine (m⁵s²U), 1-methyl-4-thio-pseudouridine (m¹s⁴ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m³ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m⁵D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp³U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp³ψ), 5-(isopentenylaminomethyl)uridine (inm⁵U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm⁵s²U), α-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m⁵Um), 2'-O-methyl-pseudouridine (ψm), 2-thio-2'-O-methyl-uridine (s²Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm⁵Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm⁵Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm⁵Um), 3,2'-O-dimethyl-uridine (m³Um), 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm⁵Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, 5-[3-(1-E-propenylamino)uridine, or any other modified uridine known in the art.

[142] In some embodiments, an RNA for use in accordance with the present disclosure comprises a 5'-cap. In some embodiments, an RNA of the present disclosure does not have uncapped 5'-triphosphates. In some embodiments, an RNA may be modified by a 5'-cap analog. The term "5'-cap" refers to a structure found on the 5'-end of an mRNA molecule and generally consists of a guanosine nucleotide connected to the mRNA via a 5'- to 5'-triphosphate linkage. In some embodiments, such a guanosine is methylated at the 7-position. Providing an RNA with a 5'-cap, or 5'-cap analog, may be achieved by in vitro transcription, in which a 5'-cap, or 5'-cap analog, is co-transcriptionally expressed into an RNA strand, or may be attached to RNA post-transcriptionally using capping enzymes. In some embodiments, a 5'-cap for RNA is m₂^{7,3'}-^oGppp(m₁^{2'-o})ApG (also sometimes referred to as m₂^{7,3'}^oG(5')ppp(5')m^{2'-o}ApG. In some embodiments, a 5'-cap for RNA of the present disclosure is an analog anti-reverse cap (ARCA Cap (m₂^{7,3'}^oG(5')ppp(5')G)). In some embodiments, a 5'-cap is Beta-S-ARCA

(m₂^{7,2'-O}G(5')ppSp(5')G). In some embodiments, a 5'-cap is beta-S-ARCA(D1) (m₂^{7,2'-O}GppSpG), or m₂^{7,3'-O}Gppp(m₁^{2'-O})ApG.

[143] In some embodiments, an RNA for use in accordance with the present disclosure comprises a 5'-UTR and/or a 3'-UTR. The term "untranslated region" or "UTR" may relate to a region in a DNA molecule which is transcribed but is not translated into an amino acid sequence, or to the corresponding region in an RNA molecule, such as an mRNA molecule. An UTR can be present 5' (upstream) of an open reading frame (5'-UTR) and/or 3' (downstream) of an open reading frame (3'-UTR). A 5'-UTR, if present, is located at the 5' end, upstream of the start codon of a protein-encoding region. A 5'-UTR is downstream of the 5'-cap (if present), *e.g.* directly adjacent to the 5'-cap. A 3'-UTR, if present, is located at the 3' end, downstream of the termination codon of a protein-encoding region, but the term "3'-UTR" preferably does not include a poly(A) sequence. Thus, a 3'-UTR is upstream of a poly(A) sequence (if present), *e.g.* directly adjacent to a poly(A) sequence.

[144] As used herein, the term "poly(A) sequence" or "poly-A tail" refers to an uninterrupted or interrupted sequence of adenylate residues which is typically located at the 3'-end of an RNA molecule. Poly(A) sequences are known to those of skill in the art and may follow the 3'-UTR in the RNAs described herein. An uninterrupted poly(A) sequence is characterized by consecutive adenylate residues. In nature, an uninterrupted poly(A) sequence is typical. RNAs disclosed herein can have a poly(A) sequence attached to the free 3'-end of the RNA by a template-independent RNA polymerase after transcription or a poly(A) sequence encoded by DNA and transcribed by a template-dependent RNA polymerase. It has been demonstrated that a poly(A) sequence of about 120 A nucleotides has a beneficial influence on the levels of RNA in transfected eukaryotic cells, as well as on the levels of protein that is translated from an open reading frame that is present upstream (5') of the poly(A) sequence (Holtkamp *et al.*, 2006, Blood, vol. 108, pp. 4009-4017).

[145] In different embodiments, a poly(A) sequence may be of different lengths. In some embodiments, a poly(A) sequence comprises, essentially consists of, or consists of at least 20, at least 30, at least 40, at least 80, or at least 100 A nucleotides. In some embodiments, a poly(A) sequence comprises, essentially consists of, or consists of up to 500, up to 400, up to 300, up to 200, or up to 150 A nucleotides. In some embodiments, a poly(A) sequence

comprises about 120 A nucleotides. In this context, "essentially consists of" means that most nucleotides in the poly(A) sequence, typically at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by number of nucleotides in the poly(A) sequence are A nucleotides, but permits that remaining nucleotides are nucleotides other than A nucleotides, such as U nucleotides (uridylate), G nucleotides (guanylate), or C nucleotides (cytidylate). In this context, "consists of" means that all nucleotides in the poly(A) sequence, *i.e.*, 100% by number of nucleotides in the poly(A) sequence, are A nucleotides. The term "A nucleotide" or "A" refers to adenylate.

[146] In some embodiments, a poly(A) sequence is attached during RNA transcription, *e.g.*, during preparation of *in vitro* transcribed RNA, based on a DNA template comprising repeated dT nucleotides (deoxythymidylate) in the strand complementary to the coding strand. The DNA sequence encoding a poly(A) sequence (coding strand) is referred to as poly(A) cassette. In some embodiments, the poly(A) cassette present in the coding strand of DNA essentially consists of dA nucleotides, but is interrupted by a random sequence of the four nucleotides (dA, dC, dG, and dT). Such random sequence may be 5 to 50, 10 to 30, or 10 to 20 nucleotides in length. Such a cassette is disclosed in WO 2016/005324 A1, hereby incorporated by reference. Any poly(A) cassette disclosed in WO 2016/005324 A1 may be used in the present disclosure. A poly(A) cassette that essentially consists of dA nucleotides, but is interrupted by a random sequence having an equal distribution of the four nucleotides (dA, dC, dG, dT) and having a length of *e.g.*, 5 to 50 nucleotides shows, on DNA level, constant propagation of plasmid DNA in *E. coli* and is still associated, on RNA level, with the beneficial properties with respect to supporting RNA stability and translational efficiency is encompassed. Consequently, in some embodiments, a poly(A) sequence contained in an RNA molecule described herein essentially consists of A nucleotides, but is interrupted by a random sequence of the four nucleotides (A, C, G, U). Such random sequence may be 5 to 50, 10 to 30, or 10 to 20 nucleotides in length.

[147] In some embodiments, no nucleotides other than A nucleotides flank a poly(A) sequence at its 3'-end, *i.e.*, the poly(A) sequence is not masked or followed at its 3'-end by a nucleotide other than A.

[148] In some embodiments, a poly(A) sequence may comprise at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, a poly(A) sequence may essentially consist of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, a poly(A) sequence may consist of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, a poly(A) sequence comprises at least 100 nucleotides. In some embodiments, a poly(A) sequence comprises about 150 nucleotides. In some embodiments, a poly(A) sequence comprises about 120 nucleotides.

[149] In some embodiments, a nucleic acid for use in accordance with the present disclosure are codon-optimized and/or guanosine/cytosine (G/C) content is increased compared to wild type coding sequence. This also includes embodiments, wherein one or more sequence regions of a coding sequence are codon-optimized and/or increased in G/C content compared to corresponding sequence regions of a wild type coding sequence. In some embodiments, codon-optimization and/or increase in G/C content does not change the sequence of a encoded amino acid sequence.

G/C Content

[150] In some embodiments of the disclosure, the G/C content of a coding region (*e.g.*, of an RNA) described herein is increased compared to G/C content of a corresponding WT coding sequence, wherein an encoded amino acid sequence is not modified compared to such corresponding WT sequence. In some embodiments, an increase in G/C content may increase translation efficiency of an RNA including such increased G/C content. Those skilled in the art are aware that sequences having an increased G/C content have been reported to be more stable than sequences having an increased adenosine/uracil (A/U) content.

[151] In respect to the fact that several codons code for one and the same amino acid (so-called degeneration of the genetic code), the most favorable codons for stability can be determined (so-called alternative codon usage). Depending on desired amino acid to be encoded by an RNA, there are various possibilities for modification of said RNA sequence, compared to its wild type sequence. In particular, codons which contain A and/or U nucleotides can be

modified by substituting these codons by other codons, which code for the same amino acids but contain no A and/or U, or contain a lower content of A and/or U nucleotides.

[152] In various embodiments, the G/C content of a coding region of an RNA utilized in accordance with the present disclosure is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 55%, or even more compared to G/C content of a coding region of a wild type RNA.

Encoded Polypeptides

[153] As noted herein, in some embodiments, a nucleic acid payload (*e.g.*, an RNA) encodes a polypeptide.

[154] In some embodiments, an encoded polypeptide is or comprises comprises an antibody agent, or a polypeptide chain or functional fragment thereof. In some embodiments, an antibody agent is or comprises a single chain antibody agent such as an scFC, a camelid antibody, etc.

[155] In some embodiments, an encoded polypeptide is or comprises a cytokine, a growth factor, an apoptotic factor, a differentiation-inducing factor, a cell-surface receptor, a ligand, a hormone, etc.

[156] In some embodiments, an encoded polypeptide is an enzyme.

[157] In some embodiments, an encoded polypeptide is a regulatory polypeptide such as a transcription factor, a chaperone, etc.

[158] In some embodiments, an encoded polypeptide is or comprises a polypeptide whose expression replaces or activates an activity that is reduced or lacking in a subject.

[159] In some embodiments, an encoded polypeptide is or comprises a polypeptide that induces and/or enhances an immune response in a subject. In some embodiments, an encoded polypeptide is or comprises at least one epitope that is specifically bound by an immunoglobulin agent (*e.g.*, an antibody and/or a T cell receptor, etc).

[160] In some embodiments, an encoded polypeptide is or comprises an antigen (or epitope thereof). In some embodiments, an antigen may be characteristic of a particular disease, disorder or condition. For example, an antigen may be or comprise a tumor antigen (*e.g.*, a

neoantigen) and/or an antigen associated with an infectious agent (*e.g.*, a virus or microbe such as a bacterium or fungus). In some embodiments, an antigen associated with an infectious agent may be an antigen that is displayed on a surface of such infectious agent and/or may mediate infection by such agent (*e.g.*, by participating in interaction with a receptor on recipient cells).

[161] In some embodiments, an antigen may be or comprise a viral antigen, *e.g.* an antigen associated with a virus selected from the group consisting of: adenovirus, cytomegalovirus, herpes virus, human papillomavirus, measles virus, rubella virus, coronavirus, respiratory syncytial virus, influenza virus, and mumps virus. In some embodiments, an antigen may be or comprise a viral antigen associated with a virus selected from a Class I, Class II, Class III, Class IV, Class V, Class VI, or Class VII virus, based on the Baltimore classification system. In some embodiments, an antigen may be or comprise a viral antigen associated with a virus selected from viral family Adenoviridae, Papovaviridae, Parvoviridae, Herpesviridae, Poxviridae, Anelloviridae, Pleolipoviridae, Reoviridae, Picornaviridae, Caliciviridae, Togaviridae, Arenaviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Bunyaviridae, Rhabdoviridae, Filoviridae, Coronaviridae, Astroviridae, Bornaviridae, Arteriviridae, and Hepeviridae. In some particular embodiments, a viral antigen may be a coronaviral antigen.

[162] In some particular embodiments, a viral antigen may be an antigen derived from a SARS-CoV-2 protein sequence (*e.g.*, may be or comprise such sequence, a fragment thereof, or a variant of either). In some embodiments, the present disclosure provides a polypeptide with an antigen sequence derived from a SARS-CoV-2 S protein sequence. In some embodiments, a polypeptide is or comprises an antigen sequence derived from a Receptor Binding Domain (RBD) of SARS-COV-2 S protein sequence.

[163] In some embodiments, a payload as described herein is associated, or encapsulated within the lipid portion of a LNP. In some embodiments, a payload as described herein is associated within a lipid portion of the LNP. In some embodiments, a payload as described here is encapsulated within a lipid portion of the LNP. In some embodiments, association with (*e.g.*, encapsulation within) such lipid portion reduces susceptibility of a payload degradation (*e.g.*, enzymatic degradation), for example over a given period of time and/or under particular conditions.

[164] According to some embodiments, a signal peptide is fused, either directly or through a linker, to an antigenic peptide or protein. In some embodiments, signal peptides for use in accordance with the present disclosure are sequences, which typically exhibit a length of about 15 to about 30 amino acids and may be located at an N-terminus of an antigenic peptide or protein, without being limited thereto. In some embodiments, signal peptides as defined herein allow the transport of an antigenic peptide or protein as encoded by an RNA into a defined cellular compartment, *e.g.*, a cell surface, endoplasmic reticulum (ER) or endosomal-lysosomal compartment.

[165] A signal peptide sequence as may be utilized in accordance with certain embodiments of the present disclosure may be or comprise, for example, a signal peptide sequence of an immunoglobulin, *e.g.*, a signal peptide sequence of an immunoglobulin heavy chain variable region, wherein an immunoglobulin may be human immunoglobulin.

[166] Signal peptides for use in accordance with the present disclosure are used in order to promote secretion of an encoded antigenic peptide or protein. In some embodiments, a signal peptide as defined herein is fused to an encoded antigenic peptide or protein as defined herein. In some embodiments, an RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a signal peptide, where said signal peptide are fused to an antigenic peptide or protein, *e.g.*, to an N-terminus of an antigenic peptide or protein as described herein.

[167] In some embodiments, a trimerization domain is fused, either directly or through a linker, *e.g.*, a glycine/serine linker, to an antigenic peptide or protein. In some embodiments, a trimerization domain is fused, either directly or through a linker, *e.g.*, a glycine/serine linker, to an antigenic peptide or protein, which is also fused to a signal peptide as described herein.

[168] In some embodiments, such trimerization domains are located at a C-terminus of an antigenic peptide or protein, without being limited thereto. Trimerization domains as defined herein allow trimerization of an antigenic peptide or protein as encoded by RNA. Examples of trimerization domains as defined herein include, without being limited thereto, foldon, a natural trimerization domain of T4 fibrin. A C-terminal domain of T4 fibrin (foldon) is obligatory for the formation of a fibrin trimer structure and can be used as an artificial trimerization domain.

[169] In some embodiments, a transmembrane domain is fused, either directly or through a linker, *e.g.*, a glycine/serine linker, to an antigenic peptide or protein. Accordingly, in some embodiments, a transmembrane domain is fused, either directly or through a linker, *e.g.*, a glycine/serine linker, to an antigenic peptide or protein, which is also fused to a signal peptide and/or trimerization domain as described herein).

[170] In many embodiments, a transmembrane domains utilized in accordance with the present disclosure is located at a C-terminus of an antigenic peptide or protein, without being limited thereto. In some embodiments, such transmembrane domains are located at a C-terminus of a trimerization domain, if present, without being limited thereto. In some embodiments, a trimerization domain is present between a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, *i.e.*, an antigenic peptide or protein, and a transmembrane domain.

[171] In some embodiments, a transmembrane domain utilized in accordance with the present disclosure may allow the anchoring into a cellular membrane of an antigenic peptide or protein as encoded by an RNA.

Coronavirus

[172] Coronaviruses are enveloped, positive-sense, single-stranded RNA ((+) ssRNA) viruses. They have the largest genomes (26–32 kb) among known RNA viruses and are phylogenetically divided into four genera (α , β , γ , and δ), with betacoronaviruses further subdivided into four lineages (A, B, C, and D). Coronaviruses infect a wide range of avian and mammalian species, including humans. Some human coronaviruses generally cause mild respiratory diseases, although severity can be greater in infants, the elderly, and the immunocompromised. Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), belonging to betacoronavirus lineages C and B, respectively, are highly pathogenic. Both viruses emerged into the human population from animal reservoirs within the last 15 years and caused outbreaks with high case-fatality rates. The outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes atypical pneumonia (coronavirus disease 2019; COVID-19) has raged in China since mid-December 2019, and has developed to be a public health emergency of international concern. SARS-CoV-2 (MN908947.3) belongs to betacoronavirus lineage B. It has at least 70% sequence similarity to SARS-CoV.

[173] In general, coronaviruses have four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S). The E and M proteins have important functions in the viral assembly, and the N protein is necessary for viral RNA synthesis. The critical glycoprotein S is responsible for virus binding and entry into target cells. The S protein is synthesized as a single-chain inactive precursor that is cleaved by furin-like host proteases in the producing cell into two noncovalently associated subunits, S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which recognizes the host-cell receptor. The S2 subunit contains the fusion peptide, two heptad repeats, and a transmembrane domain, all of which are required to mediate fusion of the viral and host-cell membranes by undergoing a large conformational rearrangement. The S1 and S2 subunits trimerize to form a large prefusion spike.

[174] The S precursor protein of SARS-CoV-2 can be proteolytically cleaved into S1 (685 aa) and S2 (588 aa) subunits. The S1 subunit consists of the receptor-binding domain (RBD), which mediates virus entry into sensitive cells through the host angiotensin-converting enzyme 2 (ACE2) receptor.

[175] SARS-CoV-2 coronavirus full length spike (S) protein consist of 1273 amino acids (see SEQ ID NO: 1).

[176] In some embodiments, the present disclosure utilizes RNA encoding a peptide or protein comprising at least an epitope SARS-CoV-2 S protein for inducing an immune response against coronavirus S protein, in particular SARS-CoV-2 S protein in a subject. In some embodiments, RNA of the present disclosure encodes an amino acid sequence comprising SARS-CoV-2 S protein, an immunogenic fragment of SARS-CoV-2 S protein, or immunogenic variants thereof.

[177] In some embodiments, full length spike (S) protein according to SEQ ID NO: 1 is modified in such a way that the prototypical prefusion conformation is stabilized. Stabilization of the prefusion conformation may be obtained by introducing two consecutive proline substitutions at AS residues 986 and 987 in the full length spike protein. Specifically, spike (S) protein stabilized protein variants are obtained in a way that the amino acid residue at position 986 is exchanged to proline and the amino acid residue at position 987 is also exchanged to proline. In some embodiments, a SARS-CoV-2 S protein variant comprises the amino acid sequence shown in SEQ ID NO: 7.

[178] In some embodiments, the vaccine antigen described herein comprises, consists essentially of or consists of a spike protein (S) of SARS-CoV-2, a variant thereof, or a fragment thereof.

[179] In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7. In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[180] In some embodiments, a vaccine antigen comprises, consists essentially of, or consists of SARS-CoV-2 spike S1 fragment (S1) (the S1 subunit of a spike protein (S) of SARS-CoV-2), a variant thereof, or a fragment thereof.

[181] In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an amino acid

sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1. In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1.

[182] In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1. In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1.

[183] In some embodiments, a vaccine antigen comprises, consists essentially of, or consists of receptor binding domain (RBD) of the S1 subunit of a spike protein (S) of SARS-CoV-2, a variant thereof, or a fragment thereof. The amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, a variant thereof, or a fragment thereof is also referred to herein as "RBD" or "RBD domain".

[184] In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1. In some embodiments, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9; and/or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[185] According to some embodiments, a signal peptide is fused, either directly or through a linker, to a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, *i.e.*, an antigenic peptide or protein. Accordingly, in some embodiments, a signal peptide is fused to the above described amino acid sequences derived from SARS-CoV-2 S protein or immunogenic fragments thereof (antigenic peptides or proteins) comprised by vaccine antigens described herein.

[186] In some embodiments, signal peptides for use in accordance with the present disclosure are sequences, which typically exhibit a length of about 15 to about 30 amino acids and are located at an N-terminus of an antigenic peptide or protein, without being limited thereto. In some embodiments, signal peptides as defined herein allow the transport of an antigenic peptide or protein as encoded by an RNA into a defined cellular compartment, *e.g.*, a cell surface, endoplasmic reticulum (ER) or an endosomal-lysosomal compartment. In some embodiments, a signal peptide sequence as defined herein includes, without being limited thereto, a signal peptide sequence of SARS-CoV-2 S protein, in particular a sequence comprising

the amino acid sequence of amino acids 1 to 16 or 1 to 19 of SEQ ID NO: 1 or a functional variant thereof.

[187] A signal peptide sequence as may be utilized in accordance with certain embodiments of the present disclosure may be or comprise, for example, a signal peptide sequence of an immunoglobulin, *e.g.*, a signal peptide sequence of an immunoglobulin heavy chain variable region, wherein an immunoglobulin may be human immunoglobulin.

[188] Signal peptides for use in accordance with the present disclosure are used in order to promote secretion of an encoded antigenic peptide or protein. In some embodiments, a signal peptide as defined herein is fused to an encoded antigenic peptide or protein as defined herein. In some embodiments, an RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a signal peptide, where said signal peptide is fused to an antigenic peptide or protein, *e.g.*, to an N-terminus of an antigenic peptide or protein as described herein.

[189] In some embodiments, a trimerization domain is fused, either directly or through a linker, *e.g.*, a glycine/serine linker, to a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, *i.e.*, an antigenic peptide or protein. Accordingly, in some embodiments, a trimerization domain is fused to the above described amino acid sequences derived from SARS-CoV-2 S protein or immunogenic fragments thereof (antigenic peptides or proteins) comprised by vaccine antigens described above (which may optionally be fused to a signal peptide as described herein).

[190] In some embodiments, such trimerization domains are located at a C-terminus of an antigenic peptide or protein, without being limited thereto. Trimerization domains as defined herein allow trimerization of an antigenic peptide or protein as encoded by RNA. Examples of trimerization domains as defined herein include, without being limited thereto, foldon, a natural trimerization domain of T4 fibrin. A C-terminal domain of T4 fibrin (foldon) is obligatory for the formation of a fibrin trimer structure and can be used as an artificial trimerization domain.

[191] In some embodiments, a transmembrane domain is fused, either directly or through a linker, *e.g.*, a glycine/serine linker, to a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, *i.e.*, an antigenic peptide or protein. Accordingly, in some embodiments, a transmembrane domain is fused to the above described amino acid sequences derived from

SARS-CoV-2 S protein or immunogenic fragments thereof (antigenic peptides or proteins) comprised by vaccine antigens described above (which may optionally be fused to a signal peptide and/or trimerization domain as described herein).

[192] In many embodiments, a transmembrane domains utilized in accordance with the present disclosure is located at a C-terminus of an antigenic peptide or protein, without being limited thereto. In some embodiments, such transmembrane domains are located at a C-terminus of a trimerization domain, if present, without being limited thereto. In some embodiments, a trimerization domain is present between a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, *i.e.*, an antigenic peptide or protein, and a transmembrane domain.

[193] In some embodiments, a transmembrane domain utilized in accordance with the present disclosure may allow the anchoring into a cellular membrane of an antigenic peptide or protein as encoded by an RNA.

[194] In some embodiments, a transmembrane domain sequence as defined herein includes, without being limited thereto, a transmembrane domain sequence of SARS-CoV-2 S protein, in particular a sequence comprising the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1, or a functional variant thereof.

[195] As presented herein, trimerization domains are used in order to promote trimerization of an encoded antigenic peptide or protein. In some embodiments, a trimerization domain as defined herein is fused to an antigenic peptide or protein as defined herein. In some embodiments, an RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a trimerization domain as defined herein, said trimerization domain being fused to an antigenic peptide or protein, *e.g.*, to a C-terminus of an antigenic peptide or protein.

[196] In some embodiments, vaccine antigens described herein comprise a contiguous sequence of SARS-CoV-2 coronavirus spike (S) protein that consists of or essentially consists of the above described amino acid sequences derived from SARS-CoV-2 S protein or immunogenic fragments thereof (antigenic peptides or proteins) comprised by vaccine antigens described herein. In some embodiments, vaccine antigens described herein comprise a contiguous sequence of SARS-CoV-2 coronavirus spike (S) protein of no more than 220 amino acids, 215 amino acids, 210 amino acids, or 205 amino acids.

[197] In some embodiments, an RNA encoding a vaccine antigen is nucleoside modified messenger RNA (modRNA) described herein as BNT162b2 (RBP020.1 or RBP020.2). In some embodiments, an RNA encoding a vaccine antigen is nucleoside modified messenger RNA (modRNA) described herein as RBP020.2.

[198] As described herein, different embodiments of nucleoside modified messenger RNA (modRNA) are as follows:

BNT162b2; RBP020.1 (SEQ ID NO: 19; SEQ ID NO: 7)

Structure: m27,3'-OGppp(m12'-O)ApG)-hAg-Kozak-S1S2-PP-FI-A30L70

Encoded antigen: Viral spike protein (S1S2 protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)

BNT162b2; RBP020.2 (SEQ ID NO: 20; SEQ ID NO: 7)

Structure: m27,3'-OGppp(m12'-O)ApG)-hAg-Kozak-S1S2-PP-FI-A30L70

Encoded antigen: Viral spike protein (S1S2 protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)

[199] Nucleotide Sequence of RBP020.1

Nucleotide sequence is shown with individual sequence elements as indicated in bold letters. In addition, the sequence of the translated protein is shown in italic letters below the coding nucleotide sequence (* = stop codon).

10	20	30	40	50	53
AGAAUAAACU AGUAUUCUUC UGGUCCCCAC AGACUCAGAG AGAACCCGCC ACC					
hAg-Kozak					
63	73	83	93	103	113
AUGUUUGUGU UUCUUGUGCU GCUGCCUCUU GUGUCUUCUC AGUGUGUGAA UUUGACAACA					
<i>M F V F L V L L P L V S S Q C V N L T T</i>					
S protein					
123	133	143	153	163	173

AGAACACAGC UGCCACCAGC UUAUACAAU UCUUUUACCA GAGGAGUGUA UUAUCCUGAU

R T Q L P P A Y T N S F T R G V Y Y P D

S protein

183 193 203 213 223 233

AAAGUGUUUA GAUCUUCUGU GCUGCACAGC ACACAGGACC UGUUUCUGCC AUUUUUUAGC

K V F R S S V L H S T Q D L F L P F F S

S protein

243 253 263 273 283 293

AAUGUGACAU GGUUUC AUGC AAUUC AUGUG UCUGGAACAA AUGGAACAAA AAGAUUUGAU

N V T W F H A I H V S G T N G T K R F D

S protein

303 313 323 333 343 353

AAUCCUGUGC UGCCUUUUAA UGAUGGAGUG UAUUUUGCUU CAACAGAAAA GUCAAAUAUU

N P V L P F N D G V Y F A S T E K S N I

S protein

363 373 383 393 403 413

AUUAGAGGAU GGAUUUUUGG AACAAACACUG GAUUCUAAAA CACAGUCUCU GCUGAUUGUG

I R G W I F G T T L D S K T Q S L L I V

S protein

423 433 443 453 463 473

AAUAAUGCAA CAAUUGUGGU GAUUAAGUG UGUGAAUUUC AGUUUUGUAA UGAUCCUUUU

N N A T N V V I K V C E F Q F C N D P F

S protein

483 493 503 513 523 533

CUGGGAGUGU AUUAUCACAA AAUAUAUAAA UCUUGGAUGG AAUCUGAAUU UAGAGUGUUAU

L G V Y Y H K N N K S W M E S E F R V Y

S protein

543 553 563 573 583 593
UCCUCUGCAA AUAAUUGUAC AUUUGAAUUAU GUGUCUCAGC CUUUUCUGAU GGAUCUGGAA
S S A N N C T F E Y V S Q P F L M D L E

S protein

603 613 622 633 643 653
GGAAAACAGG GCAAUUUUAA AAAUCUGAGA GAAUUUGUGU UAAAAAAUUAU UGAUGGAUUAU
G K Q G N F K N L R E F V F K N I D G Y

S protein

663 673 683 693 703 713
UUUAAAAUUU AUUCUAAACA CACACCAAUU AAUUUAGUGA GAGAUUCGCC UCAGGGAUUU
F K I Y S K H T P I N L V R D L P Q G F

S protein

723 733 743 753 763 773
UCUGCUCUGG AACCUCUGGU GGAUCUGCCA AUUGGCAUUA AUAUUACAAG AUUUCAGACA
S A L E P L V D L P I G I N I T R F Q T

S protein

783 793 803 813 823 833
CUGCUGGCUC UGCACAGAUC UUAUCUGACA CCUGGAGAUU CUUCUUCUGG AUGGACAGCC
L L A L H R S Y L T P G D S S S G W T A

S protein

843 853 863 873 883 893
GGAGCUGCAG CUUAUUUAUGU GGGCUAUCUG CAGCCAAGAA CAUUUCUGCU GAAAUUAUAAU
G A A A Y Y V G Y L Q P R T F L L K Y N

S protein

903 913 923 933 943 953
GAAAAUGGAA CAAUUACAGA UGCUGUGGAU UGUGCUCUGG AUCCUCUGUC UGAAACAAAA
E N G T I T D A V D C A L D P L S E T K

S protein

963 973 983 993 1003 1013
 UGUACAUAUAA AAUCUUUUUAC AGUGGAAAAA GGCAUUUAUC AGACAUCUAA UUUUAGAGUG
 C T L K S F T V E K G I Y Q T S N F R V

S protein

1023 1033 1043 1053 1063 1073
 CAGCCAACAG AAUCUAUUGU GAGAUUUCCA AAUAUUACAA AUCUGUGUCC AUUUGGAGAA
 Q P T E S I V R F P N I T N L C P F G E

S protein

1083 1093 1103 1113 1123 1133
 GUGUUUAAUG CAACAAGAUU UGCAUCUGUG UAUGCAUGGA AUAGAAAAAG AAUUCUAAU
 V F N A T R F A S V Y A W N R K R I S N

S protein

1143 1153 1163 1173 1183 1193
 UGUGUGGCUG AUUAUUCUGU GCUGUAUAAU AGUGCUUCUU UUUCCACAUU UAAAUGUUAU
 C V A D Y S V L Y N S A S F S T F K C Y

S protein

1203 1213 1223 1233 1243 1253
 GGAGUGUCUC CAACAAAUAU AAAUGAUUUA UGUUUUACAA AUGUGUAUGC UGAUUCUUUU
 G V S P T K L N D L C F T N V Y A D S F

S protein

1263 1273 1283 1293 1303 1313
 GUGAUCAGAG GUGAUGAAGU GAGACAGAUU GCCCCCGGAC AGACAGGAAA AAUUGCUGAU
 V I R G D E V R Q I A P G Q T G K I A D

S protein

1323 1333 1343 1353 1363 1373
 UACAAUUACA AACUGCCUGA UGAUUUUACA GGAUGUGUGA UUGCUUGGAA UUCUAAUAAU

Y N Y K L P D D F T G C V I A W N S N N

S protein

1383 1393 1403 1413 1423 1433
 UUAGAUUCUA AAGUGGGAGG AAAUUACAAU UAUCUGUACA GACUGUUUAG AAAAUCAAU
 L D S K V G G N Y N Y L Y R L F R K S N

S protein

1443 1453 1463 1473 1483 1493
 CUGAAACCUU UUGAAAGAGA UAUUUCAACA GAAAUUUUUAUC AGGCUGGAUC AACACCUUGU
 L K P F E R D I S T E I Y Q A G S T P C

S protein

1503 1513 1523 1533 1543 1553
 AAUGGAGUGG AAGGAUUUAA UUGUUUUUUU CCAUUACAGA GCUAUGGAUU UCAGCCAACC
 N G V E G F N C Y F P L Q S Y G F Q P T

S protein

1563 1573 1583 1593 1603 1613
 AAUGGUGUGG GAUAUCAGCC AUAUAGAGUG GUGGUGCUGU CUUUUGAACU GCUGCAUGCA
 N G V G Y Q P Y R V V V L S F E L L H A

S protein

1623 1633 1643 1653 1663 1673
 CCUGCAACAG UGUGUGGACC UAAAAAUCU ACAAUUUUAUUG UGAAAAUAA AUGUGUGAAU
 P A T V C G P K K S T N L V K N K C V N

S protein

1683 1693 1703 1713 1723 1733
 UUUAAUUUUA AUGGAUUUAA AGGAACAGGA GUGCUGACAG AAUCUAAUAA AAAAUUUCUG
 F N F N G L T G T G V L T E S N K K F L

S protein

1743 1753 1763 1773 1783 1793

CCUUUUCAGC AGUUUGGCAG AGAUAUUGCA GAUACCACAG AUGCAGUGAG AGAUCCUCAG

P F Q Q F G R D I A D T T D A V R D P Q

S protein

1803 1813 1823 1833 1843 1853

ACAUUAGAAA UUCUGGAUUAU UACACCUUGU UCUUUUGGGG GUGUGUCUGU GAUUACACCU

T L E I L D I T P C S F G G V S V I T P

S protein

1863 1873 1883 1893 1903 1913

GGAACAAUA CAUCUAAUCA GGUGGCUGUG CUGUAUCAGG AUGUGAAUUG UACAGAAGUG

G T N T S N Q V A V L Y Q D V N C T E V

S protein

1923 1933 1943 1953 1963 1973

CCAGUGGCAA UUCAUGCAGA UCAGCUGACA CCAACAUGGA GAGUGUAUUC UACAGGAUCU

P V A I H A D Q L T P T W R V Y S T G S

S protein

1983 1993 2003 2013 2023 2033

AAUGUGUUUC AGACAAGAGC AGGAUGUCUG AUUGGAGCAG AACAUUGUGAA UAAUUCUUUAU

N V F Q T R A G C L I G A E H V N N S Y

S protein

2043 2053 2063 2073 2083 2093

GAAUGUGAUA UUCCAAUUGG AGCAGGCAUU UGUGCAUCUU AUCAGACACA GACAAAUUC

E C D I P I G A G I C A S Y Q T Q T N S

S protein

2103 2113 2123 2133 2143 2153

CCAAGGAGAG CAAGAUCUGU GGCAUCUCAG UCUAUUAUUG CAUACACCAU GUCUCUGGGA

P R R A R S V A S Q S I I A Y T M S L G

S protein

2163 2173 2183 2193 2203 2213
 GCAGAAAAUU CUGUGGCAUA UUCUAAUAAU UCUAUUGCUA UUCCAACAAA UUUUACCAUU
 A E N S V A Y S N N S I A I P T N F T I

S protein

2223 2233 2243 2253 2263 2273
 UCUGUGACAA CAGAAAUUUU ACCUGUGUCU AUGACAAAAA CAUCUGUGGA UUGUACCAUG
 S V T T E I L P V S M T K T S V D C T M

S protein

2283 2293 2303 2313 2323 2333
 UACAUUUGUG GAGAUUCUAC AGAAUGUUCU AAUCUGCUGC UGCAGUAUGG AUCUUUUUGU
 Y I C G D S T E C S N L L L Q Y G S F C

S protein

2343 2353 2363 2373 2383 2393
 ACACAGCUGA AUAGAGCUUU AACAGGAAUU GCUGUGGAAC AGGAUAAAAA UACACAGGAA
 T Q L N R A L T G I A V E Q D K N T Q E

S protein

2403 2413 2423 2433 2443 2453
 GUGUUUGCUC AGGUGAAACA GAUUUACAAA ACACCACCAA UUAAGAUUU UGGAGGAUUU
 V F A Q V K Q I Y K T P P I K D F G G F

S protein

2463 2473 2483 2493 2503 2513
 AAUUUUAGCC AGAUUCUGCC UGAUCCUUCU AAACCUUCUA AAAGAUCUUU UAUUGAAGAU
 N F S Q I L P D P S K P S K R S F I E D

S protein

2523 2533 2543 2553 2563 2573
 CUGCUGUUUA AUAAAGUGAC ACUGGCAGAU GCAGGAUUUA UUAACAGUA UGGAGAUUGC
 L L F N K V T L A D A G F I K Q Y G D C

S protein

2583 2593 2603 2613 2623 2633
 CUGGGUGAUA UUGCUGCAAG AGAUCUGAUU UGUGCUCAGA AAUUUAAUGG ACUGACAGUG
 L G D I A A R D L I C A Q K F N G L T V

S protein

2643 2653 2663 2673 2683 2693
 CUGCCUCCUC UGCUGACAGA UGAAAUGAUU GCUCAGUACA CAUCUGCUUU ACUGGCUGGA
 L P P L L T D E M I A Q Y T S A L L A G

S protein

2703 2713 2723 2733 2743 2753
 ACAAUUACAA GCGGAUGGAC AUUUGGAGCU GGAGCUGCUC UGCAGAUUCC UUUUGCAAUG
 T I T S G W T F G A G A A L Q I P F A M

S protein

2763 2773 2783 2793 2803 2813
 CAGAUGGCUU ACAGAUUUAA UGGAAUUGGA GUGACACAGA AUGUGUUUAU UGAAAAUCAG
 Q M A Y R F N G I G V T Q N V L Y E N Q

S protein

2823 2833 2843 2853 2863 2873
 AAACUGAUUG CAAAUCAGUU UAAUUCUGCA AUUGGCAAAA UUCAGGAUUC UCUGUCUUCU
 K L I A N Q F N S A I G K I Q D S L S S

S protein

2883 2893 2903 2913 2923 2933
 ACAGCUUCUG CUCUGGGAAG ACUGCAGGAU GUGGUGAAUC AGAAUGCACA GGCACUGAAU
 T A S A L G K L Q D V V N Q N A Q A L N

S protein

2943 2953 2963 2973 2983 2993
 ACUCUGGUGA AACAGCUGUC UAGCAAUUUU GGGGCAAUUU CUUCUGUGCU GAAUGAUUU

T L V K Q L S S N F G A I S S V L N D I

S protein

3003 3013 3023 3033 3043 3053
 CUGUCUAGAC UGGAUCCUCC UGAAGCUGAA GUGCAGAUUG AUAGACUGAU CACAGGAAGA
 L S R L D P P E A E V Q I D R L I T G R

S protein

3063 3073 3083 3093 3103 3113
 CUGCAGUCUC UGCAGACUUA UGUGACACAG CAGCUGAUUA GAGCUGCUGA AAUUGAGCU
 L Q S L Q T Y V T Q Q L I R A A E I R A

S protein

3123 3133 3143 3153 3163 3173
 UCUGCUAAUC UGGCUGCUAC AAAAAUGUCU GAAUGUGUGC UGGGACAGUC AAAAAGAGUG
 S A N L A A T K M S E C V L G Q S K R V

S protein

3183 3193 3203 3213 3223 3233
 GAUUUUUGUG GAAAAGGAUA UCAUCUGAUG UCUUUUCCAC AGUCUGCUCC ACAUGGAGUG
 D F C G K G Y H L M S F P Q S A P H G V

S protein

3243 3253 3263 3273 3283 3293
 GUGUUUUUAC AUGUGACAUU UGUGCCAGCA CAGGAAAAGA AUUUUACCAC AGCACCAGCA
 V F L H V T Y V P A Q E K N F T T A P A

S protein

3303 3313 3323 3333 3343 3353
 AUUUGUCAUG AUGGAAAAGC ACAUUUUCCA AGAGAAGGAG UGUUUGUGUC UAAUGGAACA
 I C H D G K A H F P R E G V F V S N G T

S protein

3363 3373 3383 3393 3403 3413

CAUUGGUUUG UGACACAGAG AAAUUUUUUAU GAACCUCAGA UUAUUACAAC AGAUAAUACA

H W F V T Q R N F Y E P Q I I T T D N T

S protein

3423 3433 3443 3453 3463 3473

UUUGUGUCAG GAAAUUGUGA UGUGGUGAUU GGAAUUGUGA AUAUACAGU GUAUGAUCCA

F V S G N C D V V I G I V N N T V Y D P

S protein

3483 3493 3503 3513 3523 3533

CUGCAGCCAG AACUGGAUUC UUUUAAAGAA GAACUGGAUA AAUAAUUUAA AAAUCACACA

L Q P E L D S F K E E L D K Y F K N H T

S protein

3543 3553 3563 3573 3583 3593

UCUCCUGAUG UGGAUUUUAGG AGAUUUUUCU GGAAUCAUUG CAUCUGUGGU GAAUUAUUCAG

S P D V D L G D I S G I N A S V V N I Q

S protein

3603 3613 3623 3633 3643 3653

AAAGAAAUUG AUAGACUGAA UGAAGUGGCC AAAAAUCUGA AUGAAUCUCU GAUUGAUCUG

K E I D R L N E V A K N L N E S L I D L

S protein

3663 3673 3683 3693 3703 3713

CAGGAACUUG GAAAAUAUGA ACAGUACAUU AAAUGGCCUU GGUACAUUUG GCUUGGAUUU

Q E L G K Y E Q Y I K W P W Y I W L G F

S protein

3723 3733 3743 3753 3763 3773

AUUGCAGGAU UAAUUGCAAU UGUGAUGGUG ACAAUUAUGU UAUGUUGUUAU GACAUCAUGU

I A G L I A I V M V T I M L C C M T S C

S protein

3783 3793 3803 3813 3823 3833

UGUUCUUGUU UAAAAGGAUG UUGUUCUUGU GGAAGCUGUU GUAAAUUUGA UGAAGAUGAU

C S C L K G C C S C G S C C K F D E D D

S protein

3843 3853 3863 3873 3878

UCUGAACCUG UGUUAAAAGG AGUGAAAUUG CAUUACACAU GAUGA

S E P V L K G V K L H Y T * *

S protein

3888 3898 3908 3918 3928 3938

CUCGAGCUGG UACUGCAUGC ACGCAAUGCU AGCUGCCCCU UUCCCGUCCU GGGUACCCCG

FI element

3948 3958 3968 3978 3988 3998

AGUCUCCCCC GACCUCGGGU CCCAGGUAUG CUCCCACCUC CACCUGCCCC ACUCACCACC

FI element

4008 4018 4028 4038 4048 4058

UCUGCUAGUU CCAGACACCU CCCAAGCACG CAGCAAUGCA GCUCAAAACG CUUAGCCUAG

FI element

4068 4078 4088 4098 4108 4118

CCACACCCCC ACGGGAAACA GCAGUGAUUA ACCUUUAGCA AUAACGAAA GUUUAACUAA

FI element

4128 4138 4148 4158 4168 4173

GCUAUACUAA CCCAGGGUU GGUCAAUUUC GUGCCAGCCA CACCUGGAG CUAGC

FI element

4183 4193 4203 4213 4223 4233

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA GCAUAUGACU AAAAAAAAAA AAAAAAAAAA

Poly(A)

4243 4253 4263 4273 4283

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

Poly(A)

[200] Nucleotide Sequence of RBP020.2

Nucleotide sequence is shown with individual sequence elements as indicated in bold letters. In addition, the sequence of the translated protein is shown in italic letters below the coding nucleotide sequence (* = stop codon).

10	20	30	40	50	53
AGAAUAAACU AGUAUUCUUC UGGUCCCCAC AGACUCAGAG AGAACCCGCC ACC					
hAg-Kozak					
63	73	83	93	103	113
AUGUUCGUGU UCCUGGUGCU GCUGCCUCUG GUGUCCAGCC AGUGUGUGAA CCUGACCACC					
<i>M F V F L V L L P L V S S Q C V N L T T</i>					
S protein					
123	133	143	153	163	173
AGAACACAGC UGCCUCCAGC CUACACCAAC AGCUUUACCA GAGGCGUGUA CUACCCCGAC					
<i>R T Q L P P A Y T N S F T R G V Y Y P D</i>					
S protein					
183	193	203	213	223	233
AAGGUGUUCA GAUCCAGCGU GCUGCACUCU ACCCAGGACC UGUUCCUGCC UUUCUUCAGC					
<i>K V F R S S V L H S T Q D L F L P F F S</i>					
S protein					
243	253	263	273	283	293
AACGUGACCU GGUUCCACGC CAUCCACGUG UCCGGCACCA AUGGCACCAA GAGAUUCGAC					
<i>N V T W F H A I H V S G T N G T K R F D</i>					
S protein					
303	313	323	333	343	353
AACCCCGUGC UGCCCUCUAA CGACGGGGUG UACUUUGCCA GCACCGAGAA GUCCAACAUC					
<i>N P V L P F N D G V Y F A S T E K S N I</i>					
S protein					

363 373 383 393 403 413
AUCAGAGGCU GGAUCUUCGG CACCACACUG GACAGCAAGA CCCAGAGCCU GCUGAUCGUG
I R G W I F G T T L D S K T Q S L L I V

S protein

423 433 443 453 463 473
AACAACGCCA CCAACGUGGU CAUCAAGUG UGCGAGUUC AGUUCUGCAA CGACCCCUUC
N N A T N V V I K V C E F Q F C N D P F

S protein

483 493 503 513 523 533
CUGGGCGUCU ACUACCACAA GAACAACAAG AGCUGGAUGG AAAGCGAGUU CCGGGUGUAC
L G V Y Y H K N N K S W M E S E F R V Y

S protein

543 553 563 573 583 593
AGCAGCGCCA ACAACUGCAC CUUCGAGUAC GUGUCCAGC CUUCCUGAU GGACCUGGAA
S S A N N C T F E Y V S Q P F L M D L E

S protein

603 613 623 633 643 653
GGCAAGCAGG GCAACUUCAA GAACCUGCGC GAGUUCGUGU UUAAGAACAU CGACGGCUAC
G K Q G N F K N L R E F V F K N I D G Y

S protein

663 673 683 693 703 713
UUCAAGAUCU ACAGCAAGCA CACCCCUAUC AACCUCGUGC GGGAUCUGCC UCAGGGCUUC
F K I Y S K H T P I N L V R D L P Q G F

S protein

723 733 743 753 763 773
UCUGCUCUGG AACCCUGGU GGAUCUGCCC AUCGGCAUCA ACAUACCCG GUUUCAGACA
S A L E P L V D L P I G I N I T R F Q T

S protein

783 793 803 813 823 833
 CUGCUGGCC C UGCACAGAAG CUACCUGACA CCUGGCGAUA GCAGCAGCGG AUGGACAGCU
 L L A L H R S Y L T P G D S S S G W T A

S protein

843 853 863 873 883 893
 GGUGCCGCC C CUUACUAUGU GGGCUACCUG CAGCCUAGAA CCUCCUGCU GAAGUACAAC
 G A A A Y Y V G Y L Q P R T F L L K Y N

S protein

903 913 923 933 943 953
 GAGAACGGCA CCAUCACCGA CGCCGUGGAU UGUGCUCUGG AUCCUCUGAG CGAGACAAAG
 E N G T I T D A V D C A L D P L S E T K

S protein

963 973 983 993 1003 1013
 UGCACCCUGA AGUCCUUCAC CGUGGAAAAG GGCAUCUACC AGACCAGCAA CUUCCGGGUG
 C T L K S F T V E K G I Y Q T S N F R V

S protein

1023 1033 1043 1053 1063 1073
 CAGCCCACCG AAUCCAUCGU GCGGUUCCCC AAUAUCACCA AUCUGUGCCC CUUCGGCGAG
 Q P T E S I V R F P N I T N L C P F G E

S protein

1083 1093 1103 1113 1123 1133
 GUGUCAAUG CCACCAGAUU CGCCUCUGUG UACGCCUGGA ACCGGAAGCG GAUCAGCAAU
 V F N A T R F A S V Y A W N R K R I S N

S protein

1143 1153 1163 1173 1183 1193
 UGCGUGGCCG ACUACUCCGU GCUGUACAAC UCCGCCAGCU UCAGCACCUU CAAGUGCUAC

C V A D Y S V L Y N S A S F S T F K C Y

S protein

1203 1213 1223 1233 1243 1253
 GCGGUGUCCC CUACCAAGCU GAACGACCUG UGCUUCACAA ACGUGUACGC CGACAGCUUC
 G V S P T K L N D L C F T N V Y A D S F

S protein

1263 1273 1283 1293 1303 1313
 GUGAUCCGGG GAGAUGAAGU GCGGCAGAUU GCCCCUGGAC AGACAGGCAA GAUCGCCGAC
 V I R G D E V R Q I A P G Q T G K I A D

S protein

1323 1333 1343 1353 1363 1373
 UACAACUACA AGCUGCCCCG CGACUUCACC GGCUGUGUGA UUGCCUGGAA CAGCAACAAC
 Y N Y K L P D D F T G C V I A W N S N N

S protein

1383 1393 1403 1413 1423 1433
 CUGGACUCCA AAGUCGGCGG CAACUACAAU UACCUGUACC GGCUGUCCG GAAGUCCAAU
 L D S K V G G N Y N Y L Y R L F R K S N

S protein

1443 1453 1463 1473 1483 1493
 CUGAAGCCCU UCGAGCGGGA CAUCUCCACC GAGAUCUAUC AGGCCGGCAG CACCCCUUGU
 L K P F E R D I S T E I Y Q A G S T P C

S protein

1503 1513 1523 1533 1543 1553
 AACGGCGUGG AAGGCUUCAA CUGCUACUUC CCACUGCAGU CCUACGGCUU UCAGCCCACA
 N G V E G F N C Y F P L Q S Y G F Q P T

S protein

1563 1573 1583 1593 1603 1613

AAUGGCGUGG GCUAUCAGCC CUACAGAGUG GUGGUGCUGA GCUUCGAACU GCUGCAUGCC

N G V G Y Q P Y R V V V L S F E L L H A

S protein

1623 1633 1643 1653 1663 1673

CCUGCCACAG UGUGCGGCCC UAAGAAAAGC ACCAAUCUCG UGAAGAACAA AUGCGUGAAC

P A T V C G P K K S T N L V K N K C V N

S protein

1683 1693 1703 1713 1723 1733

UUCAACUUCA ACGGCCUGAC CGGCACCGGC GUGCUGACAG AGAGCAACAA GAAGUUCCUG

F N F N G L T G T G V L T E S N K K F L

S protein

1743 1753 1763 1773 1783 1793

CCAUUCCAGC AGUUUGGCCG GGAUAUCGCC GAUACCACAG ACGCCGUUAG AGAUCCCCAG

P F Q Q F G R D I A D T T D A V R D P Q

S protein

1803 1813 1823 1833 1843 1853

ACACUGGAAA UCCUGGACAU CACCCCUUGC AGCUUCGGCG GAGUGUCUGU GAUCACCCCU

T L E I L D I T P C S F G G V S V I T P

S protein

1863 1873 1883 1893 1903 1913

GGCACCAACA CCAGCAAUCA GGUGGCAGUG CUGUACCAGG ACGUGAACUG UACCGAAGUG

G T N T S N Q V A V L Y Q D V N C T E V

S protein

1923 1933 1943 1953 1963 1973

CCCGUGGCCA UUCACGCCGA UCAGCUGACA CCUACAUGGC GGGUGUACUC CACCGGCAGC

P V A I H A D Q L T P T W R V Y S T G S

S protein

1983 1993 2003 2013 2023 2033
 AAUGUGUUUC AGACCAGAGC CGGCUGUCUG AUCGGAGCCG AGCACGUGAA CAAUAGCUAC
 N V F Q T R A G C L I G A E H V N N S Y

S protein

2043 2053 2063 2073 2083 2093
 GAGUGCGACA UCCCCAUCGG CGCUGGAAUC UGCGCCAGCU ACCAGACACA GACAAACAGC
 E C D I P I G A G I C A S Y Q T Q T N S

S protein

2103 2113 2123 2133 2143 2153
 CCUCGGAGAG CCAGAAGCGU GGCCAGCCAG AGCAUCAUUG CCUACACAAU GUCUCUGGGC
 P R R A R S V A S Q S I I A Y T M S L G

S protein

2163 2173 2183 2193 2203 2213
 GCCGAGAACA GCGUGGCCUA CUCCAACAAC UCUAUCGCUA UCCCCACCAA CUUCACCAUC
 A E N S V A Y S N N S I A I P T N F T I

S protein

2223 2233 2243 2253 2263 2273
 AGCGUGACCA CAGAGAUCCU GCCUGUGUCC AUGACCAAGA CCAGCGUGGA CUGCACCAUG
 S V T T E I L P V S M T K T S V D C T M

S protein

2283 2293 2303 2313 2323 2333
 UACAUCUGCG GCGAUUCCAC CGAGUGCUCC AACCUGCUGC UGCAGUACGG CAGCUUCUGC
 Y I C G D S T E C S N L L L Q Y G S F C

S protein

2343 2353 2363 2373 2383 2393
 ACCCAGCUGA AUAGAGCCCU GACAGGGAUC GCCGUGGAAC AGGACAAGAA CACCCAAGAG
 T Q L N R A L T G I A V E Q D K N T Q E

S protein

2403 2413 2423 2433 2443 2453
 GUGUUCGCCC AAGUGAAGCA GAUCUACAAG ACCCCUCCUA UCAAGGACUU CGGCGGCUUC
 V F A Q V K Q I Y K T P P I K D F G G F

S protein

2463 2473 2483 2493 2503 2513
 AAUUUCAGCC AGAUUCUGCC CGAUCCUAGC AAGCCCAGCA AGCGGAGCUU CAUCGAGGAC
 N F S Q I L P D P S K P S K R S F I E D

S protein

2523 2533 2543 2553 2563 2573
 CUGCUGUUCA ACAAAGUGAC ACUGGCCGAC GCCGGCUUCA UCAAGCAGUA UGGCGAUUGU
 L L F N K V T L A D A G F I K Q Y G D C

S protein

2583 2593 2603 2613 2623 2633
 CUGGGCGACA UUGCCGCCAG GGAUCUGAUU UGCGCCCAGA AGUUUACGG ACUGACAGUG
 L G D I A A R D L I C A Q K F N G L T V

S protein

2643 2653 2663 2673 2683 2693
 CUGCCUCCUC UGCUGACCGA UGAGAUGAUC GCCCAGUACA CAUCUGCCCU GCUGGCCGGC
 L P P L L T D E M I A Q Y T S A L L A G

S protein

2703 2713 2723 2733 2743 2753
 ACAAUCACAA GCGGCUGGAC AUUUGGAGCA GGCGCCGCUC UGCAGAUCCC CUUUGCUAUG
 T I T S G W T F G A G A A L Q I P F A M

S protein

2763 2773 2783 2793 2803 2813
 CAGAUGGCCU ACCGGUUCAA CGGCAUCGGA GUGACCCAGA AUGUGCUGUA CGAGAACCAG

Q M A Y R F N G I G V T Q N V L Y E N Q

S protein

2823 2833 2843 2853 2863 2873
AAGCUGAUCG CCAACCAGUU CAACAGCGCC AUCGGCAAGA UCCAGGACAG CCUGAGCAGC
K L I A N Q F N S A I G K I Q D S L S S

S protein

2883 2893 2903 2913 2923 2933
ACAGCAAGCG CCCUGGGAAA GCUGCAGGAC GUGGUCAACC AGAAUGCCCA GGCACUGAAC
T A S A L G K L Q D V V N Q N A Q A L N

S protein

2943 2953 2963 2973 2983 2993
ACCCUGGUCA AGCAGCUGUC CUCCAACUUC GGCGCCAUCA GCUCUGUGCU GAACGAUAUC
T L V K Q L S S N F G A I S S V L N D I

S protein

3003 3013 3023 3033 3043 3053
CUGAGCAGAC UGGACCCUCC UGAGGCCGAG GUGCAGAU CGAGACUGAU CACAGGCAGA
L S R L D P P E A E V Q I D R L I T G R

S protein

3063 3073 3083 3093 3103 3113
CUGCAGAGCC UCCAGACAU CGUGACCCAG CAGCUGAUCA GAGCCGCCGA GAUUAGAGCC
L Q S L Q T Y V T Q Q L I R A A E I R A

S protein

3123 3133 3143 3153 3163 3173
UCUGCCAAUC UGGCCGCCAC CAAGAUGUCU GAGUGUGUGC UGGGCCAGAG CAAGAGAGUG
S A N L A A T K M S E C V L G Q S K R V

S protein

3183 3193 3203 3213 3223 3233

GACUUUUGCG GCAAGGGCUA CCACCUGAUG AGCUUCCCUC AGUCUGCCCC UCACGGCGUG

D F C G K G Y H L M S F P Q S A P H G V

S protein

3243 3253 3263 3273 3283 3293

GUGUUUCUGC ACGUGACAUU UGUGCCCGCU CAAGAGAAGA AUUUCACCAC CGCUCCAGCC

V F L H V T Y V P A Q E K N F T T A P A

S protein

3303 3313 3323 3333 3343 3353

AUCUGCCACG ACGGCAAAGC CCACUUUCCU AGAGAAGGCG UGUUCGUGUC CAACGGCACC

I C H D G K A H F P R E G V F V S N G T

S protein

3363 3373 3383 3393 3403 3413

CAUUGGUUCG UGACACAGCG GAACUUCUAC GAGCCCCAGA UCAUCACCAC CGACAACACC

H W F V T Q R N F Y E P Q I I T T D N T

S protein

3423 3433 3443 3453 3463 3473

UUCGUGUCUG GCAACUGCGA CGUCGUGAUC GGCAUUGUGA ACAAUACCGU GUACGACCCU

F V S G N C D V V I G I V N N T V Y D P

S protein

3483 3493 3503 3513 3523 3533

CUGCAGCCCC AGCUGGACAG CUUCAAGAG GAACUGGACA AGUACUUUAA GAACCACACA

L Q P E L D S F K E E L D K Y F K N H T

S protein

3543 3553 3563 3573 3583 3593

AGCCCCGACG UGGACCUGGG CGAUUUCAGC GGAAUCAAUG CCAGCGUCGU GAACAUCAG

S P D V D L G D I S G I N A S V V N I Q

S protein

3603 3613 3623 3633 3643 3653
 AAAGAGAUCG ACCGGCUGAA CGAGGUGGCC AAGAAUCUGA ACGAGAGCCU GAUCGACCUG
 K E I D R L N E V A K N L N E S L I D L

S protein

3663 3673 3683 3693 3703 3713
 CAAGAACUGG GGAAGUACGA GCAGUACAUC AAGUGGCCCCU GGUACAUCUG GCUGGGCUUU
 Q E L G K Y E Q Y I K W P W Y I W L G F

S protein

3723 3733 3743 3753 3763 3773
 AUCGCCGGAC UGAUUGCCAU CGUGAUGGUC ACAAUCAUGC UGUGUUGCAU GACCAGCUGC
 I A G L I A I V M V T I M L C C M T S C

S protein

3783 3793 3803 3813 3823 3833
 UGUAGCUGCC UGAAGGGCUG UUGUAGCUGU GGCAGCUGCU GCAAGUUCGA CGAGGACGAU
 C S C L K G C C S C G S C C K F D E D D

S protein

3843 3853 3863 3873 3878
 UCUGAGCCCCG UGCUGAAGGG CGUGAAACUG CACUACACAU GAUGA
 S E P V L K G V K L H Y T * *

S protein

3888 3898 3908 3918 3928 3938
 CUCGAGCUGG UACUGCAUGC ACGCAAUGCU AGCUGCCCCU UUCCCGUCCU GGGUACCCCG

FI element

3948 3958 3968 3978 3988 3998
 AGUCUCCCCC GACCUCGGGU CCCAGGUAUG CUCCCACCUC CACCUGCCCC ACUCACCACC

FI element

4008 4018 4028 4038 4048 4058

UCUGCUAGUU CCAGACACCU CCCAAGCACG CAGCAAUGCA GCUCAAAACG CUUAGCCUAG

FI element

4068 4078 4088 4098 4108 4118

CCACACCCCC ACGGGAAACA GCAGUGAUUA ACCUUUAGCA AUAACGAAA GUUUAACUAA

FI element

4128 4138 4148 4158 4168 4173

GCUAUACUAA CCCCAGGGUU GGUCAAUUUC GUGCCAGCCA CACCUGGAG CUAGC

FI element

4183 4193 4203 4213 4223 4233

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA GCAUAUGACU AAAAAAAAAA AAAAAAAAAA

Poly(A)

4243 4253 4263 4273 4283

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

Poly(A)

Lipid Nanoparticles (LNPs)

[201] In some embodiments, one or more nucleic acids (*e.g.*, RNA) as described herein are formulated and/or administered in the form of LNPs. In some embodiments, a LNP of the present disclosure comprises one or more lipids known in the art and/or established herein to produce lipid particles. In some embodiments, LNPs of the present disclosure comprise one or more lipids selected from the group consisting of: cationic lipid, neutral lipid, polymer conjugated lipid, and combinations thereof. In some embodiments, LNPs of the present disclosure comprise a steroid, such as cholesterol, or derivatives thereof.

[202] As used herein, a "neutral lipid" refers to a lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH. In some embodiments, an additional lipid comprises one of the following neutral lipid components: (1) a phospholipid, (2) cholesterol or a derivative thereof; or (3) a mixture of a phospholipid and cholesterol or a derivative thereof. In some embodiments, a phospholipid may include, but are not limited to, phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidic acids, phosphatidylserines or sphingomyelin. Such phospholipids include in particular diacylphosphatidylcholines, such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphosphatidylcholine (DLPC), palmitoyl-oleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC) and phosphatidylethanolamines, in particular diacylphosphatidylethanolamines, such as dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE), diphytanoyl-phosphatidylethanolamine (DPyPE), and further phosphatidylethanolamine lipids with different hydrophobic chains.


[203] Examples of cholesterol derivatives include, but are not limited to, cholestanol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, tocopherol and derivatives thereof, and mixtures thereof.








[204] The term “cationic lipid” refers to any of a number of lipid species that carry a net positive charge at a selected pH. Such as physiological pH (e.g., pH of about 7.0). Examples of cationic lipids include, but are not limited to 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); N,N-dimethyl-2,3-dioleoyloxypropylamine (DODMA), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 3-(N—(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), dimethyldioctadecylammonium (DDAB); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propanes; 1,2-dialkyloxy-3-dimethylammonium propanes; dioctadecyldimethyl ammonium chloride (DODAC), 1,2-distearoyloxy-N,N-dimethyl-3-aminopropane (DSDMA), 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium (DMRIE), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), 1,2-dioleoyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE), and 2,3-dioleoyloxy- N-[2(spermine carboxamide)ethyl]-N,N-dimethyl-1-propanamium trifluoroacetate (DOSPA), 1,2-dilinoleoyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), dioctadecylamidoglycyl spermine (DOGS), 3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5'-(cholest-5-en-3-beta-oxy)-3'-oxapentoxy]-3-dimethyl-1-(cis,cis-9',12'-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleoyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylecarbamyl-3-dimethylaminopropane (DOcarbDAP), 2,3-Dilinoleoyloxy-N,N-dimethylpropylamine (DLinDAP), 1,2-N,N'-Dilinoleylecarbamyl-3-dimethylaminopropane (DLincarbDAP), 1,2-Dilinoleylecarbamyl-3-dimethylaminopropane (DLinCDAP), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-K-XTC2-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin-MC3-DMA), N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (DMRIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyl)-1-propanaminium bromide (GAP-DMORIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium








bromide (GAP-DLRIE), ($\pm$)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (GAP-DMRIE), N-(2-Aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (β AE-DMRIE), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium (DOBAQ), 2-({8-[(3 β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA), 1,2-dimyristoyl-3-dimethylammonium-propane (DMDAP), 1,2-dipalmitoyl-3-dimethylammonium-propane (DPDAP), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleoyloxy]-benzamide (MVL5), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 2,3-bis(dodecyloxy)-N-(2-hydroxyethyl)-N,N-dimethylpropan-1-aminium bromide (DLRIE), N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-aminium bromide (DMORIE), di((Z)-non-2-en-1-yl) 8,8'-(((2(dimethylamino)ethyl)thio)carbonyl)azanediyl)dioctanoate (ATX), N,N-dimethyl-2,3-bis(dodecyloxy)propan-1-amine (DLDMA), N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-amine (DMDMA), Di((Z)-non-2-en-1-yl)-9-((4-(dimethylaminobutanoyl)oxy)heptadecanedioate (L319), N-Dodecyl-3-((2-dodecylcarbamoyl-ethyl)-{2-[(2-dodecylcarbamoyl-ethyl)-2-{(2-dodecylcarbamoyl-ethyl)-[2-(2-dodecylcarbamoyl-ethylamino)-ethyl]-amino}-ethylamino)propionamide (lipidoid 98N12-5), 1-[2-[bis(2-hydroxydodecyl)amino]ethyl]-[2-[4-[2-[bis(2 hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl]amino]dodecan-2-ol (lipidoid C12-200).








[205] In some embodiments, a cationic lipid has a chemical structure as disclosed in WO 2017/075531, some of which are set forth in Table A below:








Table A: Exemplary cationic lipids







No.	Structure
I-1	


No.	Structure
I-2	
I-3	
I-4	
I-5	
I-6	
I-7	
I-8	

No.	Structure
I-9	
I-10	
I-11	
I-12	
I-13	
I-14	
I-15	

No.	Structure
I-16	
I-17	
I-18	
I-19	
I-20	
I-21	
I-22	







No.	Structure
I-23	
I-24	
I-25	
I-26	
I-27	
I-28	
I-29	

No.	Structure
I-30	
I-31	
I-32	
I-33	
I-34	
I-35	


No.	Structure
I-36	

[206] Further examples of a cationic lipid are shown in Table B below.

Table B: Additional exemplary cationic lipids

No.	Structure
A	
B	
C	
D	
E	
F	

[207] In certain embodiments, a cationic lipid is an ionizable lipid-like material (lipidoid). An exemplary lipidoid is C12-200, which has the following structure:



[208] In some embodiments, particles described herein include a polymer conjugated lipid such as a pegylated lipid. The term "pegylated lipid" refers to a molecule comprising both a lipid portion and a polyethylene glycol portion. Pegylated lipids are known in the art.

[209] In some embodiments, LNPs of the present disclosure comprise ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315). In some embodiments, LNPs of the present disclosure comprise 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159). In some embodiments, the present disclosure provides LNPs that comprise distearoylphosphatidylcholine (DSPC). In some embodiments, LNPs of the present disclosure comprise cholesterol. In some embodiments, LNPs of the present disclosure comprise lipids that include: ALC-0315, ALC-0159, DSPC, and cholesterol.

[210] In some embodiments, a LNP of the present disclosure comprises from about 40 to about 55 mol percent, from about 40 to about 50 mol percent, from about 41 to about 49 mol percent, from about 41 to about 48 mol percent, from about 42 to about 48 mol percent, from about 43 to about 48 mol percent, from about 44 to about 48 mol percent, from about 45 to about 48 mol percent, from about 46 to about 48 mol percent, from about 47 to about 48 mol percent, or from about 47.2 to about 47.8 mol percent of ALC-0315. In some embodiments, a LNP comprises about 47.0, about 47.1, about 47.2, about 47.3, about 47.4, about 47.5, about 47.6, about 47.7, about 47.8, about 47.9, or about 48.0 mol percent of ALC-0315.

[211] In some embodiments, a LNP of the present disclosure comprises from about 6 mg/ml to about 9 mg/ml, about 6 mg/ml to about 8 mg/ml, about 6 mg/ml to about 7 mg/ml, about 7 mg/ml to about 9 mg/ml, about 8 mg/ml to about 9 mg/ml, or about 7 mg/ml to about 8 mg/ml of ALC-0315. In some embodiments, a LNP comprises about 7 mg/ml to about 8 mg/ml

of ALC-0315. In some embodiments, ALC-0315 is present in a concentration of about 7.17 mg/ml.

[212] In some embodiment, a LNP of the present disclosure comprises from about 5 to about 15 mol percent, from about 7 to about 13 mol percent, or from about 9 to about 11 mol percent DSPC. In some embodiments, DSPC is present in a concentration of about 9.5, about 10, or about 10.5 mol percent.

[213] In some embodiments, a LNP of the present disclosure comprises from about 1 mg/ml to about 2.5 mg/ml, about 1 mg/ml to about 2 mg/ml, or about 1 mg/ml to about 1.5 mg/ml of DSPC. In some embodiments, a LNP comprises about 1.5 mg/ml to about 2 mg/ml of DSPC. In some embodiments, ALC-0315 is present in a concentration of about 1.56 mg/ml.

[214] In some embodiments, cholesterol is present in a concentration ranging from about 30 to about 50 mol percent, from about 35 to about 45 mol percent, or from about 38 to about 43 mol percent. In some embodiments, cholesterol is present in a concentration of about 40, about 41, about 42, about 43, about 44, about 45, or about 46 mol percent.

[215] In some embodiments, cholesterol is present in a concentration from about 2 mg/ml to about 4 mg/ml, about 2 mg/ml to about 3.5 mg/ml, about 2 mg/ml to about 3 mg/ml, about 2 mg/ml to about 2.5 mg/ml, about 2.5 mg/ml to about 4 mg/ml, about 3 mg/ml to about 4 mg/ml, or about 3.5 mg/ml to about 4 mg/ml. In some embodiments, cholesterol is present in a concentration of about 3 mg/ml to about 3.5 mg/ml. In some embodiments, cholesterol is present in a concentration of about 3.1 mg/ml.

[216] In some embodiments, ALC-0159 is present in a concentration ranging from about 1 to about 10 mol percent, about 2 to about 8 mol percent, about 4 to about 8 mol percent, about 4 to about 6 mol percent, about 1 to about 5 mol percent, or about 1 to about 3 mol percent.

[217] In some embodiments, ALC-0159 is present in a concentration ranging from about 0.5 mg/ml to about 2.5 mg/ml, about 1 mg/ml to about 2.5 mg/ml, about 1.5 mg/ml to about 2.5 mg/ml, about 2 mg/ml to about 2.5 mg/ml, about 0.5 mg/ml to about 2 mg/ml, about 0.5 mg/ml to about 1.5 mg/ml, or about 0.5 mg/ml to about 1 mg/ml. In some embodiments, ALC-0159 is present in a concentration of about 0.5 mg/ml to about 1 mg/ml. In some embodiments, ALC-0159 is present in a concentration of about 0.89 mg/ml.

[218] In some embodiments, mol percent is determined based on total mol of lipid present in LNPs described herein.

[219] In some embodiments, the present disclosure provides LNPs comprising lipids that include ALC-0315, ALC-0159, DSPC, and cholesterol that are present in mass ratios ranging from about 8:1:1.5:3 to about 9:1:2:3.5.

[220] In some embodiments, lipid particles of the present disclosure (*e.g.*, LNPs) may have an average diameter of at least 30 nm, at least 40 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 200 nm, at least 300 nm, at least 400 nm, at least 500 nm, or at least 1000 nm. In some embodiments, lipid particles of the present disclosure (*e.g.*, LNPs) may have an average diameter of at most 30 nm, at most 40 nm, at most 50 nm, at most 60 nm, at most 70 nm, at most 80 nm, at most 90 nm, at most 100 nm, at most 200 nm, at most 300 nm, at most 400 nm, at most 500 nm, at most 1000 nm, or at most 1200 nm. In some embodiments, lipid particles of the present disclosure (*e.g.*, LNPs) may have an average diameter in the range of about 30 nm to about 1000 nm, about 50 nm to about 1000 nm, about 70 nm to about 1000 nm, about 30 nm to about 500 nm, about 30 nm to about 100 nm, or about 30 nm to about 80 nm.

[221] Nucleic acids described herein can be packaged into lipids (*e.g.*, RNA/LNPs) using a wide range of methods (*e.g.*, film hydration method, reverse phase evaporation, ethanol injection technique) that may involve obtaining a colloid from at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer and mixing the colloid with nucleic acid to obtain lipid particles (*e.g.*, RNA/LNPs).

[222] In some embodiments, an RNA is packaged into a lipid particle (*e.g.*, LNP) using an ethanol injection technique, where ethanol solution comprising lipids is rapidly injected into an aqueous solution through a needle. Accordingly, in some embodiments, nucleic acid containing lipid particles (*e.g.*, RNA/LNPs) are made as follows: an ethanol solution comprising lipids, such as cationic lipids and additional lipids (*e.g.*, lipid compositions as described herein), is injected into an aqueous solution comprising nucleic acid (*e.g.*, RNA) under stirring, or agitation of the combined solution. Prepared nucleic acids in lipid particles yielded from this method can be further processed, *e.g.*, concentrated, transferred to one or more different buffer systems, etc.

[223] In some embodiments, an RNA as described herein is packaged into a lipid particle (*e.g.*, LNP) by admixing said RNA with particle forming lipids (*e.g.*, those described herein) in accordance with LNP forming methods described herein. In some embodiments, RNA containing LNPs (RNA/LNPs) are prepared in a first buffer system before being exchanged into a second buffer system for storage and/or use.

[224] In some embodiments, a first buffer system comprises an aqueous buffer, *e.g.*, PBS buffer, Tris buffer, HEPES buffer, His buffer, etc. In some embodiments, a first buffer system comprises a PBS buffer. In some embodiment of the present disclosure, a first buffer system comprises about 5 mg/ml to about 7 mg/ml, about 6 mg/ml to about 7 mg/ml, or about 5 mg/ml to about 6 mg/ml sodium chloride. In some embodiments, a first buffer system comprises about 6 mg/ml sodium chloride. In some embodiments, a first buffer system is substantially free of sodium chloride. One skilled in the art will understand that substantially free in this context means that no sodium chloride has been added, and that sodium and/or chloride ions may still be present due to other components in such a formulation. Accordingly, in some embodiments, PBS buffer of the present disclosure is a PBS buffer that is substantially free of sodium chloride and comprises 0.15 g/L KCl, 1.08 g/L Na₂HPO₄, and 0.15 g/L KH₂PO₄. In some embodiments, PBS of the present disclosure comprises 6 g/L NaCl, 0.15 g/L KCl, 1.08 g/L Na₂HPO₄, and 0.15 g/L KH₂PO₄.

[225] In some embodiments, a first buffer system comprises a protectant, *e.g.*, sucrose, trehalose, or combinations thereof. In some embodiments a protectant in a first buffer system is sucrose, and/or trehalose. In some embodiments, sucrose is at a concentration of about 10% w/v. In some embodiments, sucrose is at a concentration of about 5%. In some embodiments, trehalose is at a concentration of about 10% w/v. In some embodiments, trehalose is at a concentration of about 5%.

[226] In some embodiments, a second buffer system of the present disclosure comprises an aqueous buffer, *e.g.*, PBS buffer, Tris buffer, HEPES buffer, His buffer, etc. In some embodiments, a second buffer system comprises PBS. In some embodiments, PBS of the present disclosure comprises 6 g/L NaCl, 0.15 g/L KCl, 1.08 g/L Na₂HPO₄, and 0.15 g/L KH₂PO₄. In some embodiments, PBS of the present disclosure is a PBS buffer that is substantially free of sodium chloride (as defined herein), and comprises 0.15 g/L KCl, 1.08 g/L Na₂HPO₄, and 0.15

g/L KH_2PO_4 . In some embodiments, a second buffer system comprises a Tris buffer. In some embodiments, a second buffer system comprises a Tris buffer at a concentration of about 10 mM. In some embodiments, a Tris buffer is substantially free of sodium chloride. In some embodiments, a Tris buffer comprises about 6 mg/ml sodium chloride. In some embodiments, a second buffer system comprises a His buffer. In some embodiments, a second buffer system comprises a His buffer at a concentration of about 10 mM. In some embodiments, a His buffer is substantially free of sodium chloride. In some embodiments, a His buffer comprises about 6 mg/ml sodium chloride. In some embodiments, a second buffer system comprises a HEPES buffer. In some embodiments, a second buffer system comprises a HEPES buffer at a concentration of about 10 mM. In some embodiments, a HEPES buffer is substantially free of sodium chloride. In some embodiments, a HEPES buffer comprises about 6 mg/ml sodium chloride.

[227] In some embodiments, RNA-LNPs comprises about 0.4 mg/ml to about 0.6 mg/ml, about 0.4 mg/ml to about 0.5 mg/ml, or about 0.5 mg/ml to about 0.6 mg/ml mRNA. In some embodiments, RNA-LNPs comprise about 0.5 mg/ml mRNA.

Formulations

[228] The present disclosure provides, among other things, technologies relating to formulation of RNA therapeutics, and particular to LNP formulations comprising nucleic acid (*e.g.*, mRNA) payloads. Such RNA/LNP formulations, include particular components (*e.g.*, protectant and/or buffer components), and/or are prepared according to particular processes, that differ from those of a reference formulation and that modify (*e.g.*, improve) one or more properties relative to that reference formulation. For example, in some embodiments, provided formulations show improvement(s) relative to a reference formulation that comprises the same lipids and nucleic acid, but that differs in protectant and/or buffer, and/or in certain production or processing steps.

[229] In some embodiments, the present disclosure provides compositions that are amenable to drying and/or that are dry. In some embodiments, compositions described herein are dried by lyophilization.

[230] In some embodiments, compositions described herein are substantially free of water, or are dried until they are substantially free of water. In some embodiments, a composition comprises less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, or less than 0.3% w/w water. In some embodiments, compositions as described herein maintain less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, or less than 0.3% w/w water for a period of time, *e.g.*, about 1, 2, 3, 4, 5, 6, weeks or more, including for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more, and above certain low temperature thresholds, *e.g.*, above about -80°C, -70°C, -50°C, -30°C, -20°C, 0°C, 2°C, 4°C, 8°C, 15°, 20°C, 30°C, 40°C or higher.

[231] In some embodiments of the present disclosure, a composition is annealed during drying (*e.g.*, lyophilization). In some embodiments, a composition is not annealed during drying.

[232] In some embodiments, compositions are provided that are stable to storage for at least a specified period of time at temperatures above a low temperature threshold. In some embodiments, compositions provided herein are stable to storage for a period of time at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, weeks or more, including for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more. In some embodiments, compositions provided herein are stable to storage for at least about 12 weeks. In some embodiments, compositions are stable to storage above a low temperature threshold that may be about -80°C, -70°C, -50°C, -30°C, -20°C, 0°C, 2°C, 4°C, 8°C, 15°, 20°C, 30°C, 40°C or higher. In some embodiments, compositions are stable to storage at temperatures of about 0°C, 2°C, 5°C, 8°C, 25°C, 40°C or higher. In some embodiments, compositions provided herein are stable to storage for a period of time of at least about 12 weeks at temperatures ranges of about 2°C to about 40°C, 2°C to about 30°C, about 2°C to about 20°C, about 2°C to about 10°C, about 8°C to about 40°C, about 20°C to about 40°C, or about 30°C to about 40°C.

[233] In some embodiments, a composition as described herein is considered to be stable based on maintenance of colloidal content comprising lipid nanoparticles (LNPs). In some embodiments, provided compositions described herein are considered to be stable based on maintenance of one or more of LNP characteristics (including, *e.g.*, but not limited to its Z-average and/or polydispersity index (PDI)). In some embodiments, provided compositions described herein are considered to be stable based on maintenance of nucleic acid integrity,

degree (*e.g.*, percent) of nucleic acid encapsulation, and/or nucleic acid expressibility (*e.g.*, level of expression of an encoded polypeptide, as may be expressed for example as percent of a relevant reference level). In some embodiments, provided compositions described herein are considered to be stable if lipid nanoparticles within such compositions exhibit less than about 20 nm change in Z-average (including, *e.g.*, less than 19 nm, 18 nm, 17 nm, 16 nm, 15 nm, 14 nm, 13 nm, 12 nm, 11 nm, or less change in Z-average) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if lipid nanoparticles within such compositions exhibit less than about 10 nm change in Z-average (including, *e.g.*, less than 9 nm, 8 nm, 7 nm, 6 nm, 5 nm, 4 nm, 3 nm, 2 nm, 1 nm, 0.5 nm, or less change in Z-average) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if lipid nanoparticles within such compositions exhibit less than 0.1 change in polydispersity index (PDI) (including, *e.g.*, less than 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, or less change in PDI) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if at least 50% (including *e.g.*, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more) nucleic acid encapsulation is maintained in such compositions over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if at least 50% (including *e.g.*, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more) of expression level of an encoded polypeptide is maintained over a certain period of time under a designated set of conditions compared to a relevant reference level.

[234] In some embodiments, compositions (*e.g.*, LNP compositions) as described herein are prepared in a first buffer system and then exchanged into a second buffer system as described herein.

[235] In some embodiments, LNP compositions as described herein comprise one or more particle forming lipids. In some embodiments, particle forming lipids include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 2-

[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159), distearoylphosphatidylcholine (DSPC), and cholesterol.

[236] In some embodiments, LNP compositions include ALC-0315, ALC-0159, DSPC, and cholesterol, present in relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5, respectively.

[237] In some embodiments, LNP compositions described herein include ALC-0315, ALC-0159, DSPC, and cholesterol in concentrations of 7.17 mg/ml, 0.89 mg/ml, 1.56 mg/ml, and 3.1 mg/ml, respectively.

[238] Certain embodiments of the present disclosure utilize one or more protectants. In some embodiments, protectants are or comprise sucrose, trehalose, or combinations thereof. In some embodiments, sucrose is at a concentration of about 10% w/v in a composition or method of the present disclosure. In some embodiments, trehalose is at a concentration of about 10% w/v in a composition or method of the present disclosure. In some embodiments, sucrose is at a concentration of about 5% w/v and trehalose is at a concentration of about 5% w/v in a composition or method of the present disclosure.

[239] In certain embodiments, a lyoprotectant is added to a composition and brought to a desired concentration (*e.g.*, those described herein) prior to a step of freezing or a step of drying.

[240] In some embodiments, a protectant is added to a first buffer system in which LNPs are prepared, *e.g.*, as described herein. In some embodiments, a protectant is added to both a first buffer system and a second buffer system. In embodiments where a protectant is added to both a first buffer system and a second buffer system, a different protectant may be used for each buffer system, or the same protectant may be used. In embodiments where a protectant is added to both a first buffer system and a second buffer system, different concentrations of protectant may be used, or the same concentration may be used.

[241] Certain embodiments of the present disclosure utilize one or more buffer systems. In some embodiments, first and second buffer systems are utilized.

[242] In some embodiments, preparation and/or use of a provided composition may involve a step of dilution, for example by adding a buffer system, which may in some embodiments be the same as and in other embodiments may be different from a previously-used

buffer system such as, for example, a buffer system included in an LNP composition that is subjected to dilution.

[243] In some embodiments, a utilized buffer (*e.g.*, a buffer utilized in a buffer system described herein) is substantially free of sodium chloride. One skilled in the art will understand that substantially free in this context means that no sodium chloride salt has been added, even though in some embodiments sodium and/or chloride ions may still be present due to other components in such a composition or formulation.

[244] In some embodiments, provided compositions comprise LNPs (*i.e.*, nucleic acid/LNPs), a protectant, and a buffer. In some embodiments, the buffer does not include sodium ions. In some embodiments the buffer does not include a salt. In some embodiments, the buffer is a HEPES buffer, a Tris buffer, or a His buffer as described herein. In some embodiments, the buffer is a phosphate buffered saline variant that is made without NaCl. In some embodiments, the buffer is a PBS variant that has a reduced level of sodium ions relative to a reference PBS that comprises NaCl, KCl, Na₂HPO₄, and KH₂PO₄; in some embodiments, such reference PBS is a “standard” PBS that comprises (or consists of) 137 mM NaCl (*i.e.*, 8 g/L NaCl), 2.7 mM KCl (*i.e.*, 0.2 g/L KCl), 10 mM Na₂HPO₄ (*i.e.*, 1.44 g/L Na₂HPO₄), and 1.8 mM KH₂PO₄ (*i.e.*, 0.24 g/L KH₂PO₄). In some embodiments, a buffer utilized in accordance with the present disclosure is a PBS variant that has a lower level of sodium ions than found in such reference standard PBS. In some embodiments, a buffer utilized in accordance with the present disclosure is a Tris buffer at about 10 mM. In some embodiments, a buffer utilized in accordance with the present disclosure is a His buffer at about 10 mM. In some embodiments, a buffer utilized in accordance with the present disclosure is a HEPES buffer at about 10 mM. In some embodiments, a buffer utilized in accordance with the present disclosure is supplemented with 6 mg/ml sodium chloride.

[245] In some embodiments, compositions of the present disclosure are prepared into a dosage form by dilution with a buffer.

Uses

[246] As described herein, technologies provided by the present disclosure relate to and/or are useful for preparation and/or administration of one or more nucleic acid/LNP (*e.g.*, RNA/LNP) compositions.

[247] In some embodiments, technologies described herein provide LNP compositions (*e.g.*, LNP/RNA compositions) that are stable to storage for a period of time at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, weeks or more, including for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more. In some embodiments, technologies of the present disclosure provide LNP compositions that are stable to storage for at least about 12 weeks. In some embodiments, provided compositions are stable to storage above a low temperature threshold that may be about -80°C, -70°C, -50°C, -30°C, -20°C, 0°C, 2°C, 4°C, 8°C, 15°, 20°C, 30°C, 40°C or higher. In some embodiments, provided compositions are stable to storage at temperatures of about 0°C, 2°C, 5°C, 8°C, 25°C, 40°C or higher. In some embodiments, LNP compositions provided herein are stable to storage for a period of time of at least about 12 weeks at temperatures ranges of about 2°C to about 40°C, 2°C to about 30°C, about 2°C to about 20°C, about 2°C to about 10°C, about 8°C to about 40°C, about 20°C to about 40°C, or about 30°C to about 40°C.

[248] Provided compositions described herein are considered to be stable based on maintenance of colloidal content comprising lipid nanoparticles (LNPs). In some embodiments, provided compositions described herein are considered to be stable based on maintenance of one or more of LNP characteristics (including, *e.g.*, but not limited to its Z-average and/or polydispersity index (PDI)). In some embodiments, provided compositions described herein are considered to be stable based on maintenance of nucleic acid integrity, degree (*e.g.*, percent) of nucleic acid encapsulation, and/or nucleic acid expressibility (*e.g.*, level of expression of an encoded polypeptide, as may be expressed for example as percent of a relevant reference level). In some embodiments, provided compositions described herein are considered to be stable if lipid nanoparticles within such compositions exhibit less than about 20 nm change in Z-average (including, *e.g.*, less than 19 nm, 18 nm, 17 nm, 16 nm, 15 nm, 14 nm, 13 nm, 12 nm, 11 nm, or less change in Z-average) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if lipid nanoparticles within such compositions exhibit less than about 10 nm change in Z-average (including, *e.g.*, less than 9 nm, 8 nm, 7 nm, 6 nm, 5 nm,

4 nm, 3 nm, 2 nm, 1 nm, 0.5 nm, or less change in Z-average) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if lipid nanoparticles within such compositions exhibit less than 0.1 change in polydispersity index (PDI) (including, *e.g.*, less than 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, or less change in PDI) over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if at least 50% (including *e.g.*, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more) nucleic acid encapsulation is maintained in such compositions over a certain period of time under a designated set of conditions compared to a relevant reference level. In some embodiments, provided compositions described herein are considered to be stable if at least 50% (including *e.g.*, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more) of expression level of an encoded polypeptide is maintained over a certain period of time under a designated set of conditions compared to a relevant reference level.

[249] In some embodiments, technologies provided herein utilize an antigen that may be or comprise a viral antigen, *e.g.* an antigen associated with a virus selected from the group consisting of: adenovirus, cytomegalovirus, herpes virus, human papillomavirus, measles virus, rubella virus, coronavirus, respiratory syncytial virus, influenza virus, and mumps virus. In some embodiments, an antigen may be or comprise a viral antigen associated with a virus selected from a Class I, Class II, Class III, Class IV, Class V, Class VI, or Class VII virus, based on the Baltimore classification system. In some embodiments, technologies described herein provide immunity in a subject from a virus selected from viral family Adenoviridae, Papovaviridae, Parvoviridae, Herpesviridae, Poxviridae, Anelloviridae, Pleolipoviridae, Reoviridae, Picornaviridae, Caliciviridae, Togaviridae, Arenaviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Bunyaviridae, Rhabdoviridae, Filoviridae, Coronaviridae, Astroviridae, Bornaviridae, Arteriviridae, or Hepeviridae. In some embodiments, technologies described herein provide immunity in a subject to a viral infection. In some embodiments, technologies described herein provide immunity in a subject to coronavirus, coronavirus infection, or to a disease or disorder associated with coronavirus. The present disclosure thus provides

compositions and methods for treating or preventing an infection, disease, or disorder associated with coronavirus.

[250] In some embodiments, technologies described herein provide LNP compositions that are administered to a subject having an infection, disease, or disorder associated with coronavirus. In some embodiments, technologies described herein provide LNP compositions that are administered to a subject at risk for developing the infection, disease, or disorder associated with coronavirus. For example, technologies described herein provide LNP compositions that may be administered to a subject who is at risk for being in contact with coronavirus. In some embodiments, technologies described herein provide LNP compositions that are administered to a subject who lives in, traveled to, or is expected to travel to a geographic region in which coronavirus is prevalent. In some embodiments, technologies described herein provide LNP compositions that are administered to a subject who is in contact with or expected to be in contact with another person who lives in, traveled to, or is expected to travel to a geographic region in which coronavirus is prevalent. In some embodiments, technologies described herein provide LNP compositions that are administered to a subject who has knowingly been exposed to coronavirus through their occupation, or other contact. In some embodiments, a coronavirus is SARS-CoV-2.

[251] In some embodiments, technologies described herein provide compositions that may be administered prophylactically (*i.e.*, to prevent a disease or disorder) or therapeutically (*i.e.*, to treat a disease or disorder) to subjects suffering from, or at risk of (or susceptible to) developing a disease or disorder. Such subjects may be identified using standard clinical methods. In the context of the present disclosure, prophylactic administration occurs prior to the manifestation of overt clinical symptoms of disease, such that a disease or disorder is prevented (*e.g.*, reduce burden of mortality or morbidity of disease) or alternatively delayed in its progression.

Administration

[252] Provided herein are compositions (*e.g.*, pharmaceutical compositions) and methods for delivering a payload (*e.g.*, mRNA) to a cell in a subject in need of such a payload. In some embodiments, provided compositions are administered for prophylactic purposes against

a viral infection and/or therapeutic purposes to treat a viral infection. In some embodiments, technologies of the present disclosure provide for compositions that can be used as therapeutic or prophylactic agents for treatment of coronavirus, *e.g.*, SARS-CoV-2.

[253] Pharmaceutical compositions of the present disclosure may be administered to prophylactic purposes, *e.g.*, in a subject that has not been diagnosed, and/or has not displayed one or more particular symptoms or characteristics of a particular disease, disorder or condition. In some embodiments, pharmaceutical compositions provided herein are administered in amounts to a cell or tissue of a subject in amounts effective for immune prophylaxis. Pharmaceutical compositions provided herein may be administered with other therapeutic or prophylactic compounds.

[254] In some embodiments, pharmaceutical compositions are administered therapeutically, *e.g.*, in a subject that has been diagnosed, and/or has displayed one or more particular symptoms or characteristics of a particular disease, disorder, or condition. In some embodiments, pharmaceutical compositions provided herein are administered in amounts to a cell or tissue of a subject in therapeutically effective amounts. Such pharmaceutical compositions provided herein may be administered with other therapeutic or prophylactic compounds.

[255] The exact amount of a provided pharmaceutical composition (*e.g.*, RNA/LNP composition) required for prophylactic and/or therapeutic purposes will vary from subject to subject, depending on the species, age, and general condition of the subject, severity of the disease, mode of administration, and mode of activity, among other considerations. It will be understood, however, that usage of provided compositions may be decided by the attending physician within the scope of sound medical judgment. Accordingly, a specific therapeutically and/or prophylactically effective dose for a particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder, the activity or potency of the specific composition employed, the age, body weight, general health, sex, and diet of the patient, time of administration, route of administration, and rate of excretion of the specific compound employed, duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.

[256] In some embodiments, provided pharmaceutical compositions are administered to a subject who has received, is receiving, or will receive other therapy. In some embodiments, other therapies administered with, *e.g.*, concomitantly, or in an alternating regimen, address one or more symptoms or features of a disease, disorder, or condition treated by provided therapy. Alternatively, or additionally, in some embodiments, an other therapy addresses one or more symptoms or features of a different disease. To give but one example, in various embodiments, it may be desirable to administer a plurality of prophylactic therapies (*e.g.*, prophylactic vaccines) substantially contemporaneously.

[257] Pharmaceutical compositions described herein may comprise one or more adjuvants or may be administered in combination with (*i.e.*, may be administered to subjects who have received, will receive, or are receiving) one or more adjuvants. An adjuvant utilized in the present disclosure may relate to any compound which prolongs, enhances or accelerates an immune response. Adjuvants comprise a heterogeneous group of compounds such as oil emulsions (*e.g.*, Freund's adjuvants), mineral compounds (such as alum), bacterial products (such as *Bordetella pertussis* toxin), or immune-stimulating complexes. Examples of adjuvants include, without limitation, LPS, GP96, CpG oligodeoxynucleotides, growth factors, and cytokines, such as monokines, lymphokines, interleukins, chemokines. Cytokines utilized in accordance with the present disclosure may be IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IFN α , IFN γ , GM-CSF, LT-a, or combinations thereof. Further known adjuvants that may be used in accordance with the present disclosure are aluminium hydroxide, Freund's adjuvant or oil such as Montanide® ISA51. Other suitable adjuvants for use in the present disclosure include lipopeptides, such as Pam3Cys.

[258] Pharmaceutical compositions described herein may be provided as a frozen concentrate for solution for injection, *e.g.*, at a concentration of about 0.50 mg/mL. In some embodiments, for preparation of solution for injection, a drug product is thawed and diluted, and/or rehydrated and diluted, with isotonic sodium chloride solution (*e.g.*, 0.9% NaCl, saline), *e.g.*, by a one-step dilution process. The concentration of the final solution for injection varies depending on the respective dose level to be administered.

[259] In some embodiments, an amount of RNA described herein from 0.1 μ g to 300 μ g, 0.5 μ g to 200 μ g, or 1 μ g to 100 μ g, such as about 1 μ g, about 3 μ g, about 10 μ g, about 30

µg, about 50 µg, or about 100 µg may be administered per dose. In some embodiments, the disclosure composition described herein is administered in single dose. In some embodiments, compositions described herein are administered in a priming dose followed by one or more booster doses. In some embodiments, a booster dose or a first booster dose may be administered 7 to 28 days or 14 to 24 days following administration of a priming dose.

[260] In some embodiments, an amount of RNA described herein of 60 µg or lower, 50 µg or lower, 40 µg or lower, 30 µg or lower, 20 µg or lower, 10 µg or lower, 5 µg or lower, 2.5 µg or lower, or 1 µg or lower may be administered per dose.

[261] In some embodiments, an amount of RNA described herein of at least 0.25 µg, at least 0.5 µg, at least 1 µg, at least 2 µg, at least 3 µg, at least 4 µg, at least 5 µg, at least 10 µg, at least 20 µg, at least 30 µg, or at least 40 µg may be administered per dose.

[262] In some embodiments, an amount of RNA described herein of 0.25 µg to 60 µg, 0.5 µg to 55 µg, 1 µg to 50 µg, 5 µg to 40 µg, or 10 µg to 30 µg may be administered per dose.

[263] In some embodiments, an amount of RNA described herein of about 30 µg is administered per dose. In some embodiments, at least two of such doses are administered. For example, a second dose may be administered about 21 days following administration of a first dose.

[264] In some embodiments, RNA administered as described above is nucleoside modified messenger RNA (modRNA) described herein as BNT162b2 (RBP020.1 or RBP020.2). In some embodiments, RNA administered as described above is nucleoside modified messenger RNA (modRNA) described herein as RBP020.2.

[265] In some embodiments, administration of an immunogenic composition or vaccine of the present disclosure may be performed by single administration or boosted by multiple administrations.

Sequence Listing

[266] SEQ ID NO: 1

Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val

1	5	10	15
Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe			
20	25	30	
Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu			
35	40	45	
His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp			
50	55	60	
Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp			
65	70	75	80
Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu			
85	90	95	
Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser			
100	105	110	
Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile			
115	120	125	
Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr			
130	135	140	
Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr			
145	150	155	160
Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu			
165	170	175	
Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe			
180	185	190	
Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr			
195	200	205	
Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu			
210	215	220	

Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr
 225 230 235 240
 Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser
 245 250 255
 Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro
 260 265 270
 Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala
 275 280 285
 Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys
 290 295 300
 Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val
 305 310 315 320
 Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys
 325 330 335
 Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala
 340 345 350
 Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu
 355 360 365
 Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro
 370 375 380
 Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe
 385 390 395 400
 Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly
 405 410 415
 Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys
 420 425 430
 Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn

435 440 445
 Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe
 450 455 460
 Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys
 465 470 475 480
 Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly
 485 490 495
 Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val
 500 505 510
 Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys
 515 520 525
 Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn
 530 535 540
 Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu
 545 550 555 560
 Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val
 565 570 575
 Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe
 580 585 590
 Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val
 595 600 605
 Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile
 610 615 620
 His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser
 625 630 635 640
 Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val
 645 650 655

Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala
 660 665 670
 Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala
 675 680 685
 Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser
 690 695 700
 Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile
 705 710 715 720
 Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val
 725 730 735
 Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu
 740 745 750
 Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr
 755 760 765
 Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln
 770 775 780
 Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe
 785 790 795 800
 Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser
 805 810 815
 Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly
 820 825 830
 Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp
 835 840 845
 Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu
 850 855 860
 Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly

865 870 875 880
 Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile
 885 890 895
 Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr
 900 905 910
 Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn
 915 920 925
 Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala
 930 935 940
 Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn
 945 950 955 960
 Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val
 965 970 975
 Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln
 980 985 990
 Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val
 995 1000 1005
 Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn
 1010 1015 1020
 Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys
 1025 1030 1035
 Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro
 1040 1045 1050
 Gln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr Val
 1055 1060 1065
 Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys His
 1070 1075 1080

Asp Gly	Lys Ala His Phe Pro	Arg Glu Gly Val Phe	Val Ser Asn
1085	1090	1095	
Gly Thr	His Trp Phe Val Thr	Gln Arg Asn Phe Tyr	Glu Pro Gln
1100	1105	1110	
Ile Ile	Thr Thr Asp Asn Thr	Phe Val Ser Gly Asn	Cys Asp Val
1115	1120	1125	
Val Ile	Gly Ile Val Asn Asn	Thr Val Tyr Asp Pro	Leu Gln Pro
1130	1135	1140	
Glu Leu	Asp Ser Phe Lys Glu	Glu Leu Asp Lys Tyr	Phe Lys Asn
1145	1150	1155	
His Thr	Ser Pro Asp Val Asp	Leu Gly Asp Ile Ser	Gly Ile Asn
1160	1165	1170	
Ala Ser	Val Val Asn Ile Gln	Lys Glu Ile Asp Arg	Leu Asn Glu
1175	1180	1185	
Val Ala	Lys Asn Leu Asn Glu	Ser Leu Ile Asp Leu	Gln Glu Leu
1190	1195	1200	
Gly Lys	Tyr Glu Gln Tyr Ile	Lys Trp Pro Trp Tyr	Ile Trp Leu
1205	1210	1215	
Gly Phe	Ile Ala Gly Leu Ile	Ala Ile Val Met Val	Thr Ile Met
1220	1225	1230	
Leu Cys	Cys Met Thr Ser Cys	Cys Ser Cys Leu Lys	Gly Cys Cys
1235	1240	1245	
Ser Cys	Gly Ser Cys Cys Lys	Phe Asp Glu Asp Asp	Ser Glu Pro
1250	1255	1260	
Val Leu	Lys Gly Val Lys Leu	His Tyr Thr	
1265	1270		

[267] SEQ ID NO: 2

auguuugugu uucuugugcu gcugccucuu gugucuucuc agugugugaa uuugacaaca	60
agaacacagc ugccaccagc uuauacaaau uuuuuuacca gaggagugua uuauccugau	120
aaaguguuuu gaucuucugu gcugcacagc acacaggacc uguuucugcc auuuuuuagc	180
aaugugacau gguuucaugc aaaucaugug ucuggaacaa auggaacaaa aagauuugau	240
aauccugugc ugccuuuuua ugauggagug uauuuugcuu caacagaaaa gucaaaauuu	300
auuagaggau ggauuuuugg aacaacacug gauucuaaaa cacagucucu gcugauugug	360
aaauaugcaa caauuguggu gauuaaagug ugugaauuuc aguuuuguaa ugauccuuuu	420
cugggagugu auuauacaaa aaauaauaaa ucuuggaugg aaucugaauu uagaguguaa	480
uccucugcaa auauuuguac auuugaauau gugucucagc cuuucugau ggaucuggaa	540
ggaaaacagg gcauuuuuaa aaucugaga gaauuugugu uaaaaauau ugauggauau	600
uuuaaaauuu auucuaaaca cacaccaauu aauuaguga gagaucugcc ucagggaauu	660
ucugcucugg aaccucuggu ggaucugcca auuggcauuu auauuacaag auuucagaca	720
cugcuggcuc ugcacagauc uuauucugaca ccuggagauu cuucucugc auggacagcc	780
ggagcugcag cuuauuauu gggcuauucug cagccaagaa cauucugcu gaaauauau	840
gaaaauuggaa cauuacaga ugcuguggau ugugcucugg auccucuguc ugaaacaaaa	900
uguacauuaa auucuuuuac aguggaaaaa ggcauuuauc agacaucuaa uuuuagagug	960
cagccaacag auucuaauu gagauuuca aaauuacaa aucugugucc auuuggagaa	1020
guguuuauug caacaagauu ugcaucugug uaugcaugga auagaaaaag auuucuaau	1080
uguguggcug auuauucugu gcuguauauu agugcuucuu uuuccacauu uaaauguuau	1140
ggagugucuc caacaaaaau aaugauuuu uguuuuacaa auguguauuc ugaucuuuu	1200
gugaucagag gugaugaagu gagacagauu gccccggac agacaggaaa auuugcugau	1260
uacaauuaca aacugccuga ugaauuuaca ggauguguga uugcuuggaa uucuaauau	1320
uuagauucua aagugggagg aaauuacaa uaucuguaca gacuguuuag aaaaucuuu	1380
cugaaaccuu uugaaagaga uauuuaaca gaaauuuauc aggcuggauc aacaccuugu	1440
aauggagugg aaggauuuua uuguauuuu ccauuacaga gcuauggauu ucagccaacc	1500
aauggugugg gauaucagcc auauagagug guugugcugu cuuuugaacu gcugcaugca	1560
ccugcaacag uguguggacc uaaaaaauu acaauuuuag ugaaaaaua augugugaau	1620

uuuaauuuua	auggauuaac	aggaacagga	gugcugacag	aaucuaauaa	aaaauuucug	1680
ccuuuucagc	aguuuaggcag	agauauugca	gauaccacag	augcagugag	agauccucag	1740
acauuagaaa	uucuggauau	uacaccuugu	ucuuuuuggg	gugugucugu	gauuacaccu	1800
ggaacaaaau	caucuaauca	ggugggcugug	cuguaucagg	augugaauug	uacagaagug	1860
ccaguggcaa	uucaugcaga	ucagcugaca	ccaacaugga	gaguguauuc	uacaggauuc	1920
aauguguuuc	agacaagagc	aggaugucug	auuggagcag	aacaugugaa	uaauucuuau	1980
gaaugugaua	uuccaaauug	agcaggcauu	ugugcaucuu	aucagacaca	gacaaaucc	2040
ccaaggagag	caagaucugu	ggcaucucag	ucuaauauug	cauacaccu	gucucuggga	2100
gcagaaaauu	cuguggcaua	uucuaauau	ucuaauugca	uuccaacaaa	uuuuaccuu	2160
ucugugacaa	cagaaaauuu	accugugucu	augacaaaaa	caucugugga	uuguaccaug	2220
uacauuugug	gagauucua	agaauuguuc	aaucugcugc	ugcaguaug	aucuuuuugu	2280
acacagcuga	auagagcuuu	aacaggauuu	gcuguggaac	aggauaaaaa	uacacaggaa	2340
guguuugcuc	aggugaaaca	gauuuacaaa	acaccaccaa	uuaaagauuu	uggaggauuu	2400
aauuuuagcc	agauucugcc	ugaucuuuc	aaaccuucua	aaagaucuuu	uauugaagau	2460
cugcuguuuu	auaaagugac	acuggcagau	gcaggauuuu	uuaaacagua	uggagauugc	2520
cugggugaua	uugcugcaag	agaucugauu	ugugcucaga	aauuuaaugg	acugacagug	2580
cugccuccuc	ugcugacaga	ugaaaugauu	gcucaguaca	caucugcuuu	acuggcugga	2640
acaauuacaa	gcggauggac	auuuggagcu	ggagcugcuc	ugcagauucc	uuuugcaaug	2700
cagauggcuu	acagauuuua	uggaaauugga	gugacacaga	auguguuaua	ugaaaaucag	2760
aaacugauug	caaaucaguu	uaauucugca	auuggcaaaa	uucaggauuc	ucugucuucu	2820
acagcuucug	cucugggaaa	acugcaggau	guggugaauc	agaauugcaca	ggcacugaau	2880
acucuggguga	aacagcuguc	uagcauuuuu	ggggcauuuu	cuucugugcu	gaaugauuuu	2940
cugucuagac	uggauaaaagu	ggaagcugaa	gugcagauug	auagacugau	cacaggaaga	3000
cugcagucuc	ugcagacuua	ugugacacag	cagcugauua	gagcugcuga	aaauagagcu	3060
ucugcuauuc	uggcugcuac	aaaaaugucu	gaaugugugc	ugggacaguc	aaaaagagug	3120
gauuuuugug	gaaaaggaua	ucaucugaug	ucuuuuuccac	agucugcucc	acauggagug	3180
guguuuuuac	augugacaua	ugugccagca	caggaaaaga	auuuuaccac	agcaccagca	3240

```

auuugucaug auggaaaagc acauuuucca agagaaggag uguuuguguc uaauggaaca      3300
cauugguuug ugacacagag aaauuuuuau gaaccucaga uuauuacaac agauaaauaca      3360
uuugugucag gaaaauuguga uguggugauu ggaauuguga auaauacagu guaugaucca      3420
cugcagccag aacuggauuc uuuuaaagaa gaacuggaua aaauuuuuaa aaaucaacaca      3480
ucuccugaug uggauuuagg agauuuuucu ggaaucaaug caucuguggu gaauauucag      3540
aaagaaaauug auagacugaa ugaaguggcc aaaaaucuga augaaucucu gauugaucug      3600
caggaacuug gaaaauauga acaguacauu aaauggccuu gguacauuug gcuuggauuu      3660
auugcaggau uaaauugcaau ugugauggug acaauuangu uanguuguau gacaucaugu      3720
uguucuuguu uaaaaggauug uguuucuugu ggaagcuguu guaaaauuga ugaagaugau      3780
ucugaaccug uguuaaaagg agugaaaauug cauuacaca                               3819

```

[268] SEQ ID NO: 7

```

Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val
1           5           10           15
Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe
           20           25           30
Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu
           35           40           45
His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp
           50           55           60
Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp
65           70           75           80
Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu
           85           90           95
Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser
           100          105          110
Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile
           115          120          125

```

Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr
 130 135 140
 Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr
 145 150 155 160
 Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu
 165 170 175
 Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe
 180 185 190
 Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr
 195 200 205
 Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu
 210 215 220
 Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr
 225 230 235 240
 Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser
 245 250 255
 Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro
 260 265 270
 Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala
 275 280 285
 Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys
 290 295 300
 Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val
 305 310 315 320
 Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys
 325 330 335
 Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala

340	345	350	
Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu			
355	360	365	
Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro			
370	375	380	
Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe			
385	390	395	400
Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly			
405	410	415	
Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys			
420	425	430	
Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn			
435	440	445	
Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe			
450	455	460	
Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys			
465	470	475	480
Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly			
485	490	495	
Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val			
500	505	510	
Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys			
515	520	525	
Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn			
530	535	540	
Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu			
545	550	555	560

Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val
 565 570 575
 Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe
 580 585 590
 Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val
 595 600 605
 Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile
 610 615 620
 His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser
 625 630 635 640
 Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val
 645 650 655
 Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala
 660 665 670
 Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala
 675 680 685
 Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser
 690 695 700
 Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile
 705 710 715 720
 Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val
 725 730 735
 Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu
 740 745 750
 Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr
 755 760 765
 Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln

770	775	780	
Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe			
785	790	795	800
Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser			
	805	810	815
Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly			
	820	825	830
Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp			
	835	840	845
Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu			
	850	855	860
Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly			
865	870	875	880
Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile			
	885	890	895
Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr			
	900	905	910
Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn			
	915	920	925
Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala			
	930	935	940
Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn			
945	950	955	960
Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val			
	965	970	975
Leu Asn Asp Ile Leu Ser Arg Leu Asp Pro Pro Glu Ala Glu Val Gln			
	980	985	990

Ile Asp Arg Leu Ile Thr Gly Arg	Leu Gln Ser Leu Gln	Thr Tyr Val
995	1000	1005
Thr Gln Gln Leu Ile Arg Ala	Ala Glu Ile Arg Ala	Ser Ala Asn
1010	1015	1020
Leu Ala Ala Thr Lys Met Ser	Glu Cys Val Leu Gly	Gln Ser Lys
1025	1030	1035
Arg Val Asp Phe Cys Gly Lys	Gly Tyr His Leu Met	Ser Phe Pro
1040	1045	1050
Gln Ser Ala Pro His Gly Val	Val Phe Leu His Val	Thr Tyr Val
1055	1060	1065
Pro Ala Gln Glu Lys Asn Phe	Thr Thr Ala Pro Ala	Ile Cys His
1070	1075	1080
Asp Gly Lys Ala His Phe Pro	Arg Glu Gly Val Phe	Val Ser Asn
1085	1090	1095
Gly Thr His Trp Phe Val Thr	Gln Arg Asn Phe Tyr	Glu Pro Gln
1100	1105	1110
Ile Ile Thr Thr Asp Asn Thr	Phe Val Ser Gly Asn	Cys Asp Val
1115	1120	1125
Val Ile Gly Ile Val Asn Asn	Thr Val Tyr Asp Pro	Leu Gln Pro
1130	1135	1140
Glu Leu Asp Ser Phe Lys Glu	Glu Leu Asp Lys Tyr	Phe Lys Asn
1145	1150	1155
His Thr Ser Pro Asp Val Asp	Leu Gly Asp Ile Ser	Gly Ile Asn
1160	1165	1170
Ala Ser Val Val Asn Ile Gln	Lys Glu Ile Asp Arg	Leu Asn Glu
1175	1180	1185
Val Ala Lys Asn Leu Asn Glu	Ser Leu Ile Asp Leu	Gln Glu Leu

1190	1195	1200
Gly Lys Tyr Glu Gln Tyr Ile	Lys Trp Pro Trp Tyr	Ile Trp Leu
1205	1210	1215
Gly Phe Ile Ala Gly Leu Ile	Ala Ile Val Met Val	Thr Ile Met
1220	1225	1230
Leu Cys Cys Met Thr Ser Cys	Cys Ser Cys Leu Lys	Gly Cys Cys
1235	1240	1245
Ser Cys Gly Ser Cys Cys Lys	Phe Asp Glu Asp Asp	Ser Glu Pro
1250	1255	1260
Val Leu Lys Gly Val Lys Leu	His Tyr Thr	
1265	1270	

[269] SEQ ID NO: 8

auguuugugu uucuugugcu gcugccucuu gugucuucuc agugugugaa uuugacaaca	60
agaacacagc ugccaccagc uuauacaaau ucuuuuacca gaggagugua uuauccugau	120
aaaguguuua gaucuucugu gcugcacagc acacaggacc uguuucugcc auuuuuuagc	180
aaugugacau gguuucaugc aaaucaugug ucuggaacaa auggaacaaa aagauuugau	240
aauccugugc ugccuuuuua ugauggagug uauuuugcuu caacagaaaa gucaaaauuu	300
auuagaggau ggauuuuugg aacaacacug gauucuaaaa cacagucucu gcugauugug	360
aaauaugcaa caaauugugu gauuaaagug ugugaauuuc aguuuuguaa ugauccuuuu	420
cugggagugu auuauacaaa aaauaaauaaa ucuuggaugg aaucugaauu uagaguguau	480
uccucugcaa auauuuguac auuugaauau gugucucagc cuuuucugau ggaucuggaa	540
ggaaaacagg gcauuuuuaa aaucugaga gaauuugugu uaaaaauau ugauggauau	600
uuuuuuuuu auucuaaaca cacaccaauu aaauuaguga gagaucugcc ucagggauuu	660
ucugcucugg aaccucuggu ggaucugcca auuggcauu auauuacaag auuucagaca	720
cugcuggcuc ugcacagauc uuaucugaca ccuggagauu cuucuucugg auggacagcc	780
ggagcugcag cuuauuauu gggcuauucug cagccaagaa cauuucugcu gaaauauauu	840
gaaaauuggaa caauuacaga ugcuguggau ugugcucugg auccucuguc ugaaacaaaa	900

uguacauuaa aaucuuuuac aguggaaaaa ggcauuuauuc agacaucuaa uuuuagagug	960
cagccaacag aaucuaauugu gagauuuucca aaauuuacaa aucugugucc auuuggagaa	1020
guguuuuaug caacaagauu ugcaucugug uaugcaugga auagaaaaag aaauucuaau	1080
uguguggcug auuauucugu gcuguauaau agugcuucuu uuuccacauu uaaauguuau	1140
ggagugucuc caacaaaaau aaugauuuu uguuuuacaa auguguauuc ugaucuuuuu	1200
gugaucagag gugaugagu gagacagauu gccccggac agacaggaaa aaugcugau	1260
uacaauuaca aacugccuga ugauuuuaca ggauguguga uugcuuggaa uucuaauau	1320
uuagauucua aagugggagg aaauuacaa uaucuguaca gacuguuag aaaaucaau	1380
cugaaaccuu uugaaagaga uauuucaaca gaaauuuauc aggcuggauc aacaccuugu	1440
aauggagugg aaggauuuu uuguuuuuu ccuuuacaga gcuauggauu ucagccaacc	1500
aauggugugg gauaucagcc auauagagug guggugcugu cuuuugaacu gcugcaugca	1560
ccugcaacag uguguggacc uaaaaauuc acaauuuuag ugaaaaaua augugugaau	1620
uuuauuuuu auggauuac aggaacagga gugcugacag aaucuaaua aaaauucug	1680
ccuuuucagc aguuggcag agauauugca gauaccacag augcagugag agauccucag	1740
acauuagaaa uucuggauu uacaccuugu ucuuuuggg gugugucugu gauuacaccu	1800
ggaacaaaua caucuaauca gguggcugug cuguaucagg augugaauug uacagaagug	1860
ccaguggcaa uucaugcaga ucagcugaca ccaacaugga gaguguauuc uacaggauu	1920
aauguguuuc agacaagagc aggaugucug auuggagcag acaugugaa uauuucuuu	1980
gauguguaa uucaauugg agcaggcauu ugugcaucuu aucagacaca gacaaauucc	2040
ccaaggagag caagaucugu ggcaucucag ucuauuuuug cauacaccu gucucuggga	2100
gcagaaaau cuguggcau uucuaauau ucuauugcua uucaacaaa uuuuaccau	2160
ucugugacaa cagaaauuu accugugucu augacaaaa caucugugga uuguaccaug	2220
uacauuugug gagauucua agaauuucu aaucugcugc ugcaguaugg aucuuuuugu	2280
acacagcuga auagagcuu aacaggauu gcuguggaac aggaauaaaa uacacaggaa	2340
guguuugcuc agguuuaaca gaaauacaaa acaccaccaa uuaaagauuu uggaggauu	2400
aaauuuagcc agauucugcc ugaucuuu aaaccuucua aaagauuuu uauugaagau	2460
cugcuguuuu auaaagugac acuggcagau gcaggauuuu uuaaacagua uggagauugc	2520

cugggugaua uugcugcaag agaucugauu ugugcucaga aauuuaaugg acugacagug	2580
cugccuccuc ugcugacaga ugaaaugauu gcucaguaca caucugcuuu acuggcugga	2640
acaauuacaa gcggauggac auuuggagcu ggagcugcuc ugcagauucc uuugcaaug	2700
cagauggcuu acagauuuua uggaauugga gugacacaga auguguuaua ugaauucag	2760
aaacugauug caaaucaguu uaauucugca auuggcaaaa uucaggauuc ucugucuucu	2820
acagcuucug cucugggaaa acugcaggau guggugaauc agaaugcaca ggcacugaau	2880
acucugguga aacagcuguc uagcauuuu ggggcauuu cuucugugcu gaugauauu	2940
cugucuagac uggauccucc ugaagcugaa gugcagauug auagacugau cacaggaaga	3000
cugcagucuc ugcagacuua ugugacacag cagcugauua gagcugcuga aauuagagcu	3060
ucugcuauuc uggcugcuac aaaaugucu gaugugugc uggaacaguc aaaaagagug	3120
gaauuuugug gaaaaggaua ucaucugaug ucuuuuccac agucugcucc acauggagug	3180
guguuuuuac augugacaua ugugccagca caggaaaaga auuuuaccac agcaccagca	3240
auuugucaug auggaaaagc acauuuucca agagaaggag uguuuguguc uaauggaaca	3300
cauugguuug ugacacagag aaauuuuuau gaaccucaga uuauuacaac agauauaca	3360
uuugugucag gaaaauugua uguggugauu ggaauugua auauuacagu guaugaucca	3420
cugcagccag aacuggauuc uuuaaagaa gaacuggaua aaauuuuuaa aaucacaca	3480
ucuccugaug uggaauuagg agauuuucu ggaaucaaug caucuguggu gaauuucag	3540
aaagaaaug auagacugaa ugaaguggcc aaaaucuga augaauucu gauugaucug	3600
caggaacuug gaaaauauga acaguacauu aaauuggccuu gguacauuug gcuuggauuu	3660
auugcaggau uaaauugcau ugugauggug acauuuauu auguuguau gacauaugu	3720
uguucuuguu uaaaaggauu uguuucuugu ggaagcuguu guaaaauuga ugaagauau	3780
ucugaaccug uguuaaaagg agugaaauug cauucacaca	3819

[270] SEQ ID NO: 9

auguucgugu uccuggugcu gcugccucug guguccagcc agugugugaa ccugaccacc	60
agaacacagc ugccuccagc cuacaccaac agcuuuacca gaggcgugua cuaccccgac	120
aagguguuca gauccagcgu gcugcacucu acccaggacc uguuccugcc uuucuucagc	180
aacgugaccu gguuccacgc cauccacgug uccggcacca auggcaccaa gagauucgac	240

aaccccgugc ugcccucaa cgacggggug uacuuugcca gcaccgagaa guccaacauc	300
aucagaggcu ggaucuucgg caccacacug gacagcaaga cccagagccu gcugaucgug	360
aacaacgcca ccaacguggu caucaaagug ugcgaguucc aguucugcaa cgaccccuuc	420
cugggcgucu acuaccacaa gaacaacaag agcuggaugg aaagcgaguu ccggguguuac	480
agcagcgcca acaacugcac cuucgaguac gugucccagc cuuuccugau ggaccuggaa	540
ggcaagcagg gcaacucaa gaaccugcgc gaguucgugu uuaagaacau cgacggcuac	600
uucagaucuu acagcaagca caccuccauc aaccucgugc gggaucugcc ucaggggcuuc	660
ucugcucugg aaccccgugu ggaucugccc aucggcauca acaucacccg guuucagaca	720
cugcuggccc ugcacagaag cuaccugaca ccuggcgaua gcagcagcgg auggacagcu	780
ggugccgccc cuuacuaugu gggcuaccug cagccuagaa ccuuccugcu gaaguacaac	840
gagaacggca ccaucaccga cgccguggau ugugcucugg auccucugag cgagacaaag	900
ugcaccugaa aguccuucac cguggaaaag ggcaucuacc agaccagcaa cuuccgggug	960
cagcccaccg aauccaucgu gcgguucccc aaauacacca aucugugccc cuucggcgag	1020
guguucaaag ccaccagauu cgccucugug uacgccugga accggaagcg gaucagcaau	1080
ugcguggccg acuacuccgu gcuguacaac uccgccagcu ucagcaccuu caagugcuac	1140
ggcguguccc cuaccaagcu gaacgaccug ugcuucacaa acguguacgc cgacagcuuc	1200
gugauccggg gagaugaagu gcggcagauu gcccugggac agacaggcaa gaucgccgac	1260
uacaacuaca agcugcccga cgacuucacc ggcuguguga uugccuggaa cagcaacaac	1320
cuggacucaa aagucggcgg caacuacaau uaccuguacc ggcuguuccg gaaguccaau	1380
cugaagcccu ucgagcggga caucuccacc gagaucuauc aggccggcag caccuccugu	1440
aacggcgugg aaggcucaa cugcuacuuc ccacugcagu ccuacggcuu ucagcccaca	1500
aauggcgugg gcuaucagcc cuacagagug guggugcuga gcuucgaacu gcugcaugcc	1560
ccugccacag ugugcgggcc uaagaaaagc accaauucug ugaagaacaa augcgugaac	1620
uucaacuua acggccugac cggcaccggc gugcugacag agagcaacaa gaaguuccug	1680
ccauuccagc aguuuggccg ggauaucgcc gauaccacag acgccguuag gaucucccag	1740
acacuggaaa uccuggacau caccuccuugc agcuucggcg gagugucugu gaucaccccu	1800
ggcaccaaca ccagcaauca gguggcagug cuguaccagg acgugaacug uaccgaagug	1860

cccguggcca	uucacgccga	ucagcugaca	ccuacauggc	ggguguacuc	caccggcagc	1920
aauguguuuc	agaccagagc	cggcugucug	aucggagccg	agcacgugaa	caauagcuac	1980
gagugcgaca	uccccaucgg	cgcuaggaauc	ugcgccagcu	accagacaca	gacaaacagc	2040
ccucggagag	ccagaagcgu	ggccagccag	agcaucauug	ccuacacaau	gucucugggc	2100
gccgagaaca	gcguggccua	cuccaacaac	ucuaucgcu	uccccaccaa	cuucaccauc	2160
agcgugacca	cagagauccu	gccugugucc	augaccaaga	ccagcgugga	cugcaccaug	2220
uacaucugcg	gcgauuccac	cgagugcucc	aaccugcugc	ugcaguacgg	cagcuucugc	2280
accagcguga	auagagcccu	gacagggau	gccguggaac	aggacaagaa	caccaagag	2340
guguucgccc	aagugaagca	gaucuacaag	acccuccua	ucaaggacuu	cgcgccguuc	2400
aaauucagcc	agauucugcc	cgauccuagc	aagcccagca	agcgagagcu	caucgaggac	2460
cugcuguuca	acaaagugac	acuggccgac	gccggcuuca	ucaagcagua	uggcgauugu	2520
cugggcgaca	uugccgccag	ggaucugauu	ugcgcccaga	aguuaacgg	acugacagug	2580
cugccuccuc	ugcugaccga	ugagaugauc	gcccaguaca	caucugcccu	gcuggccggc	2640
acaaucacaa	gcggcuggac	auuuggagca	ggcgccgcuc	ugcagauccc	cuuugcuau	2700
cagauggccu	accgguucaa	cggaucggga	gugaccagga	augugcugua	cgagaaccag	2760
aagcugaucg	ccaaccaguu	caacagcgcc	aucggcaaga	uccaggacag	ccugagcagc	2820
acagcaagcg	cccugggaaa	gcugcaggac	guggucaacc	agaauGCCCA	ggcacugaac	2880
accucgguca	agcagcuguc	cuccaacuuc	ggcgccauca	gcucugugcu	gaacgauauc	2940
cugagcagac	uggaccucc	ugaggccgag	gugcagaucg	acagacugau	cacaggcaga	3000
cugcagagcc	uccagacaua	cgugaccag	cagcugauca	gagccgccga	gauuagagcc	3060
ucugccaauc	uggccgccac	caagaugucu	gagugugugc	ugggccagag	caagagagug	3120
gacuuuugcg	gcaagggcu	ccaccugaug	agcuuccuc	agucugcccc	ucacggcgug	3180
guguuucugc	acgugacaua	ugugcccgc	caagagaaga	auuucaccac	cgcuccagcc	3240
aucugccacg	acggcaaagc	ccacuuccu	agagaaggcg	uguucguguc	caacggcacc	3300
cauugguucg	ugacacagcg	gaacuucua	gagccccaga	ucauaccac	cgacaacacc	3360
uucgugucug	gcaacugcga	cgucgugauc	ggcauuguga	acaauaccgu	guacgaccu	3420
cugcagcccg	agcuggacag	cuucaaagag	gaacuggaca	aguacuuaa	gaaccacaca	3480

agccccgacg uggaccuggg cgauaucagc ggaaucaaug ccagcgucgu gaacauccag 3540
aaagagaucg accggcugaa cgagguggcc aagaaucuga acgagagccu gaucgaccug 3600
caagaacugg ggaaguacga gcaguacauc aaguggcccu gguacaucug gcugggcuuu 3660
aucgccggac ugauugccau cgugaugguc acaaucaugc uguguugcau gaccagcugc 3720
uguagcugcc ugaaggcgug uuguagcugu ggcagcugcu gcaaguucga cgaggacgau 3780
ucugagccccg ugcugaaggg cgugaaacug cacuacaca 3819

[271] SEQ ID NO: 19

agaauaaacu aguauucuuc ugguccccac agacucagag agaaccggcc accauguuug 60
uguuucuugu gcugcugccu cuugugucuu cucagugugu gaauuugaca acaagaacac 120
agcugccacc agcuuauaca aaucuuuuu ccagaggagu guauuauccu gauaaagugu 180
uuagaucuuc ugugcugcac agcacacagg accuguuucu gccauuuuu agcaauguga 240
caugguuuca ugcaauucau gugucuggaa caaauuggaac aaaaagauuu gauaauccug 300
ugcugccuuu uaaugaugga guguaauuug cuucaacaga aaagucaaa auuauuagag 360
gauggauuuu uggaacaaca cuggauucua aaacacaguc ucugcugauu gugaauaau 420
caacaaaugu ggugauuaaa gugugugaau uucaguuuug uaaugauccu uuucugggag 480
uguauuauca caaaaaauau aaaucuugga uggaaucuga auuuagagug uauuccucug 540
caauuaauug uacauuugaa uaugugucuc agccuuuucu gauggaucug gaaggaaaac 600
agggcaauuu uaaaaaucug agagaauuug uguuuaaaaa uauugaugga uauuuuaaaa 660
uuuauucuaa acacacacca auuaauuuag ugagagaucu gccucaggga uuucugcuc 720
uggaaccucu gguggaucug ccaauuggca uuaauuuac aagauuucag acacugcugg 780
cucugcacag aucuauucug acaccuggag auucuucuuc uggauggaca gccggagcug 840
cagcuuauua ugugggcua cuugcagccaa gaacauuucu gcugaaaau auugaaaau 900
gaacaauuac agaugcugug gauugugcuc uggauccucu gucugaaaca aauguacau 960
uaaaauuuu uacaguggaa aaaggcauuu aucagacauc uauuuuuga gugcagccaa 1020
cagaaucau ugugagauuu ccaauuuua caaauucug uccauuugga gaaguguuuu 1080
augcaacaag auuugcaucu guguaugcau ggaauagaaa aagaauuucu auuugugugg 1140
cugauuauuc ugugcugauu aaugugcuu cuuuuuuccac auuuuuuugu uauggagugu 1200

cuccaacaaa	auuaaaugau	uuauuuuuu	caaaugugua	ugcugauucu	uuugugauca	1260
gaggugauga	agugagacag	auugcccccg	gacagacagg	aaaaauugcu	gauuacaaau	1320
acaaacugcc	ugaugauuuu	acaggaugug	ugauugcuug	gaauucuaau	aauuuagauu	1380
cuaaaguggg	aggaaaauac	aauuauucgu	acagacuguu	uagaaaauca	aaucugaaac	1440
cuuuugaaa	agauauuuca	acagaaaauu	aucagggcug	aucaacaccu	uguaauggag	1500
uggaaggauu	uaauuguuau	uuuccauuac	agagcuauug	auuucagcca	accaauggug	1560
ugggauauca	gccauauaga	gugguggugc	ugucuuuuga	acugcugcau	gcaccugcaa	1620
cagugugugg	accuaaaaaa	ucuacaaauu	uagugaaaaa	uaaaugugug	aauuuuauu	1680
uuaauggauu	aacaggaaca	ggagugcuga	cagaaucaaa	uaaaaaauu	cugccuuuuc	1740
agcaguuuug	cagagauauu	gcagauacca	cagaugcagu	gagagauccu	cagacauuag	1800
aaauucugga	uaauacaccu	uguucuuuug	gggugugugc	ugugauuaca	ccuggaacaa	1860
auacaucuaa	ucaggugggu	gugcuguauc	aggauugugaa	uuguacagaa	gugccagugg	1920
caauucaugc	agaucagcug	acaccaacau	ggagagugua	uucuacagga	ucuaaugugu	1980
uucagacaag	agcaggaugu	cugauuggag	cagaacaugu	gaauaaucu	uaugaauug	2040
auauuccaau	uggagcaggc	auuugugcau	cuuaucagac	acagacaaau	uccccaagga	2100
gagcaagauc	uguggcaucu	cagucuaaua	uugcauacac	caugucucug	ggagcagaaa	2160
auucuguggc	auauucuaau	aaauucuuug	cuauuccaac	aaauuuuacc	auuucuguga	2220
caacagaaa	uuuaccugug	ucuauagaca	aaacaucugu	ggauuguacc	auguacauuu	2280
guggagauuc	uacagaauug	ucuaaucugc	ugcugcagua	uggaucuuuu	uguacacagc	2340
ugaauagagc	uuuaacagga	auugcugugg	aacaggauaa	aaauacacag	gaaguguuug	2400
cucaggugaa	acagauuuac	aaaacaccac	caauuaaaga	uuuuggagga	uuuaauuuu	2460
gccagauucu	gccugauccu	ucuaaaccuu	cuaaaagauc	uuuuauugaa	gaucugcugu	2520
uuauuaaagu	gacacuggca	gaugcaggau	uuauuaaaca	guauggagau	ugccugggug	2580
auauugcugc	aagagauucg	auuugugcuc	agaaauuuua	uggacugaca	gugcugccuc	2640
cucugcugac	agaugaaaug	auugcucagu	acacaucugc	uuuacuggcu	ggaacaauua	2700
caagcggaug	gacauuugga	gcuggagcug	cucugcagau	uccuuuugca	augcagaugg	2760
cuuacagauu	uaauugaaau	ggagugacac	agaauugugu	auaugaaaau	cagaaacuga	2820

uugcaaaauca guuuuuuuu gcaauuggca aaauucagga uucucugucu ucuacagcuu 2880
 cugcucuggg aaaacugcag gaugugguga aucagaaugc acaggcacug aaucucugg 2940
 ugaaacagcu gucuagcaau uuuggggcaa uuucucugu gcugaaugau auucugucua 3000
 gacuggaucc uccugaagcu gaagugcaga uugauagacu gaucacagga agacugcagu 3060
 cucugcagac uuaugugaca cagcagcuga uuagagcugc ugaaauuaga gcuucugcua 3120
 aucuggcugc uacaaaaaug ucugaauugug ugcugggaca gucaaaaaga guggauuuuu 3180
 guggaaaagg auaucaucug augucuuuuc cacagucugc uccacaugga gugguguuuu 3240
 uacaugugac auaugugcca gcacaggaaa agaauuuuac cacagcacca gcaauuuguc 3300
 augauggaaa agcacauuuu ccaagagaag gaguguuugu gucuaaugga acacauuggu 3360
 uugugacaca gagaaauuuu uaugaaccuc agauuuuac aacagauauu acauuugugu 3420
 caggaaaauug ugauguggug auuggaaug ugaauauuac aguguaugau ccacugcagc 3480
 cagaacugga uucuuuuuuu gaagaacugg auaauuuuu uaaaaaucac acaucuccug 3540
 auguggauuu aggagauuuu ucuggaauca augcaucugu ggugaauuuu cagaaagaaa 3600
 uugauagacu gaaugaagug gccaaaaauc ugaaugaauuc ucugauugau cugcaggaac 3660
 uuggaaaaua ugaacaguac auuuuauugc cuugguacau uuggcuugga uuuaauugcag 3720
 gauuaauugc aaauugugaug gugacaauua uguuauguug uaugacauca uguuguucuu 3780
 guuuuuuagg auguuguucu uguggaagcu guuguuuuu ugaugaagau gauucugaac 3840
 cuguguuuuu aggagugaaa uugcauuaca caugaugacu cgagcuggua cugcaugcac 3900
 gcaaugcuag cugcccccuuu cccguccugg guaccccgag ucucucccgga ccucgggucc 3960
 cagguaugcu cccaccucca ccugcccccac ucaccaccuc ugcuauguucc agaccucc 4020
 caagcacgca gcaaugcagc ucaaaacgcu uagccuagcc acacccccac gggaaacagc 4080
 agugauuaac cuuuagcaau aaacgaaagu uuaacuaagc uauacuaacc ccagguugg 4140
 ucaauuucgu gccagccaca cccuggagcu agcaaaaaaa aaaaaaaaaa aaaaaaaaaa 4200
 aaagcauug acuaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4260
 aaaaaaaaaa aaaaaaaaaa aaa 4283

[272] SEQ ID NO: 20

agaauaaacu aguauucuuu ugguccccac agacucagag agaaccgcc accauguucg 60

uguuccuggu gcugcugccu cuggugucca gccagugugu gaaccugacc accagaacac	120
agcugccucc agccuacacc aacagcuuaa ccagaggcggu guacuacccc gacaaggugu	180
ucagauccag cgugcugcac ucuacccagg accuguuccu gccuuucuuc agcaacguga	240
ccugguucca cgccauccac guguccggca ccaauggcac caagagauuc gacaaccccc	300
ugcugcccuu caacgacggg guguacuuug ccagcaccga gaaguccaac aucaucagag	360
gcuggaucuu cggcaccaca cuggacagca agaccagag ccugcugauc gugaacaacg	420
ccaccaacgu ggucaucaaa gugugcgagu uccaguucug caacgacccc uuccugggcg	480
ucuacuacca caagaacaac aagagcugga uggaaagcga guuccgggug uacagcagcg	540
ccaacaacug caccuucgag uacguguccc agccuuuccu gauggaccug gaaggcaagc	600
agggcaacuu caagaaccug cgcgaguucg uguuuuagaa caucgacggc uacuuaaga	660
ucuacagcaa gcacaccccu aucaaccucg ugcgggauuc gccucagggc uucucugcuc	720
uggaaccccu gguggaucug cccaucggca ucaacaucac ccgguuucag acacugcugg	780
cccugcacag aagcuaccug acaccuggcg auagcagcag cggauaggaca gcuggugccg	840
ccgcuuacua ugugggcuac cugcagccua gaaccuuccu gcugaaguac aacgagaacg	900
gcaccaucac cgacgccgug gauugugcuc uggauccucu gagcgagaca aagugcacc	960
ugaaguccuu caccguggaa aagggcacuu accagaccag caacuuccgg gugcagccca	1020
ccgaauccau cgugcgguuc cccaauauca ccaaucugug ccccuucggc gagguguuca	1080
augccaccag auucgccucu guguacgccu ggaaccggaa gcggauacgc aaugcgugg	1140
ccgacuacuc cgugcuguac aacuccgcca gcuucagcac cuucaagugc uacggcgugu	1200
cccuaccaa gcugaacgac cugugcuua caaacgugua cgccgacagc uucgugauc	1260
ggggagauga agugcggcag auugccccug gacagacagg caagaucgcc gacuacaacu	1320
acaagcugcc cgacgacuuc accggcugug ugauugccug gaacagcaac aaccuggacu	1380
ccaaagucgg cggcaacuac aauuaccugu accggcuguu ccggaagucc aaucugaagc	1440
ccuucgagcg ggacauucc accgagauuc aucaggcccg cagcaccucc uguaacggcg	1500
uggaaggcuu caacugcuac uucccacugc aguccuacgg cuuucagccc aaaauggcg	1560
ugggcuauca gcccuacaga guggugugc ugagcuucga acugcugcau gcccugcca	1620
cagugugcgg ccuaagaaa agcaccaauc ucgugaagaa caauggcgug aacuuaacu	1680

ucaacggccu gaccggcacc ggcgugcuga cagagagcaa caagaaguuc cugccauucc	1740
agcaguuugg ccgggauauc gccgauacca cagacgccgu uagagauccc cagacacugg	1800
aaauccugga caucaccccu ugcagcuucg gcgaguguc ugugaucacc ccuggcacca	1860
acaccagcaa ucagguggca gugcuguacc aggacgugaa cuguaccgaa gugcccugg	1920
ccauucacgc cgaucagcug acaccuacau ggcgggugua cuccaccggc agcaaugugu	1980
uucagaccag agccggcugu cugaucggag ccgagcacgu gaacaauagc uacgagucg	2040
acaucccau cggcgugga aucugcgcca gcuaccagac acagacaaac agcccucgga	2100
gagccagaag cguggccagc cagagcauca uugccuacac aaugucucug ggcgccgaga	2160
acagcguggc cuacuccaac aacucuaucg cuaucccccac caacuucacc aucagcguga	2220
ccacagagau ccugccugug uccaugacca agaccagcgu ggacugcacc auguacauu	2280
ggggcgauuc caccgagugc uccaaccugc ugcugcagua cggcagcuuc ugcaccagc	2340
ugaauagagc ccugacaggg aucgccuggg aacaggacaa gaacacccaa gagguguucg	2400
ccaagugaa gcagaucuaa aagaccccuc cuaucaagga cuucggcggc uucauuuca	2460
gccagauucu gcccgaucuu agcaagcccc gcaagcggag cuucaucgag gaccugcugu	2520
ucaacaaagu gacacuggcc gacgccggcu ucaucaagca guauggcgau ugucugggcg	2580
acauugccgc cagggaucug auuugcgccc agaaguuaa cggacugaca gugcugccuc	2640
cucugcugac cgaugagaug aucgcccagu acacaucugc ccugcuggcc ggcacauca	2700
caagcggcug gacauuugga gcaggcgccg cucugcagau ccccuuugcu augcagaug	2760
ccuaccgguu caacgggauc ggagugaccc agaauugcu guacgagaac cagaagcuga	2820
ucgccaacca guucaacagc gccaucggca agauccagga cagccugagc agcacagcaa	2880
gcgcccuggg aaagcugcag gacgugguca accagaaugc ccaggcacug aacaccucg	2940
ucaagcagcu guccuccaac uucggcgcca ucagcucugu gcugaacgau auccugagca	3000
gacuggaccc uccugaggcc gaggugcaga ucgacagacu gaucacaggc agacugcaga	3060
gccuccagac auacgugacc cagcagcuga ucagagccgc cgagauuaga gccucugcca	3120
aucuggccgc caccaagaug ucugagugug ugcugggcca gagcaagaga guggacuuu	3180
ggggcaaggg cuaccaccug augagcuucc cucagucugc ccucacggc gugguguuuc	3240
ugcacgugac auaugugccc gcucaagaga agaauuucac caccgcucca gccaucugcc	3300

```

acgacggcaa agcccacuuu ccuagagaag gcguguucgu guccaacggc acccauuggu      3360
ucgugacaca gcggaacuuc uacgagcccc agaucaucac caccgacaac accuucgugu      3420
cuggcaacug cgacgucgug aucggcauug ugaacaauac cguguacgac ccucugcagc      3480
ccgagcugga cagcuucaa gaggaacugg acaaguacuu uaagaaccac acaagccccg      3540
acguggaccu gggcgauauc agcggaauca augccagcgu cgugaacauc cagaaagaga      3600
ucgaccggcu gaacgaggug gccaaagauc ugaacgagag ccugaucgac cugcaagaac      3660
ugggggaagua cgagcaguac aucaaguggc ccugguacau cuggcugggc uuuaucgccg      3720
gacugauugc caucgugaug gucacaauca ugcuguguug caugaccagc ugcuguagcu      3780
gccugaaggg cuguuguagc uguggcagcu gcugcaaguu cgacgaggac gauucugagc      3840
ccgugcugaa gggcgugaaa cugcacuaca caugaugacu cgagcuggua cugcaugcac      3900
gcaaugcuag cugcccccuu cccguccugg guacccccgag ucucucccca ccucgggucc      3960
cagguaugcu cccaccucca ccugccccac ucaccaccuc ugcuauguucc agacaccucc      4020
caagcacgca gcaaugcagc ucaaaacgcu uagccuagcc acacccccac gggaaacagc      4080
agugauuaac cuuuagcaau aaacgaaagu uuaacuaagc uauacuaacc ccagggguugg      4140
ucaauuucgu gccagccaca ccugggagcu agcaaaaaaa aaaaaaaaaa aaaaaaaaaa      4200
aaagcauau acuaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      4260
aaaaaaaaaa aaaaaaaaaa aaa                                     4283

```

Exemplification

[273] The following Examples are provided for illustration and are not in any way to limit the scope of the disclosure. One of skill in the art will appreciate that certain design and selection criteria as described herein may be changed according to common practices in the field.

Example 1: Exemplary Compositions and Characterization

[274] The present example describes development and/or characterization of certain RNA/LNP compositions in accordance with the present disclosure.

[275] The RNA payload utilized in the present Example was a modified RNA payload in that it included 4283 nucleotide residues. The RNA payload utilized in the present Example

encoded a viral antigen, in particular the SARS-CoV-2 S protein. Specifically, the RNA payload utilized in the present Example was the BNT162b2 construct as represented by RBP020.2 (v9) described herein.

[276] The present example assessed certain protectants (specifically dissacharide protectants sucrose and trehalose) and particular buffers (*e.g.*, non-phosphate buffers such as Tris and histidine buffers, and/or buffers that do not include NaCl).

[277] Without wishing to be bound by any particular theory, it was considered that isotonicity might be desirable; certain assessed compositions included protectant at a concentration of 10% w/v since it yields a nearly isotonic solution.

[278] Buffer concentration was selected to be sufficient for maintaining pH of the compositions.

[279] Assessed compositions did not include mannitol.

[280] In this example, compositions were not frozen (*e.g.*, were maintained at a temperature within a range of about 2°C to about 8°C) prior to drying. In this example, drying was performed by freeze-drying (specifically, lyophilization).

[281] Electrical conductivity of compositions was measured, and low temperature DSC experiments were performed prior to initiation of freeze-drying. LNP size and polydispersity were determined using dynamic light scattering after the 2°C-8°C temperature hold and prior to lyophilization.

[282] Table 1 below presents certain assessed compositions; as can be seen, (i) protectant type and concentration was varied; an alternate fabrication process was assessed (specifically for a sucrose-containing formulation, RNA stock was diluted into a sucrose-citrate buffer, rather than a citrate-only buffer) during fabrication; (ii) buffers lacking NaCl were assessed; and (iii) non-phosphate buffers (*e.g.*, Tris, His, HEPES) were assessed.

Table 1. Compositions of formulations for lyophilization assessment

Formulation #	Buffer	Protectant	Notes	Volume, mL
1	10 mM Tris, pH 7.4	10% w/v Sucrose	alternate fabrication process	15+15=30*
2	10 mM Tris, pH 7.4	10% w/v Trehalose	-	15+15=30*
3	10 mM Tris, pH 7.4	5% w/v Sucrose 5% w/v Trehalose	-	15+15=30*
4	10 mM His, pH 7.4	10% w/v Sucrose	alternate fabrication process	15+15=30*

*Two aliquots of 15 mL each should be prepared and stored separately for lyophilization cycles with and without annealing during freezing.

[283] The utilized lyophilization process involved cooling and warming ramps during the freezing step that were performed at 0.5°C/min. The formulations were frozed to a temperature below Tg' of the relevant formulation. Without wishing to be bound by any particular theory, an annealing temperature of -10°C was selected to maximize Ostwald ripening during the isothermal hold (and thereby increase the size of ice crystals) and decrease cake resistance while keeping product below melting point of formulations. The ramp rate to secondary drying was 0.2°C/min.

Claims

We claim:

1. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is

at a concentration of about 10 mM in the formulation.

2. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is

at a concentration of about 10 mM in the formulation.

3. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

(ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) sucrose at a concentration of about 10% w/v in the formulation before drying;

c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

4. A method of preparing a formulation, the method comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

i) a payload that is or comprises one or more mRNAs;

ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

i) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and

ii) sucrose at a concentration of about 10% w/v in the formulation.

5. The method of claim 4, further comprising a step of:

c) freezing the formulation.

6. The method of claim 4, further comprising a step of:

c) drying the formulation.

7. A method of preparing a dosage form, the method comprising a step of:

a) diluting a formulation of claim 1;

b) thawing and diluting a formulation of claim 2; and/or

c) resuspending and diluting a formulation of claim 3.

8. The method of claim 7, further comprising administering the dosage form to a subject in need of thereof.

9. The method of claim 8, wherein the subject is in need of an expression product of the mRNA.

10. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

i) mRNA at a concentration of about 0.5 mg/ml;

ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

v) cholesterol at a concentration of about 3.1 mg/ml;

b) sucrose at a concentration of about 10% w/v;

c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

11. A formulation comprising:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

i) a payload that is or comprises one or more mRNAs;

ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) trehalose at a concentration of about 10% w/v in the formulation;

c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

12. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is

at a concentration of about 10 mM in the formulation.

13. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation before drying;
- c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is

at a concentration of about 10 mM in the formulation before drying.

14. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) trehalose at a concentration of about 10% w/v in the formulation.

15. The method of claim 14, further comprising a step of:

- c) freezing the formulation.

16. The method of claim 14, further comprising a step of:

- c) drying the formulation.

17. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 11;
- b) thawing and diluting a formulation of claim 12; and/or
- c) resuspending and diluting a formulation of claim 13.

18. The method of claim 17, further comprising administering the dosage form to a subject in need of thereof.

19. The method of claim 18, wherein the subject is in need of an expression product of the mRNA.

20. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
 - b) trehalose at a concentration of about 10% w/v;
 - c) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- wherein the formulation is diluted into the dosage form prior to administration.

21. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

22. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

23. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation before drying;
- c) trehalose at a concentration of about 5% w/v in the formulation before drying;
- d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is

at a concentration of about 10 mM in the formulation before drying.

24. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
 - ii) sucrose at a concentration of about 5% w/v in the formulation; and
 - iii) trehalose at a concentration of about 5% w/v in the formulation.

25. The method of claim 24, further comprising a step of:

- c) freezing the formulation.

26. The method of claim 24, further comprising a step of:

- c) drying the formulation.

27. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 21;
- b) thawing and diluting a formulation of claim 22; and/or
- c) resuspending and diluting a formulation of claim 23.

28. The method of claim 27, further comprising administering the dosage form to a subject in need of thereof.

29. The method of claim 28, wherein the subject is in need of an expression product of the mRNA.

30. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

31. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and

is at a concentration of about 10 mM in the formulation.

32. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and

is at a concentration of about 10 mM in the formulation.

33. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation before drying;

c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

34. A method of preparing a formulation comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) sucrose at a concentration of about 10% w/v in the formulation.

35. The method of claim 34, further comprising a step of:

- c) freezing the formulation.

36. The method of claim 34, further comprising a step of:

- c) drying the formulation.

37. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 31;
- b) thawing and diluting a formulation of claim 32; and/or
- c) resuspending and diluting a formulation of claim 33.

38. The method of claim 37, further comprising administering the dosage form to a subject in need of thereof.

39. The method of claim 38, wherein the subject is in need of an expression product of the mRNA.

40. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

i) mRNA at a concentration of about 0.5 mg/ml;

ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;

iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

v) cholesterol at a concentration of about 3.1 mg/ml;

b) sucrose at a concentration of about 10% w/v in the formulation;

c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

41. A formulation comprising:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

i) a payload that is or comprises one or more mRNAs;

ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) trehalose at a concentration of about 10% w/v in the formulation;

c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

42. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation;
- c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

43. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation before drying;
- c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

44. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation; and
- ii) trehalose at a concentration of about 10% w/v in the formulation.

45. The method of claim 44, further comprising a step of:

- c) freezing the formulation.

46. The method of claim 44, further comprising a step of:

- c) drying the formulation.

47. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 41;
- b) thawing and diluting a formulation of claim 42; and/or
- c) resuspending and diluting a formulation of claim 43.

48. The method of claim 47, further comprising administering the dosage form to a subject in need of thereof.

49. The method of claim 48, wherein the subject is in need of an expression product of the mRNA.

50. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;

- v) cholesterol at a concentration of about 3.1 mg/ml;
 - b) trehalose at a concentration of about 10% w/v in the formulation;
 - c) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation;
- wherein the formulation is diluted into the dosage form prior to administration.

51. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

52. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation.

53. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation before drying;
- c) trehalose at a concentration of about 5% w/v in the formulation before drying;
- d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

54. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and is at a concentration of about 10 mM in the formulation;
 - ii) sucrose at a concentration of about 5% w/v in the formulation; and
 - iii) trehalose at a concentration of about 5% w/v in the formulation.

55. The method of claim 54, further comprising a step of:

- c) freezing the formulation.

56. The method of claim 54, further comprising a step of:

- c) drying the formulation.

57. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 51;
- b) thawing and diluting a formulation of claim 52; and/or
- c) resuspending and diluting a formulation of claim 53.

58. The method of claim 57, further comprising administering the dosage form to a subject in need of thereof.

59. The method of claim 58, wherein the subject is in need of an expression product of the mRNA.

60. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) Tris buffer, wherein the Tris buffer comprises about 6 mg/ml sodium chloride and

is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

61. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

62. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

63. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation before drying;
- c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

64. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
 - ii) sucrose at a concentration of about 10% w/v in the formulation.

65. The method of claim 64, further comprising a step of:

- c) freezing the formulation.

66. The method of claim 64, further comprising a step of:

- c) drying the formulation.

67. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 61;
- b) thawing and diluting a formulation of claim 62; and/or
- c) resuspending and diluting a formulation of claim 63.

68. The method of claim 67, further comprising administering the dosage form to a subject in need of thereof.

69. The method of claim 68, wherein the subject is in need of an expression product of the mRNA.

70. A method comprising a step of:
administering a dosage form of a formulation, wherein the formulation comprises:
- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
 - b) sucrose at a concentration of about 10% w/v in the formulation;
 - d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- wherein the formulation is diluted into the dosage form prior to administration.

71. A formulation comprising:
- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
 - b) trehalose at a concentration of about 10% w/v in the formulation;
 - c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

72. A frozen formulation comprising:
- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;

- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation;
- c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

73. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation before drying;
- c) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

74. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and

- ii) trehalose at a concentration of about 10% w/v in the formulation.

75. The method of claim 74, further comprising a step of:

- c) freezing the formulation.

76. The method of claim 74, further comprising a step of:

- c) drying the formulation.

77. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 71;
- b) thawing and diluting a formulation of claim 72; and/or
- c) resuspending and diluting a formulation of claim 73.

78. The method of claim 77, further comprising administering the dosage form to a subject in need of thereof.

79. The method of claim 78, wherein the subject is in need of an expression product of the mRNA.

80. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) trehalose at a concentration of about 10% w/v in the formulation;

d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

81. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

82. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

83. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;

- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation before drying;
- c) trehalose at a concentration of about 5% w/v in the formulation before drying;
- d) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

84. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) His buffer, wherein the His buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
 - ii) sucrose at a concentration of about 5% w/v in the formulation; and
 - iii) trehalose at a concentration of about 5% w/v in the formulation.

85. The method of claim 84, further comprising a step of:

- c) freezing the formulation.

86. The method of claim 84, further comprising a step of:

- c) drying the formulation.

87. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 81;
- b) thawing and diluting a formulation of claim 82; and/or
- c) resuspending and diluting a formulation of claim 83.

88. The method of claim 87, further comprising administering the dosage form to a subject in need of thereof.

89. The method of claim 88, wherein the subject is in need of an expression product of the mRNA.

90. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) His buffer, wherein the His buffer is substantially free of sodium chloride and is

at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

91. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;

- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

92. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

93. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation before drying;
- c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

94. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and
 - ii) sucrose at a concentration of about 10% w/v in the formulation.

95. The method of claim 94, further comprising a step of:

- c) freezing the formulation.

96. The method of claim 94, further comprising a step of:

- c) drying the formulation.

97. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 91;
- b) thawing and diluting a formulation of claim 92; and/or
- c) resuspending and diluting a formulation of claim 93.

98. The method of claim 97, further comprising administering the dosage form to a subject in need of thereof.

99. The method of claim 98, wherein the subject is in need of an expression product of the mRNA.

100. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 10% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride

and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

101. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) trehalose at a concentration of about 10% w/v in the formulation;
- c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride

and is at a concentration of about 10 mM in the formulation.

102. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

(ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) trehalose at a concentration of about 10% w/v in the formulation;

c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation.

103. A dry formulation comprising:

a) a lipid nanoparticle (LNP), wherein the LNP comprises:

i) a payload that is or comprises one or more mRNAs;

ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) trehalose at a concentration of about 10% w/v in the formulation before drying;

c) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation before drying.

104. A method of preparing a formulation, the method comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

i) a payload that is or comprises one or more mRNAs;

ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

i) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation; and

ii) trehalose at a concentration of about 10% w/v in the formulation.

105. The method of claim 104, further comprising a step of:

- c) freezing the formulation.

106. The method of claim 104, further comprising a step of:

- c) drying the formulation.

107. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 101;
- b) thawing and diluting a formulation of claim 102; and/or
- c) resuspending and diluting a formulation of claim 103.

108. The method of claim 107, further comprising administering the dosage form to a subject in need of thereof.

109. The method of claim 108, wherein the subject is in need of an expression product of the mRNA.

110. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) trehalose at a concentration of about 10% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

111. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride

and is at a concentration of about 10 mM in the formulation.

112. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride

and is at a concentration of about 10 mM in the formulation.

113. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

(ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

- b) sucrose at a concentration of about 5% w/v in the formulation before drying;
- c) trehalose at a concentration of about 5% w/v in the formulation before drying;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride

and is at a concentration of about 10 mM in the formulation before drying.

114. A method of preparing a formulation, the method comprising steps of:

a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:

- i) a payload that is or comprises one or more mRNAs;
- ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride and is at a concentration of about 10 mM in the formulation;
- ii) sucrose at a concentration of about 5% w/v in the formulation; and
- iii) trehalose at a concentration of about 5% w/v in the formulation.

115. The method of claim 114, further comprising a step of:

- c) freezing the formulation.

116. The method of claim 114, further comprising a step of:

- c) drying the formulation.

117. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 111;
- b) thawing and diluting a formulation of claim 112; and/or

- c) resuspending and diluting a formulation of claim 113.

118. The method of claim 117, further comprising administering the dosage form to a subject in need of thereof.

119. The method of claim 118, wherein the subject is in need of an expression product of the mRNA.

120. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 5% w/v in the formulation;
- c) trehalose at a concentration of about 5% w/v in the formulation;
- d) HEPES buffer, wherein the HEPES buffer is substantially free of sodium chloride

and is at a concentration of about 10 mM in the formulation;

wherein the formulation is diluted into the dosage form prior to administration.

121. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

(ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride.

122. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride.

123. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation before drying;
- c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride.

124. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

(ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

- i) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride; and
- ii) sucrose at a concentration of about 10% w/v in the formulation.

125. The method of claim 124, further comprising a step of:

- c) freezing the formulation.

126. The method of claim 124, further comprising a step of:

- c) drying the formulation.

127. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 121;
- b) thawing and diluting a formulation of claim 122; and/or
- c) resuspending and diluting a formulation of claim 123.

128. The method of claim 127, further comprising administering the dosage form to a subject in need of thereof.

129. The method of claim 128, wherein the subject is in need of an expression product of the mRNA.

130. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;

- iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
- iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
- v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 10% w/v;
- c) PBS buffer, wherein the PBS buffer is substantially free of sodium chloride; wherein the formulation is diluted into the dosage form prior to administration.

131. A formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation.

132. A frozen formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation.

133. A dry formulation comprising:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) sucrose at a concentration of about 10% w/v in the formulation before drying;
- c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation before drying.

134. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;
 - ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and
- b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:
 - i) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation; and
 - ii) sucrose at a concentration of about 10% w/v in the formulation.

135. The method of claim 134, further comprising a step of:

- c) freezing the formulation.

136. The method of claim 134, further comprising a step of:

- c) drying the formulation.

137. A method of preparing a dosage form, the method comprising a step of:

- a) diluting a formulation of claim 131;
- b) thawing and diluting a formulation of claim 132; and/or
- c) resuspending and diluting a formulation of claim 133.

138. The method of claim 137, further comprising administering the dosage form to a subject in need of thereof.

139. The method of claim 138, wherein the subject is in need of an expression product of the mRNA.

140. A method comprising a step of:

administering a dosage form of a formulation, wherein the formulation comprises:

- a) a lipid nanoparticle (LNP), wherein the LNP comprises:
 - i) mRNA at a concentration of about 0.5 mg/ml;
 - ii) ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a concentration of about 7.17 mg/ml;
 - iii) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) at a concentration of about 0.89 mg/ml;
 - iv) distearoylphosphatidylcholine (DSPC) at a concentration of about 1.56 mg/ml;
 - v) cholesterol at a concentration of about 3.1 mg/ml;
- b) sucrose at a concentration of about 10% w/v in the formulation;
- c) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride; wherein the formulation is diluted into the dosage form prior to administration.

141. A method of preparing a formulation, the method comprising steps of:

- a) preparing a lipid nanoparticle (LNP) in a first buffer system, wherein the LNP comprises:
 - i) a payload that is or comprises one or more mRNAs;

ii) lipids that include: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); distearoylphosphatidylcholine (DSPC); and cholesterol at relative mass ratios in a range of about 8:1:1.5:3 to about 9:1:2:3.5; and

b) exchanging the first buffer system for a second buffer system, wherein the second buffer system comprises:

i) PBS buffer, wherein the PBS buffer comprises about 6 mg/ml sodium chloride in the formulation; and

ii) sucrose at a concentration of about 10% w/v in the formulation wherein the first buffer system comprises sucrose at a concentration of about 10% w/v.

142. The method of claim 141, further comprising a step of:

c) freezing the formulation.

143. The method of claim 141, further comprising a step of:

c) drying the formulation.

144. A method of delivering a nucleic acid into a cell in a subject comprising a step of administering a formulation as described in any of the preceding claims.

145. A method of inducing an immune response in a subject comprising a step of administering to the subject a formulation as described in any of the preceding claims.

146. The method of claim 145, wherein the immune response is against a viral antigen, or epitope thereof, encoded by the mRNA.

147. The method of claim 146, wherein the viral antigen is an antigen of a coronavirus.

148. The method of claim 147, wherein the coronavirus is a SARS-CoV2 virus.

149. The method of claim 147 or claim 148, wherein the antigen is or comprises an S protein.

150. The formulation of any one of claims 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133, or the method of any one of claims 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, or 143, wherein the formulation is dried until it is substantially free of water.

151. The formulation of any one of claims 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, or 150, or the method of any one of claims 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 143, or 150, wherein the formulation is dried by lyophilization.

152. The formulation of any one of claims 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 150, or 151, or the method of any one of claims 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 143, 150, or 151, wherein the formulation is dried until it comprises less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, or less than 0.3% w/w water.

153. The formulation of any one of claims 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 150, 151, or 152, or the method of any one of claims 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 143, 150, 151, or 152, wherein the formulation is annealed during drying.

154. The formulation of any one of claims 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 150, 151, or 152, or the method of any one of claims 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 143, 150, 151, or 152, wherein the formulation is not annealed during drying.

155. The formulation of any one of claims 150-154, or the method of any one of claims 150-154, wherein the formulation maintains less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, or less than 0.3% w/w water for at least 12 weeks at temperatures ranging from about 2°C to about 25°C.

156. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the one or more mRNAs encodes one or more polypeptides.

157. The formulation of claim 156, wherein the one or more polypeptides are or comprise an epitope for inducing an immune response against an antigen in a subject.

158. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, wherein the one or more mRNAs are or comprise an epitope for inducing an immune response against an antigen in a subject.

159. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, 131-133, or 158, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the one or more RNAs are or comprise self-amplifying RNA molecules.

160. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, 131-133, 158, or 159, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, 141-149, or 159, wherein the one or more RNAs are or comprise modified RNA molecules, or non-modified RNA molecules.

161. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, 131-133, or 158-160, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, 141-149, 159, or 160, wherein the one or more RNAs are or comprise non-modified uridine RNA molecules.

162. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, 131-133, or 158-161, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, 141-149, or 159-161, wherein the one or more RNAs are or comprise nucleoside modified RNA molecules.

163. The formulation of claim 156, or the method of claim 156, wherein at least one of the one or more polypeptides is derived from a SARS-COV-2 S Protein of SEQ ID NO: 1 or 7.

164. The formulation of claim 156, or the method of claim 156, wherein at least one of the one or more polypeptides comprises at least 85% sequence identity to the SARS-COV-2 S Protein of SEQ ID NO: 1 or 7.

165. The formulation of claim 156, or the method of claim 156, wherein at least one of the one or more polypeptides is or comprises a full length SARS-COV-2 S Protein of SEQ ID NO: 1 or 7.

166. The formulation of claim 156, or the method of claim 156, wherein at least one of the one or more polypeptides comprises at least 85% sequence identity to the Receptor Binding Domain (RBD) of SARS-COV-2 S Protein of SEQ ID NO: 1 or 7.

167. The formulation of claim 156, or the method of claim 156, wherein at least one of the one or more polypeptides is or comprises a Receptor Binding Domain (RBD) of SARS-COV-2 S Protein of SEQ ID NO: 1 or 7.

168. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the one or more mRNAs are associated or encapsulated in the LNP.

169. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation has been stored over a time period of at least 12 weeks at a temperature above 25°C.

170. The of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation has been stored over a time period of at least 12 weeks at a temperature in a range of about 2-40°C.

171. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized in that lipid nanoparticles exhibit less than 20 nm change in Z-Average when stored over a time period of at least 12 weeks at a temperature of about 2-8°C as compared to a control formulation.

172. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized in that lipid nanoparticles exhibit less than 20 nm change in Z-Average when stored over a time period of at least 12 weeks at a temperature of about 25°C as compared to a control formulation.

173. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized in that lipid nanoparticles exhibit less than 0.1 change in Polydispersity Index (PDI) when stored over a time period of at least 12 weeks at a temperature of about 2-8°C as compared to a control formulation.

174. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized in that lipid nanoparticles exhibit less

than 0.1 change in Polydispersity Index (PDI) when stored over a time period of at least 12 weeks at a temperature of about 25°C as compared to a control formulation.

175. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized by a %mRNA encapsulation of at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% when stored over a time period of at least 12 weeks at a temperature of about 2-8°C as compared to a control formulation.

176. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized by mRNA encapsulation% of at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% when stored over a time period of at least 12 weeks at a temperature of about 25°C as compared to a control formulation.

177. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized by a %mRNA expression of at least 60%, at least 70%, at least 80%, or at least 90% when stored over a time period of at least 12 weeks at a temperature of about 2-8°C as compared to a control formulation.

178. The formulation of any one of claims 1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93, 101-103, 111-113, 121-123, or 131-133, or the method of any one of claims 4-9, 14-19, 24-29, 34-39, 44-49, 54-59, 64-69, 74-79, 84-89, 94-99, 104-109, 114-119, 124-129, 134-139, or 141-149, wherein the formulation is characterized by a %mRNA expression of at least

60%, at least 70%, at least 80%, or at least 90% when stored over a time period of at least 12 weeks at a temperature of about 25°C as compared to a control formulation.




FIG. 2A

#	Cryo/LyoP	Buffer	Salt (Y/N) [^]	Anneal (Y/N)
F1	10% Sucrose	10 mM Tris	No	No – Cycle 3 (NA) Yes – Cycle 4 (A)
F2	10% Trehalose			
F3	5% Sucrose - 5% Trehalose			
F4	10% Sucrose	10 mM Tris	Yes	No – Cycle 1 (NA) Yes – Cycle 2 (A)
F5	10% Trehalose			
F6	5% Sucrose - 5% Trehalose			
F7	10% Sucrose	10 mM His	No	Yes – Cycle 4 (A)
F8	10% Trehalose			
F9	5% Sucrose - 5% Trehalose			
F10	10% Sucrose	10 mM HEPES	No	Yes – Cycle 4 (A)
F11	10% Trehalose			
F12	5% Sucrose - 5% Trehalose			
F13	10% Sucrose	NaCl free PBS	No	Yes – Cycle 4 (A)
F15	10% Sucrose**	10 mM Tris	No	Yes – Cycle 4 (A)
F16	10% Sucrose**	10 mM Tris	No	
F17	10% Sucrose	NaCl PBS	Yes	No – Cycle 1 (NA) Yes – Cycle 2 (A)
F18	10% Sucrose		Yes	

[^] Buffers with salt comprise 6 mg/ml NaCl; buffers without salt have no added NaCl

** Sucrose added in first buffer system

FIG. 2B

Process steps	Process parameters						
	Cycle 1 (resistance from Case 1, Table 2 was used), target temperature -40°C	Time, (hrs)	Cycle 2 (resistance from Case 2, Table 2 was used), target temperature -40°C	Time, (hrs)	Cycle 3 (resistance from Case 1, Table 2 was used), target temperature -36°C	Time, (hrs)	Cycle 4 (resistance from Case 2, Table 2 was used), target temperature -36°C
Freezing	R to -45°C in 130 min	2.17	R to -45°C in 130 min	2.17	R to -45°C in 130 min	2.17	R to -45°C in 130 min
	H at -45°C for 60 min	3.17	H at -45°C for 60 min	3.17	H at -45°C for 60 min	3.17	H at -45°C for 60 min
			R to -10°C in 70 min	4.33			R to -10°C in 70 min
			H at -10°C for 180 min	7.33			H at -10°C for 180 min
			R to -45°C in 70 min	8.50			R to -45°C in 70 min
Chill condenser and pull vacuum			H at -45°C for 60 min	9.50			H at -45°C for 60 min
	Tcond<= 50°C, Pchl=30 mT	4.17	Tcond<= 50°C, Pchl=40 mT	10.50	Tcond<= 50°C, Pchl=40 mT	4.17	Tcond<= 50°C, Pchl=50 mT
Primary drying	R to -38°C in 14 min	4.40	R to -36°C in 18 min	10.80	R to -32°C in 26 min	4.60	R to -29°C in 32 min
	H at -38°C for 3600 min	64.40	H at -36°C for 2700 min	55.80	H at -32°C for 2400 min	44.60	H at -36°C for 1800 min
Secondary drying	R to 30°C in 340 min	70.07	R to 30°C in 330 min	61.30	R to 30°C in 310 min	49.77	R to 30°C in 295 min
	H at 30°C for 480 min	78.07	H at 30°C for 480 min	69.30	H at 30°C for 480 min	57.77	H at 30°C for 480 min
R=ramp, H=hold							
Note that cycle parameters were calculated assuming edge effect of 1.5. Also, the chamber pressure was chosen based on the performance of 40 sq.m commercial freeze-dryer when it is fully loaded (175770 vials). Pressure set point was at least 9 mT higher than minimum controllable pressure (with resistance scale up factor of 1) for each cycle proposed. The calculations of Pmin for Lyostar III were also made to ensure that pressure can be controlled when 560 vials (one full tray) is loaded in Lyostar III.							

Colloidal Stability

FIG. 3A





FIG. 3B



% Encapsulation

FIG. 4A






FIG. 4B





% Expression

FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7A




FIG. 7B




FIG. 7C







FIG. 7D







INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2021/081674

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2021/081674

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K9/51 A61K9/19 A61K39/00 A61P31/14
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2017/218704 A1 (MODERNATX INC [US]) 21 December 2017 (2017-12-21) table 1 examples 1-4 claims 1-19	1-178
A	WO 2020/072605 A1 (INTELLIA THERAPEUTICS INC [US]) 9 April 2020 (2020-04-09) example 52 table 1	1-178
A	WO 2017/075531 A1 (ACUITAS THERAPEUTICS INC [CA]) 4 May 2017 (2017-05-04) example 1 table 1	1-178
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 February 2022

Date of mailing of the international search report

04/03/2022

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sindel, Ulrike

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2021/081674

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2018/078053 A1 (CUREVAC AG [DE]; ACUITAS THERAPEUTICS INC [CA]) 3 May 2018 (2018-05-03) claims 1-10 example 1 -----	1-178
A	Alex K.K. Leung ET AL: "Lipid Nanoparticles for Short Interfering RNA Delivery" In: "Advances in Genetics", 1 January 2014 (2014-01-01), Academic Press, US, XP055540398, ISSN: 0065-2660 vol. 88, pages 71-110, DOI: 10.1016/B978-0-12-800148-6.00004-3, figures 4.7, 4.8 -----	1-178

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2021/081674

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2017218704 A1	21-12-2017	AU 2017286606 A1	13-12-2018	
		CA 3027201 A1	21-12-2017	
		EP 3468537 A1	17-04-2019	
		JP 2019525901 A	12-09-2019	
		US 2020069599 A1	05-03-2020	
		WO 2017218704 A1	21-12-2017	

WO 2020072605 A1	09-04-2020	AU 2019351917 A1	29-04-2021	
		BR 112021006270 A2	06-07-2021	
		CA 3114032 A1	09-04-2020	
		CN 113039174 A	25-06-2021	
		CO 2021005774 A2	30-07-2021	
		EA 202190916 A1	09-07-2021	
		EP 3860972 A1	11-08-2021	
		JP 2022501412 A	06-01-2022	
		KR 20210093871 A	28-07-2021	
		PH 12021550701 A1	03-11-2021	
		SG 11202102921W A	29-04-2021	
		TW 202028170 A	01-08-2020	
		US 2022009878 A1	13-01-2022	
		WO 2020072605 A1	09-04-2020	

WO 2017075531 A1	04-05-2017	AU 2016343803 A1	26-04-2018	
		AU 2021206881 A1	19-08-2021	
		CA 3003055 A1	04-05-2017	
		CN 108368028 A	03-08-2018	
		CN 113636947 A	12-11-2021	
		EP 3368507 A1	05-09-2018	
		IL 258501 A	31-10-2021	
		JP 2018533573 A	15-11-2018	
		US 2017119904 A1	04-05-2017	
		US 2019314524 A1	17-10-2019	
		US 2020121809 A1	23-04-2020	
		WO 2017075531 A1	04-05-2017	

WO 2018078053 A1	03-05-2018	AU 2017350488 A1	02-05-2019	
		BR 112019008481 A2	03-03-2020	
		CA 3040337 A1	03-05-2018	
		CN 110352071 A	18-10-2019	
		EP 3532094 A1	04-09-2019	
		JP 2020504764 A	13-02-2020	
		KR 20190093816 A	26-08-2019	
		SG 11201903460Q A	30-05-2019	
		US 2020163878 A1	28-05-2020	
		US 2021251898 A1	19-08-2021	
		WO 2018078053 A1	03-05-2018	
